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   Abstract  
James Odell 
Exploring the use of manual therapy as an adjunctive therapy to 'care as usual' 
on outcomes in chronic migraine 
 
Although chronic migraine (CM) has an estimated of worldwide annual prevalence of 
between1.4% and 2.2%, with the greatest impact on females, the understanding of its 
pathophysiology is still largely unknown. This has led to a lack of effective treatments 
and at the time of this study Onabotulinumtoxin A (Botox) was the only medication 
licensed specifically for CM. However, whilst there are other treatment options, 
including psychological and physical therapies, their effectiveness in CM is uncertain. A 
rationale for the use of MT in CM was developed from a narrative review, with a 
systematic literature review of peer reviewed publications confirming limited research 
into the role of MT in the treatment of CM.  The aim of this study was therefore to 
explore the effectiveness of manual therapy (MT) as an adjunctive treatment to 'care as 
usual' in females with CM, using a pragmatic, randomised controlled trial (RCT) in a 
tertiary headache clinic. Sixty-four female participants with severe CM were 
randomised into two groups: 'care as usual' and 'care as usual' with MT. The primary 
outcome was the between group difference in change scores using the Headache 
Impact Test (HIT6). Secondary outcomes included Patient Global Impression of 
Change (PGIC) and responder rates. The primary outcome favoured the use of 
adjunctive treatment with a significant difference in between-group HIT6 change 
scores. The MT group also had significantly higher responder rates in the HIT6 and 
PGIC outcomes. The presence of higher baseline levels of cutaneous allodynia, 
negative coping and emotional distress indicated a greater benefit from the combined 
MT/ 'care as usual' intervention than 'care as usual' alone. This was the first MT-CM 
RCT to take place in a UK tertiary NHS headache clinic and contributed new 
knowledge in several areas: (1) the first use of PGIC outcomes to be reported in an 
adjunctive CM study which suggested it provides a broader and potentially more 
patient centred measure of treatment effectiveness, compared to the HIT6 alone.  (2) 
the potential to use movement between allodynia symptom checklist (ASC) categories 
as a better indication of reduction in allodynia brought about by MT rather than the 
normal dichotomous cut off score.  (3) the first MT-CM study to examine psychological 
factors and propose that 'care as usual' treatment may be reinforcing negative coping 
behaviours and maintaining disability in treatment of CM. This study contributes to a 
body of knowledge on MT for CM, and concluded that MT plus 'care as usual' produced 
better outcomes versus 'care as usual' alone in females severely affected by CM. 
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CHAPTER 1  INTRODUCTION 
 
This chapter starts with a brief overview of the author’s journey with this study, 
based on professional experience of treating patients with headaches and migraines 
and involvement with a range of headache specialists. It then introduces the global 
impact of chronic migraine (CM) and its epidemiology, before examining current 
theories on the pathophysiology and chronification process, and how these theories 
form a basis for the connection between other pain conditions and migraine. A 
narrative review of the role of manual therapy (MT) in these pain conditions and 
other headaches then develops the rationale for manual therapy in the context of 
migraine treatment. It concludes with an overview of existing CM treatments and the 
need for additional approaches (Figure 1.1). 
 
 
       Figure 1-1. Developing a rationale for manual therapy in chronic migraine 
 
The overall reason for this research was to explore the issue of migraine, as a 
multifactorial condition that most likely required more than a mono-therapy treatment 
approach (Gaul et al. 2011; Gaul et al. 2016; Grazzi and D’Amico, 2019). This is an 
important area of research as migraine ranks second behind low back pain in terms 




of disability (Leonardi and Raggi. 2019) with approximately three percent of those 
with migraine transforming to CM annually (Lipton and Silberstein. 2015). CM is the 
most disabling and refractory type of migraine, disproportionately affecting females, 
in their most productive years (Weatherall, 2015; Aurora & Brin, 2016) with the 
current, limited number of, mono-therapies failing to offer relief to a substantial 
proportion of sufferers (Lipton and Silberstein. 2015; Su and Yu. 2018; Velasco-
Juanes et al. 2018).  
 
As such, the overall aim of the study was to examine the effectiveness of MT, with 
female CM patients, as part of a multi-modal approach rather than to compare MT 
against existing treatments. 
 
1.1. The author's research journey 
The idea for this study had been germinating over 10 years of working with 
headache and particularly migraine patients as a chiropractor and discussing the 
role of MT with neurologists. Many neurologists did not view MT as a useful 
approach, despite the improvements I saw in many of my migraine/headache 
patients. However, after meeting one particular headache neurologist, the lack of 
professional consensus became evident. Subsequent collaboration with this 
neurologist began to examine how MT may be useful particularly in those most 
affected - those with CM. At the time licensed medications specifically for CM did not 
exist and the success of those in use was limited, often with significant side effects.  
The introduction of Botox to the NHS in 2012 signalled a change, as this was the 
first drug targeted specifically at chronic migraine. However, the efficacy and 
effectiveness of Botox were still under debate, with a high proportion of patients not 
gaining substantive benefit.  At the same time evidence was mounting to suggest 
the pathophysiology of migraine was a multi-factorial condition amenable to a multi-
modal approach, including MT (Gaul et al. 2011; Wallasch et al. 2012; Grazzi 2013; 
Burstein et al 2015; Gaul et al. 2016; Grazzi & D’Amico. 2019). As a chiropractor, I 
always considered it unlikely that MT alone would work for everyone with CM and 
therefore sought to understand how MT might help some with CM and work with, not 
replace current approaches. Thus, my personal rationale for this study, with a focus 
on females, resulted from the evidence that they were disproportionately affected by 
CM and represented the bulk of my patients and those attending tertiary headache 
clinics.




1.2. Classification and epidemiology of migraine 
The World Health Organisation (WHO) estimates that between 50% and 75% of 
adults aged 18–65 years worldwide have headaches in a year. Of these, more than 
10% report migraine, with between 1.4% and 2.2% estimated to have chronic 
migraine (WHO, 2016). With an annual prevalence of 14.7%, migraine is classed as 
the third most prevalent neurological condition worldwide (Stovner, 2014). While the 
annual prevalence of migraine in the UK is estimated to be between 5% and 25% in 
women and 2% to 10% in men, the prevalence of chronic migraine in the UK is 
unknown, although the National Institute for Clinical Excellence (NICE) estimates 
that 1 in 1000 people are affected (NICE, 2011). 
 
However, there are still no biological markers for migraine, with the diagnosis based 
on clinical history and exclusion of alternative headache disorders. Its definition is 
classified by the International Headache Society (IHS) in its International 
Classification of Headache Disorders (IHS. 2018) and based on the symptoms 
presented (Table 1.1 and Table 1.2). 
 
In the most recent study into the global burden of health, migraine is recognised as 
the third largest cause of disability in people under fifty years of age, and the 
second-largest overall just behind low back pain, based on years lived with disability 
(YLDs) and early mortality in years of life lost (Steiner et al. 2016; Leonardi and 
Raggi. 2019). 
  





Table 1-1. Migraine classification (ICHD Beta -3)  
Migraine without Aura - episodic 
migraine (EM) 
Migraine with Aura - episodic migraine 
Previously used terms: 
Common migraine; hemicrania simplex. 
Previously used terms: 
Classic or classical migraine; ophthalmic, 
hemiparaesthetic, hemiplegic or aphasic 
migraine; migraine accompagnée; complicated 
migraine. 
Description: Description: 
Recurrent headache disorder 
manifesting in attacks lasting 4-72 
hours. Typical characteristics of the 
headache are unilateral location, 
pulsating quality, moderate or severe 
intensity, aggravation by routine 
physical activity and association with 
nausea and/or photophobia and 
phonophobia. 
Recurrent attacks, lasting minutes, of 
unilateral fully reversible visual, sensory or 
other central nervous system symptoms that 
usually develop gradually and are usually 
followed by headache and associated 
migraine symptoms. 
Diagnostic criteria: Diagnostic criteria: 
A. At least five attacks1 fulfilling 
criteria B to D 
A. At least two attacks fulfilling criteria B and 
C 
B. Headache attacks lasting 4-72 hr 













C. Headache has at least two of the 
following four characteristics: 
1. unilateral location 
2. pulsating quality 
3. moderate or severe pain intensity 
4. aggravation by or causing avoidance 
of routine physical activity (e.g., walking 
or climbing stairs) 
C. At least two of the following four 
characteristics 
1. at least one aura symptom spreads 
gradually over ≥5 min, and/or two or more 
symptoms occur in succession:  
2. each individual aura symptom lasts 5-60 min  
3. at least one aura symptom is unilateral 
4. the aura is accompanied, or followed within 
60 mins, by headache    
D. During headache at least one of the 
following: 
1. nausea and/or vomiting 
2. photophobia and phonophobia  
D. Not better accounted for by another ICHD-3 
diagnosis, and transient ischaemic attack has 
been excluded  
  
 








Table 1-2. Classification chronic migraine (ICHD Beta-3) 
Chronic Migraine (CM) 
Description: 
Headache occurring on 15 or more days per month for more than three months, 
which, on at least 8 days per month, has the features of migraine headache. 
Diagnostic criteria: 
A. Headache (tension-type-like and/or migraine-like) on =15 days per month for >3 
months2 and fulfilling criteria B and C 
B. Occurring in a patient who has had at least five attacks fulfilling criteria B-D for 1.1 
Migraine without aura and/or criteria B and C for 1.2 Migraine with aura 
C. On =8 days per month for >3 months, fulfilling any of the following 3: 
1. Criteria C and D for 1.1 Migraine without aura 
2. Criteria B and C for 1.2 Migraine with aura 
3. Believed by the patient to be migraine at onset and relieved by a triptan or ergot 
derivative 
D. Not better accounted for by another ICHD-3 diagnosis. 
 
 Headaches in primary care (when extrapolated to the whole of the UK) cost 
approximately €1.2 billion in service costs and €5.8 billion of lost productivity 
(McCrone et al. 2011). An EU study calculated migraine costs at between €18 and 
€27 billion per annum, with an average annual cost per headache patient of €370 
(Stovner, 2008; Oleson, 2011). Studies comparing episodic and chronic migraine 
consistently show annual CM costs far exceeding those of EM (Table 1.3). 
 
Table 1-3. Comparison chronic and episodic migraine costs  
Chronic Episodic Country 
€3700  €866  UK 
€2250  €526 Italy 
$8243  $2649  USA 
$471  $172  Canada 
 (Bloudek et al. 2011; Stokes et al. 2011; Lanteri-Minet et al. 
2013; Messali et al. 2016) 
 
In addition to the financial impact on migraineurs, the impact of migraines may be 
measured in social, economic, and inter-personal terms with the effects greatest for 
those with CM (Serrano et al. 2013). Individuals with chronic migraine are 20% less 
likely to be employed compared to those with episodic migraine, with losses through 
the cost of lost productive time much greater in chronic than episodic migraine at all 
ages and for both men and women (Lanteri-Minet. 2011). One study highlighted 
that, whilst chronic migraineurs comprised 8% of employed migraineurs they 
accounted for 35% of lost work time (Katsarava et al. 2012), with the highest loss in 
males and females aged 45 -54 years (Serrano et al. 2013).  




Chronic migraine is also associated with higher levels of personal disability than in 
episodic migraine (Katsarava et al. 2012).  A clinical study with over 331 subjects 
found that most standard measures of migraine disability, including health related 
quality of life (HQoL), Migraine Disability Index (MIDAS), and Migraine Specific 
Quality of Life v2.1 (MSQoL) were statistically higher in chronic migraineurs than 
episodic migraineurs (Wang et al. 2012). 
 
 
The annual prevalence figure of chronic migraine worldwide is estimated to be up to 
5.1%, with a typical range of 1.4% to 2.2% (Natoli et al. 2010; Buse et al. 2012; 
Chiang & Starling. 2018). Slightly higher figures were seen in a comparison study in 
the USA of two large scale longitudinal studies (Lipton et al. 2016), which concluded 
that annual prevalence for chronic migraine is between 6.6% and 8.8%. Further 
analysis of these figures reveals that females are most likely to have migraine, and 
even more likely to have chronic migraine. Burch et al. (2015) estimated the 3-
month prevalence of migraine or severe headache to average 20.2% in females, 
with 9.4% of them having had constant chronic migraine over the last 10 years.  
Finochi & Strada (2014) presented figures from a number of studies that 
demonstrated the gender difference in the annual prevalence of migraine (Figure 
1.2), and Natoli et al. (2010) indicated that the annual prevalence of chronic 
migraine was higher in females (1.7%–4.0%) than in males (0.6%–0.7%).  This was 
further supported by Buse et al. (2012), who concluded that the group most affected 
by chronic migraine was women aged 18-49 years (Figure 1.3). 
 
 
Figure 1-2. One-year prevalence of migraine by age and gender   
(Finochi & Strada 201) 





Despite years of investigation, the reason females seem to be more affected by 
migraine than males remain unclear, although most theories focus on hormonal 
involvement. Large USA-based and Swedish studies have noted that boys and girls 
have the same annual prevalence until puberty. Prevalence increases in both sexes 
during puberty although the gap between males and females widens. This continues 
until around 50 years of age when the gap closes again with migraine becoming less 
prevalent in both sexes (Allais et al. 2020).  Likewise, the difference between males 
and females in chronification to CM is equally not understood, although if headaches 
were seen on a continuum then the greater prevalence of migraine in females 
would, at a minimum, lead to a greater prevalence in CM. However, although the 
percentage of those transitioning from EM to CM (chronification), is thought to differ 
between males and females, figures are sparse and conflicting (Munakata et al. 
2009; Finnochi & Strada. 2014; Allais et al. 2018). Some reports have highlighted 
large differences between the transition from EM to CM women compared to men; 
with one suggesting it was 5 times greater in females (Vetvik and MacGregor.2017) 




Figure 1-3. Prevalence figures for chronic migraine by age and gender. 
(Buse et al. 2012) 
 
Despite the substantial economic and personal impact on both society and 
migraineurs (and in particular females), the understanding of the pathophysiology of 
migraine is still largely unknown (Asina et al. 2013; Burstein et al 2015; May & 
Schulte. 2016; Andreou and Edvinsson. 2019).  




This lack of understanding has led to a paucity of specific treatment approaches to 
migraine and fewer yet for chronic migraine (Su & Yu 2018). 
1.3. Pathophysiology of migraine and chronification 
Different models exist to explain both migraine and the process of chronification, 
with no single model of pathophysiology dominating.  The current consensus is that 
migraine is a neurobiological pain condition involving vascular, neurological, and 
psychological components. The most widely accepted theories of migraine 
pathophysiology suggest an inherited level of brain excitability, intracranial vessel 
dilatation, and activation and sensitisation of the trigeminovascular system with 
permanent structural and functional alterations in genetically-susceptible individuals 
(Chakravarty & Sen, 2010; Ashina et al. 2013; Burstein. 2015; Brennan & Pietrobon. 
2018). This section outlines some key strands in the theories of migraine and the 
chronification to CM that informed the study rationale. 
 
1.3.1. Central sensitisation 
Despite early theories of a discrete migraine generator in the brain that stimulates 
migraines (May & Schulte. 2016), one of the most commonly held current views is 
that migraine develops as an interaction between both the central and peripheral 
nervous systems (CNS and PNS) involving a number of components in a complex, 
multi-faceted response to initiating triggers (Striessnig. 2005; Oleson. 2009; Kojic & 
Stojanvic. 2013; Schwedt. 2014; May& Schulte. 2016; Bonivita et al. 2018).  
 
Dodick and Silberstein (2006) describe migraine as a consequence of sensitised 
nociceptors starting to load the spinal cord with increasingly large stimuli, known as 
peripheral sensitisation. This leads to the phenomenon known as central 
sensitisation, which increases pain via a dysfunctional processing pathway when 
sensitised in susceptible individuals. They concluded that peripheral sensitisation is 
associated with throbbing pain and poor response to movement, whilst central 
sensitisation results in allodynia, or the perception of pain induced by non-painful 
stimuli.  Oleson et al. (2009) suggested nociceptive input is a necessity for localised 
headache with the central nervous system and central sensitisation modulating pain. 
Exactly how the peripheral sensitisation is initiated is not clear although sources of 
the initial nociceptive input are thought to include the trigeminal perivascular and 
periarterial nociceptors, extra cranial, or dural sources (Schueler et al. 2013; 
Bonivita et al. 2018).   
 




In contrast, Panerai (2013) contested that migraine is a CNS-driven process with 
normal external inputs being affected by abnormal CNS processing and concluded 
that the answer is probably a combination of both. Migraine patients are unlikely to 
have a single dysfunction within the excitatory or inhibitory system, but rather an 
inability to maintain a cortical excitatory/inhibitory balance. Burstein et al. (2015) 
investigated cutaneous allodynia in 60 migraineurs. These authors hypothesised 
that the migraine process, from initialisation through to cutaneous allodynia, is a 
progression of the sensitisation of first-order neurones to second and finally third-




1.3.2. Migraine, pain and allostatic model  
The relationship between pain and emotions has been shown to exist in many 
conditions that, like migraine, have little readily observable cause (Lumley et al. 
2011; Bussone et al. 2012; Bussone & Grazzi. 2013; Adams et al. 2018) e.g. chronic 
pain and fibromyalgia (Phillips & Clauw. 2011; Pak et al. 2018). Buse et al. (2012) 
proposed that emotional response is a factor in the chronic pain of headache as a 
result of dysfunctional modulation in neurological system. This was consistent with 
the findings of Panerai (2013), albeit this process was specifically the integration of 
nociceptive input with the emotional network. In part this is thought to contribute to 
the increased prevalence and impact of migraine on females compared to males. 
Females with migraine have been found to have more comorbidities compared to 
 
 
1. Intracranial hypersensitivity 
Sensitisation of 1st-order dural 
nociceptors in trigeminal ganglion 
 
2. Intra cranial and cutaneous Allodynia 
with referred pain sensitisation of 2nd-
order (central) trigeminal neurons in 
brainstem 
 
3. Intracranial hypersensitivity and Extra 
cephalic allodynia sensitisation of 3rd-
order neurons receiving convergent 
information from head and forearms 
 
Figure 1-4. Process of central sensitization.  




males, with a higher incidence of anxiety, depression and pain conditions (Lantéri-
Minet et al. 2005; Vetvik & MacGregor 2017; Allais et al.2020).  This is consistent 
with findings of greater activation in areas of those brain involved with emotional 
processing compared with male migraineurs and may partly explain why males 
reported less pain than females despite similar levels of pain intensity (Bartley & 
Fillingim. 2013; Guo et al. 2019).  
 
Borsook et al. (2012) theorised that an allostatic model of migraine addressed many 
of the findings in migraine research including the variety of triggers and responses; 
pain experienced; central sensitisation; changes in brain structure; dysfunctional 
modulation of the neurological system, and the role of common psychological 
comorbidities such as anxiety and depression. The factors in this model also align 
with the biopsychosocial model of pain espoused by Engel (1977) which was later 
developed to explain the complexity of headaches and migraine (Andrasik et al. 
2005; Gil-Martinez et al. 2016; Meints et al. 2018). Based on the work of McEwen 
and Wingfield (2003), the allostatic model focussed on the brain being the major 
organ of stress. It decides what stress is and how to respond, with the “fight or flight” 
response being one such mechanism. Some responses are positive adaptations, 
whilst others are considered maladaptive.   
Allostasis is not in itself an entity but rather a mechanism by which the body protects 
itself from stresses through adaptive processes, or as McEwan (2003) stated, 
"maintaining stability through change, as a fundamental process through which 
organisms actively adjust to both predictable and unpredictable events".  Allostatic 
load is the cumulative impact on the body of allostasis, as individuals adjust their 
body, physiology, and behaviour to changes in the environment, socio-economic 
state, etc.  Borsook et al. (2012) proposed that as the stressors in life ebb and flow 
(Figure 1.5) the adaptive capability of the brain in susceptible people (i.e. the 
migraine brain) was less able to cope with this allostatic loading. The contribution of 
individual ‘effectors’ to the overall allostatic load is not known, although they may be 
additive or cumulative. Some effectors may be continuous (e.g., genetic) or episodic 
(e.g. musculoskeletal pain), or developmental over time (e.g. white matter lesions).  
 











Image redacted.  Fig 4 page 223. Borsook, D., Maleki, N., Becerra, L. 
and McEwen, B., 2012. Understanding Migraine through the Lens of 
Maladaptive Stress Responses: A Model Disease of Allostatic Load. 
Neuron, 73 (2), 219-234.  
Figure 1-5. Effectors of allostatic 
loading.  
(Borsook et al. 2012) 
  
 
1.3.3. Chronification in migraine 
Although approximately 2.5% of people with EM transform to CM, the precise 
mechanism of chronification is unknown (Bigal et al. 2008; Aguggia & Saracco. 
2010; Su & Yu. 2018).  In the allostatic model of migraine, the failure of the brain to 
adapt to effectors (stressors) may be seen initially as EM, but with higher allostatic 
loading, this inability to adapt leads to more migraines. The increase in migraines is 
an additional neurological load, thus creating a vicious cycle (Figure 1.6).  
 
Image redacted.  Fig 1 page 220. Borsook, D., Maleki, N., Becerra, L. and McEwen, 
B., 2012. Understanding Migraine through the Lens of Maladaptive Stress 
Responses: A Model Disease of Allostatic Load. Neuron, 73 (2), 219-234. 
Figure 1-6. Migraine frequency and allostatic load.  (Borsook et al. 2012). 
 




















The allostatic model may also offer an explanation of the gender differences in the 
transition to CM. Recent functional magnetic resonance imaging (fMRI) studies have 
indicated structural differences in parts of the brain associated with stress and 
anxiety in women with migraine compared with men with migraine and healthy 
women. Maleki et al. (2012) suggest that these alterations could be due to 
differences in response to intermittent stress (migraine attacks) and the effects of 
hormones. Gupta et al. (2007) proposed that female sex steroids enhance neuronal 
excitability by triggering mechanisms in migraine and involves calcitonin gene-
related peptide (CGRP) which itself impacts the trigeminovascular system and 
stimulation of pain centres. Recent studies of the new CGRP medications for CM 
support a view that trigeminal neurones may be sensitive to variations in levels of 
sex hormone, particularly oestrogens and progesterone These fluctuations may add 
directly and indirectly to the cumulative allostatic load as a recurring stressor 
(Boorsook et al. 2012; Tedeschi et al. 2015; Labastida-Ramırez et al. 2017; Allais et 
al. 2020).  
 
Another feature of chronification in migraine is the increased presence of central 
sensitisation and concomitant cutaneous allodynia. Over half of migraineurs have 
allodynia during, and over a quarter between, episodes of migraine (Lovati. 2008; 
Tietjen et al 2009; Benatto et al. 2016; Dodick et al. 2019). Bigal et al. (2007) 
proposed a model in which migraine was seen as a progressive, chronic condition 









Image redacted Fig 1 page  8. Bigal, M. and Lipton, R., 2007. 
Concepts and Mechanisms of Migraine Chronification. Headache: The 
Journal of Head and Face Pain, 48 (1), 7-15. 
Figure 1-7. Natural history of migraine.  (adapted from Bigal, 2007) 




is linked to permanent neuronal damage at or around the periaquialgrey (PAG), 
leading to poor pain modulation and resistance to treatment and thus making 
disease progression more likely. The idea of reduced pain inhibition in descending 
pathways in migraine has also been identified in studies of other chronic pain 
conditions where central sensitisation is found (Meus & Nijs, 2007; Nijs, 2009; Chen 
et al. 2015; Pak et al. 2018). 
 
Nijs et al. (2010) provided a detailed explanation of the potential relationship 
between musculoskeletal issues and central sensitisation in chronic pain (Figure 1-





1.3.4. Risk factors for chronification 
Despite the mechanisms of chronification being uncertain, multiple studies have 
identified risk and remission factors for migraine progression. These include 
medication over-use; elevated frequency of migraine at baseline; psychological 
comorbidities, particularly depression and anxiety; obesity, and being female 








Image redacted Fig 1. Page 136. Nijs, J., Van Houdenhove, B. and Oostendorp, R., 
2010. Recognition of central sensitization in patients with musculoskeletal pain: 
Application of pain neurophysiology in manual therapy practice. Manual Therapy, 15 (2), 
135-141 
 
Figure 1-8. Simplified display of nociceptive processing in the nervous system. 
(adapted from: Nijs et al. 2010)  




Although depression and anxiety have both been associated with chronic migraine 
for many years, the exact balance and prevalence vary between study authors, 
populations, and measurement tools. Smitherman et al. (2009) estimated that 
anxiety and depression are found in 25% and 66% respectively of chronic 
migraineurs, compared to 14% and 48% in episodic migraineurs. Overall, there is 
evidence to suggest that chronicity of symptoms is associated with higher levels of 
both anxiety and depression (Rossi et al. 2005; Chen et al. 2012; Oh et al. 2014; 
Tome-Piris et al. 2017; Seng et al. 2017).  Schwedt et al (2014) provided a more 
comprehensive list of these risk factors (Table 1.4), with the potential 





Table 1-4. Risk factors associated with migraine chronification and reversion 
x  
Table redacted. Table 1 page 3 Schwedt, T., 2014. Chronic migraine. BMJ, 348 









(Adapted from Schwedt. 2014) 




     
The neurobiological and the allostatic models outlined above present an argument 
for migraine and its chronification being a complex and not fully understood process. 
Blumenfeld et al. (2012) highlighted that migraine is a syndrome, with probable 
multiple pathogenic mechanisms involved in its presentation, logically lending itself 
to the possibility that there may be multiple therapeutic options besides 
pharmacological treatments (Gaul et al. 2011; Wallasch et al. 2012; Diener et al 
2015; Gaul et al 2016; Cho et al. 2017; Grazzi & D’amico.2019). 
 
1.4. Role of manual therapy in pain conditions 
As part of this narrative review, this section outlines a theoretical basis for the 
treatment of headaches with MT based on models and evidence for the benefit of 
MT in conditions with similar symptoms and pathophysiology.  
 
 
1.4.1. Overview of manual therapy  
 
For the purposes of this PhD study the definition of manual therapy is defined as a 
hands-on approach utilising mobilisation, manipulation and soft tissue work singly or 
in combination (Farrell & Jensen.1992; Bronfort et al. 2010; Moore et al. 2017). This 
is distinct from physical therapy which can include MT but also extends to include 
exercise; the use of equipment and, acupuncture.  However, the definition of MT 
differentiates the three modalities.  Manipulation used by manual therapists is often 
called “high-velocity, low amplitude (HVLA) thrust joint manipulation”. This is often 
referred to as “spinal manipulative therapy (SMT)”, or “manipulation”. It involves a 
fast thrust into a joint to establish normal motion and may be accompanied by an 
audible release. Mobilisation is rhythmic motion aimed at improving the motion of 
joints and or soft tissue. It can be done actively or passively (Hengeveld et al. 2014). 
 
 
Image redacted Fig 1 page 459. May, A. and Schulte, L., 2016. Chronic migraine: 
risk factors, mechanisms and treatment. Nature Reviews Neurology, 12 (8), 455-
464. 
 
Figure 1-9. Multiple factors contributing to chronification.  (May & Schulte, 2016) 




Soft tissue work can involve a number of different techniques, including trigger point 
work, soft tissue release, muscle energy techniques and myofascial release  
 
Bialosky et al. (2009; 2018) proposed that MT has two fundamental effects; 
biomechanical and neurophysiological. The mechanical force from the MT 
intervention results in neurophysiological responses that affect pain inhibition via 
both the peripheral and central nervous systems. This theory has been supported by 
studies and systematic reviews, each of which shows MT to produce central 
hypoanalgesia and activation of the descending anti-nociceptive pathways, which 
are thought to be involved in central sensitisation and migraine pathogenesis 
(Wright. 1995; Taylor & Murphy. 2010; Voogt, et al. 2015; Muhsen et al. 2019).    
 
However, although the effects of each method of MT may be similar, including 
improved range of motion, decreased muscle tension and reduction in localised 
pain, the mechanism of each method and the clinical relevance of the changes in 
pain inhibition remain unclear. It has been suggested that each modality may or may 
not work through the same neurophysiological pathways (Bialosky et al. 2009; Clark 
et al.2012; Bishop et al.2015; Vigotsky & Bruhns. 2015; Bialosky et al. 2018).   
 
The main neurophysiological pathway for the development of migraine and 
headaches is thought to be via localised nociception and the trigeminocervical 
complex, linked to structures in the cervical spine (Bartsch & Goadsby, 2003), 
suggesting that MT at this level should be the primary target. However, the concept 
of regional interdependency (RI) proposes that dysfunction in a remote anatomical 
area can contribute to or affect the patient’s primary condition and, as a result, MT 
aimed at dysfunction in this remote area may affect the primary condition (Wainner 
et al. 2007; Sueki et al. 2013; McDevitt et al. 2015) Thus, to gain maximum benefit 
from MT in a clinical setting, dysfunction in areas outside of the cervical spine 
should be considered as part of the MT intervention. Studies have demonstrated the 
RI between the cervical thoracic regions that result from the many muscular and 
ligamentous structures extrinsic to the cervical spine. These exert direct and indirect 
forces on the joints, soft tissue and other potentially pain generating structures. This 
may be seen, for example in the connections from the thoracic spine to the cervical 
via the trapezius, longissimus and splenius muscles and the spinal ligaments. As 
such, it has been shown that neck pain and mobility can be improved via thoracic 
MT (Sueki et al. 2013; McGregor et al. 2014; Karas et al. 2016; Engell et al. 2019) 





Whilst all of the above are theories that require further work to establish 
mechanisms and clinical relevance, they do offer a working rationale for the use of 
MT in migraine and in areas away from the cervical spine (details of the MT used in 
this study are provided in Appendix 11). 
 
 
1.4.2. Chronic pain and chronic migraine 
The theories of migraine pathophysiology and the allostatic model highlight many 
commonalities between chronic migraine and other chronic pain conditions, in terms 
of potential mechanisms, risk factors and the refractory nature towards similar 
treatment approaches.  
 
Whilst there are differences between CM and those conditions typically classed as 
chronic pain (low back pain, neck pain, fibromyalgia, osteoarthritis) these differences 
are often related to the specifics of location and type of autonomic disturbances 
(Cortelli & Pierangeli. 2003; Crofford. 2015). However, like CM, the majority of 
chronic pain conditions are associated with reductions in activity, sleep 
disturbances, fatigue and mood changes, and many involve severe disability. All are 
characterised by continuing pain/symptoms that no longer reflect measurable 
damage to tissue, combined with central sensitisation and, in many cases, allodynia 
(Bonavita et al. 2018; Pak et al. 2018; Manion et al. 2019).  
 
More recently there have been attempts to group chronic pain conditions based on 
their underlying similarities, indeed to re-code chronic pain conditions under a label 
of Chronic Primary Pain. ICD 11 (Nicholas et al. 2019): defined as pain in one or 
more anatomical regions that   (1) persists or recurs for longer than 3 months  (2) is 
associated with significant emotional distress (eg, anxiety, anger, frustration, or 
depressed mood) and/or significant functional disability (interference in activities of 
daily life and participation in social roles) and (3) the symptoms are not better 
accounted for by another diagnosis.   
 
Beneath this general definition lay primary chronic pain conditions, including chronic 
widespread pain (e.g. fibromyalgia), chronic headache (e.g. CM and CTTH) and 
chronic musculoskeletal pain (e.g. chronic cervical, thoracic and lumbar pain as well 
as chronic limb pain).  





All of these conditions are considered multi-faceted syndromes, often with significant 
overlapping or co-occurances, known as chronic overlapping pain conditions 
(COPCs). One hypothesis is that COPCs often co-occur because of common 
neurobiological vulnerabilities. These views, particularly combining physical with 
psychological components including the impact of stress, are also consistent with 
earlier models of migraine being a pain condition. Bussone et al. (2012) considered 
that Melzack's neuromatrix model (Melzack, 2001) was an effective model for 
chronic migraine (Figure 1-10).  CM was viewed as chronic pain in which the output 
from the body’s self neuromatrix produced changes in perception, homeostasis and 
behaviours after an injury, pathology or chronic stress; in a manner similar to those 
proposed in biopsychosocial and allostatic models. The neuromatrix theory 
considers that pain involves the distributed brain neural network rather than simply 
being a direct response to sensory input from injury, inflammation, and other 




The common underlying neurobiological and psychological processes proposed in 
the COPCs suggests a potential for the use of similar multi-modal treatment 
approaches, as outlined below.   
 
Despite NICE (2020) in the UK stating that a ‘number of commonly used drug 
treatments for chronic primary pain have little or no evidence that they work and 
shouldn’t be prescribed’ for all of the chronic pain disorders, in the UK the mainstay 






Image redacted  Figure 1 page 1382 Melzack, R., 2001. Pain and the Neuromatrix 
in the Brain. Journal of Dental Education, 65 (12), 1378-1382. 
  
Figure 1-10. Melzack’s neuromatrix (Melzack. 2001) 




pain with the NICE guideline on pharmacological management of neuropathic pain 
in adults recommending amitriptyline, gabapentin or pregabalin as initial treatment 
for neuropathic pain. These are some of the same choices provided for CM and for 
which the evidence is weak or non-existent e.g. gabapentin was removed from NICE 
guidelines for CM in 2015.  However, the most recent medications developed and 
licensed for CM (post this doctoral research study) are CGRP medications which 
were earlier examined for widespread chronic pain (Iyengar et al. 2017; Schou et al. 
2017). 
 
A recent evidence assessment by NICE as part of the guidelines for chronic pain 
(NICE, 2020) involved a systematic review of 46 studies of psychological therapy of 
which fibromyalgia studies represented 74%, with cognitive behavioural therapy 
(CBT) as the treatment for fibromyalgia representing 41% (19). It also produced a 
similar systematic review of 16 studies for MT and chronic pain which included 45% 
chronic neck pain and 30% fibromyalgia studies. The reviews concluded that 
psychological modalities (CBT and acceptance and commitment therapy [ACT]) and 
manual therapy (manipulation, mobilisation and soft tissue) modalities all offered 
potential for the treatment of chronic pain despite almost all of the studies being 
considered low quality. A suggestion for more research into the use of MT was also 
made.  However, a similar review by NICE (2012; 2016) for CM concluded that 
whilst psychological interventions (CBT) and MT (mobilisation, manipulation, soft 
tissue/stretching techniques) are used and recommended for people living with 
chronic painful disorders, more evidence is required for CM. 
 
The above UK summary suggests that many of the approaches for chronic pain 
treatment are beset by the limitations found in treatments for CM but also that those 
treatments developed for either condition may also offer benefit for the other. 
 
The intervention chosen for this study was manual therapy as opposed to the 
psychological or pharmaceutical options despite more research needed in all fields. 
The rationale was built partly on the use of MT in in treatment of similar chronic 
conditions including musculoskeletal pain, chronic widespread pain (e.g. 
fibromyalgia) and the requirement for more research into MT and CM and the 
professional background of the author.  The next section in this narrative review 
explores support for the range of MT interventions used in pain studies. 
 






1.4.3 Overview of manual therapy modalities in pain conditions 
Bronfort (2010) and the Warwick review (2014) both concluded that there was 
positive evidence for SMT in acute and chronic low back, migraine and various 
forms of neck pain. SMT for back pain gained more positive support in a recent 
systematic review (Paige et al. 2017) whilst Coronado et al. (2017) concluded that 
SMT seems to modulate the pain of pressure point threshold (PPT) through the 
CNS and PNS pathways. SMT had a positive effect compared with other 
interventions on increasing PPT with some subgroups experiencing a reduction in 
pain sensitivity at sites distant to the application of SMT.This indicates a possible 
influence on the CNS at higher levels. Whether SMT was better than other types of 
MT in the treatment of pain could not be elucidated from reviews of SMT and pain 
(Schmidt et al. 2008; Voigt et al. 2014). 
 
Soft tissue massage has been used for many years with a range of different 
musculoskeletal conditions. A recent systematic review of 26 studies concluded that 
massage improves function and reduces pain in the shoulder, pain from 
osteoarthritis of the knee and low back pain (Bervoet et al. 2015).  Trigger point 
therapy has been used for headaches for many years and was first clinically 
elucidated by Travell in the 1950's (Shah et al. 2015) when it was observed that 
head pain was noted to be linked to certain muscular trigger points. An earlier study 
of 98 participants found trigger points in 94% of migraineurs compared with only 
29% in a control group (Calandre et al. 2006). In the study of Calendre et al. (2006) 
the number of individual migraine trigger points correlated with the frequency of 
migraine attacks and the duration of the disease, indicating that pain and migraine 
chronicity are potentially linked (Stuginski-Barbosa et al. 2012).  Systematic reviews 
(Li et al. 2013; Yuan et al. 2015) concluded that there was moderate evidence from 
consistent findings among multiple low-quality randomised trials; controlled clinical 
trials and, one high-quality randomised trial with small but positive, clinically relevant 
effect sizes (Cohens 0.1-0.3) for myofascial release on fibromyalgia symptoms. 
Castro-Sanchez (2011) compared a placebo group with massage in 60 FMS 
patients in an RCT with similar outcomes. Consequently, approaches to the 
treatment of fibromyalgia (FMS) suggest more rationale for manual therapy and 
chronic migraine.    
 




Support for MT (specifically trigger points) also comes from the use of Botox in the 
treatment of CM. Injection sites are determined according to a standard called the 
PRE-EMPT protocol: Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy 
(Ranoux et al. 2017).  These sites are typically in the same place as common active 
trigger points associated with headaches (Figure 1.11). In their analysis of Botox 
PRE-EMPT studies Silberstein et al. (2017) suggested Botox works by reducing 
peripheral sensitisation, which in turn reduces central sensitisation; requiring 
repeated doses for best effect, in a process similar to that proposed for MT. It is 
proposed that this inhibition of nociception in the peripheral trigeminovascular 
system reduces mechanical pain signals to the spinal trigeminal nucleus, which 
leads to a cascade of other neurophysiological effects (Burstein et al. 2014; Do et al. 
2018).  Jakubowski et al. (2006) also concluded the success of Botox with migraine 
pain involves extracranial sensory fibres near the injection sites and speculated the 
involvement of activation of extracranial nociceptors of scalp tissues, bone and 
periosteum. A further mechanism of action has been proposed for Botox whereby it 
relaxes muscles by inhibiting acetylcholine (Ach) release resulting from the muscle 
trigger points. The reduction in peripheral nociception via both MT and Botox has 
been explained by a reduction of sensitisation in the mechanoreceptors with 
inhibition of C fibres, decreasing activation of muscle spindles along with the 
reduction in, and mediation of, inflammatory neurotransmitter actions. Whilst the 
neurotransmitters involved in Botox and MT are not the same, there is considerable 
overlap, including substance P, dopamine, serotonin and acetylcholine (Vigotsky & 
Bruhns. 2015; Do et al. 2018). It has also been proposed that the actions of both 
Botox and MT are not just at the neuromuscular junction but also the spinal and 
supraspinal levels. This provokes an (indirect) effect on the CNS via plastic changes 
resulting, in part, from modulation of the peripheral sensitisation. These mechanisms 
of action for Botox and MT have commonality and suggest potential 
neurophysiological effects of MT in migraine and pain. 
 
Images redacted. Fig 3 page 46, Robertson, C., Robertson, C. and Garza, I., 2012. 
Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine. 
Neuropsychiatric Disease and Treatment, 35.   Figure 1 page 245 Calandre, E., 
Hidalgo, J., Garcia-Leiva, J. and Rico-Villademoros, F., 2006. Trigger point evaluation in 
migraine patients: an indication of peripheral sensitization linked to migraine 
predisposition?. European Journal of Neurology, 13 (3), 244-249. 
 Figure 1-11. Botox injection sites (left) soft tissue MT trigger points (right). 
(Calandre et al. 2006, Roberson et al 2012) 





1.4.4. Overview of manual therapy interventions in neck pain 
One of the most common areas of musculoskeletal pain associated with headaches 
and migraine is neck pain. The one-year prevalence of neck pain in those with 
primary headache has been estimated at 85% compared to 57% without headache 
(Calhoun et al. 2010; Ashina et al. 2014). This is even more so with chronic migraine 
in which people with CM are four to five times more likely to have moderate or 
severe neck disability compared to those with episodic migraine (Florencio et al. 
2014; Ranoux, et al. 2017). Limitations to both of these studies highlighted that 
neither had a control group or placebo and Florencio et al (2014) used the neck 
disability index (NDI) which captures a range of factors that are common to both 
neck pain and migraine headaches making it difficult to disentangle effects. Ranoux 
et al (2017) also had a relatively small sample size (n=57) in comparison with similar 
studies.  
 
Although varying levels of evidence exist for MT and improvements in chronic neck 
pain, the involvement of the upper cervical joints specifically has long been held as a 
source of nociceptive input in the pathogenesis of headache. Some authors have 
proposed that a reduction in the input via MT may help reduce headaches and 
migraine (Figure 1.12) Bartsch, 2003; Wanderely et al 2015; Lin et al. 2018; Castien 













One study of 55 females found a positive relationship between both episodic and 
chronic migraine and dysfunction in the upper cervical spine, with 83%-93% having 
pain compared to 23% in healthy controls (Ferracini et al. 2017). Various forms of 
 
 
Image redacted Figure 1 page 373. Bartsch, T. and Goadsby, P., 2003. 
The trigeminocervical complex and migraine: Current concepts and 
synthesis. Current Pain and Headache Reports, 7 (5), 371-376. 
 
Figure 1-12. Cervical spine in head pain  (Bartsch & Goadsby. 2003) 




manipulation and mobilisation (including chiropractic and osteopathic) have been 
shown to help with chronic neck pain, although the evidence from good quality 
studies is still limited. Vernon et al. (2007) found moderate to high-quality evidence 
that in randomised groups receiving a course of spinal manipulation or mobilisation 
for chronic neck pain there were effect sizes of between 1.2 and 3.2 at 6 weeks and 
clinically relevant benefits up to 104 weeks post-treatment. Gross et al. (2010) 
examined 27 RCTs and suggested that there was moderate quality evidence for 
improvements in pain relief and function for cervical manipulation and mobilisation in 
people with neck pain. However, none of the trials analysed in Vernon et al. (2007) 
had a placebo group and the less than half of all studies had a sample size of 
greater than 50, which although typical of MT studies impacted on the overall quality 
of evidence.  In Gross et al (2010) there was also considerable variation between 
the MT approaches used with only 25% of the manipulation trials considered low in 
bias using the Cochrane methodology. 
 
Soft tissue therapy of different forms has been shown to help with neck pain. An 
RCT with 64 chronic neck pain patients found that therapeutic massage produced a 
40% reduction in the Neck Disability Index (NDI) after 4 weeks compared to the use 
of an educational booklet at 14% (Sherman et al. 2009). However, these outcomes 
were weakened by the fact that one in five of the booklet group visited a chiropractor 
during the study and few had chronic or severe neck pain and, as with many MT 
studies, there was no placebo group.  In a randomised controlled trial (RCT) of 122 
women, Häkkinen (2007) found that both manual soft tissue intervention and self-
stretching reduced chronic neck pain by between 50% and 60% after 4 weeks. 
Although a large study by MT standards the findings were limited by the volunteer 
self-selection process used for inclusion and a lack of medium to long term follow 
up. Two systematic reviews also found favourable evidence for both spinal 
manipulation and mobilisation with and without soft tissue work for chronic neck pain 
(Bronfort et al. 2010; Clar et al. 2014). Bronfort et al. (2010) concluded that the 
evidence was of moderate quality for most of the studies that combined 
manipulation, mobilisation and some soft tissue work. Clar et al (2014) added new 
information to the above study and came to similar conclusions with the combination 
of manipulation and mobilisations favourable and those for cervical manipulation 
alone inconclusive. 
 




In summary, the allostatic and neurobiological models both offer a mechanism of 
migraine and its chronification that has commonality with the mechanism of pain and 
its chronification in other disorders.  Since MT has been shown to help to varying 
degrees in the management of a of other chronic pain conditions, including neck 
pain it is suggested there may be a role for the use of MT the management of 
headaches and in particular CM. The basis for this is discussed in the next section. 
1.5. Overview of manual therapy in headaches  
 
1.5.1. Tension-type headaches 
A number of studies have examined MT and tension-type headaches. One of the 
earliest, Boline et al. (1998), was an RCT of 150 participants. This compared the 
efficacy of MT to that of prophylactic medication, amitriptyline, in the management of 
chronic tension-type headache. The primary outcomes, headache pain intensity, 
headache frequency and over-the-counter medication usage were collected using a 
diary. During the treatment phase both groups showed similar reductions in all 
factors. However, 4 weeks after the treatment phase the SMT group had reductions 
of 32% in headache intensity, 42% in headache frequency, 30% in medication 
usage and 16% improvement in functional health compared to baseline figures. In 
contrast, the amitriptyline therapy group showed no improvements, or were slightly 
worse compared with baseline figures, with 80% of the medication group having 
side effects compared to 4% in SMT. 
 
Chaibi and Russell (2014) completed the first systematic review of the efficacy of 
manual therapy RCTs for primary chronic headache. They identified six studies, all 
of which were chronic tension-type headache. Only one (Toro-Velasco et al. 2009) 
was a purely MT intervention (head and neck massage) versus a sham (detuned 
ultrasound). Whilst the outcomes favoured the MT with a 24% reduction in 
headache intensity compared to 3% in the sham, the study was a pilot with only 11 
participants and its primary focus was not on headache disability but immediate 
heart rate variation. All of the other studies involved varying physical therapy (PT) 
interventions including exercises. However, at the time, Chaibi and Russell (2014) 
noted that no studies investigating chronic migraine and MT existed and suggested 
this should be a focus for future work. 
 
Espi-Lopez et al. (2016) conducted an RCT focussed on the benefits of SMT and 
massage versus massage alone. It used the headache disability index (HDI) as the 




primary outcome and was powered at 90% p<0.05 (n=105, 70% female). The 
results showed a substantial improvement in the HDI scores for both groups but the 
combined group had a greater reduction in headache frequency across all data 
points compared to the control group.  A similar study by Ferragut-Garcias (2017) 
used a three- arm RCT with 97 participants of whom 80% were female. The primary 
outcome (HIT6 score) was clinically and statistically significantly reduced using a 
combination of neural mobilisation and soft tissue work. Those receiving neural 
mobilisation or soft tissue techniques each had an 8-point reduction on the HIT6 
score, which is considered a clinically significant change in tension-type headaches, 
with the combined treatment producing a reduction of 9.8 points.  
 
Lozano-Lopez et al. (2016) evaluated MT (not physical therapy) in tension-type 
headache in a systematic review of 14 headache RCTs. The Jadad measure of RCT 
quality was used, with 12 of the 14 considered of acceptable quality (Jadad>3). All 
of the studies showed positive results, particularly in the reduction in headache 
intensity frequency, reduction of medication usage and improvements in the quality 
of life. Mobilisation and manipulation techniques were used in four of the studies, 
soft tissue therapy in five and a combination of approaches in five. Twelve studies 
used headache diaries to record data although only three used the validated HIT6 
measure to record disability. Some of the studies also included mixed groups of 
headache type and only three had sample sizes greater than 50 with power 
calculations being absent in most. The conclusion was positive for MT with respect 
to improvements in headache frequency, intensity, and quality of life compared to 
placebo or standard care. However, Lozano-Lopez et al. (2016) highlighted issues 
around the lack of homogeneity in design, the use of different outcome measures 
and approaches to interventions.  More high-quality studies were recommended that 
focused on specific headache types as they all have different pathophysiological 
mechanisms, and are likely to respond differently to manual approaches. 
Wandereley et al. (2015), in a systematic review of six papers on headache relief 
from MT, came to a similar conclusion, highlighting the absence of clarity in terms of 
techniques used and the lack of power calculations as reasons for ambiguity in the 
evidence for MT and headaches. In summary, despite an increased number of 
favourable RCTs utilising manual therapies for tension-type headache there are still 
only a limited number of high-quality studies. 
 




1.5.2. Migraineous headaches 
Chaibi et al. (2011) evaluated six RCTs that included massage therapy and 
chiropractic manipulative therapy. Only five were manual therapy (excluding 
exercise) and only three studies had migraine diagnosed by a neurologist in line with 
current ICHD guidelines (Tassorelli et al. 2018). The remaining three studies were 
diagnosed by questionnaire and one by a chiropractor. The analyses led Chaibi et 
al. (2011) to comment that the included RCTs suggest MT might be equally efficient 
as propranolol and topiramate in the prophylactic management of migraine. Nelson 
et al. (1998) included a measure of the adjunctive benefit of chiropractic spinal 
manipulative therapy (CSMT) by comparing three groups: CSMT; Amitriptyline; 
Amitriptyline and CSMT combined. The reduction in headache index scores 
compared with baseline was 49% for amitriptyline, 41% for the combined group and 
40% for CSMT alone. Thus, the combination did not show any benefit over 
medication alone. However, in the post-treatment period (one month) the reduction 
was 42% for CSMT alone and 25% for amitriptyline. 
The study of Chaibi et al. (2011) has been analysed in several systematic reviews 
and each concluded something different depending on the process of analysis used. 
Bronfort et al. (2001) highlighted the decreases in medication use and longer-term 
maintenance of effect for SMT, although the primary outcome measure (headache 
index) showed no difference between groups. The methodology scored 87% but 
concluded the trial’s design was not for equivalence and was underpowered. Bryans 
et al. (2011) had similar conclusions and gave it a quality rating of 5/10. However, 
Pozadzki & Ernst (2011) concluded there was no difference between groups, 
although these authors failed to discuss any findings other than the primary one 
(headache index).   
 
The other four studies in evaluated in Chaibi et al. (2011) used different 
interventions: massage therapy (Hernadez-Reif et al. 1998; Lawler & Cameron. 
2006), cervical manipulation (Parker et al. 1978), and chiropractic SMT (Tuchin et al. 
2000). Hernandez-Reif et al. (1998) demonstrated a mean reduction of 71% in pain 
intensity post massage intervention and unchanged in the control group, Parker et 
al. (1978) compared SMT delivered by a medical professional, physiotherapist and 
chiropractor, with mean reductions in attack frequency of 13%, 34% and 40% and in 
intensity of 12%, 15% and 43% in each of the three groups respectively. The 
outcomes in Tuchin et al. (2000) were statistically better in the SMT than the control 
group for migraine frequency, disability and medication use. The frequency of 




headache from baseline to the two-month follow-up was reduced by 35% in the SMT 
group and 17% in the control. Lawler and Cameron (2006) conducted a two-arm 
randomised study with 48 participants of massage versus diary control in migraine 
(in which 80% were females). The overall outcomes were in favour of massage, 
which had a reduction in frequency of migraine but not intensity, with the control 
group having neither. Although this study’s primary outcome was the stress 
response, with migraine frequency and intensity as secondary measures, the results 
were marred by a lack of valid measurement instruments, such as HIT 6, and of 
power calculations. 
 
Apart from Lawler and Cameron (2006) there are few other recorded studies of 
massage and migraine.  Jahangiri Noudeh et al. (2012) used massage and spinal 
manipulation of the upper back and cervical spine in 10 migraineurs. Pain was 
assessed using a verbal analogue scale with post-treatment pain reduced by 50% in 
eight of the ten patients. However, this was a poorly designed study with no control, 
no validated outcome instruments, and all of the patients were male i.e. not a 
representative sample of migraine patients. The measurements were also taken 
after one hour with patients still in the clinic, which is most likely to have raised the 
placebo response. Voight et al. (2011) conducted the first recorded RCT of 
osteopathy and migraine in females. The study design had several weaknesses 
including a lack of both power calculation, for sample size, and primary outcome 
measures. The participants were also diagnosed with migraine via a telephone 
discussion. There was no blinding and the control group received no active 
intervention. However, the validated HRQoL and MIDAS instruments were used to 
measure outcomes with the osteopathic group observing a reduction of four days 
per month in their headache days compared to no change in the ‘care as usual’ 
group.  
 
Chaibi et al. (2016) conducted a three-arm migraine-chiropractic RCT: sham 
manipulation (placebo); chiropractic manipulation; and treatment as usual 
(medication, control), involving 105 migraineurs. The location was a tertiary clinic 
and 80% of participants were female. Although the primary outcome (reduction in 
headache days/month) was similar for each group, the placebo and manipulation 
groups maintained the improvements at the follow-up times of 3, 6 and 12 months, 
whereas the control group returned to base line. Medication usage was statistically 
reduced in the chiropractic group compared to the placebo and control. Despite this, 




Chaibi et al. (2016) concluded that the effect in the manipulation group was most 
likely placebo. However, Chaibi limited the MT to Gonstead chiropractic which is not 
as well used as the analysis suggested (Cooperstein 2003) as it is a technique that 
requires radiographic intervention prior to treatment (placebo and manipulation 
groups had a full spinal x-ray prior to the study). No mobilisation or soft tissue work 
was performed which may have limited the results as previous research suggests 
that a combination of manipulation, mobilisation and soft tissue technique is more 
beneficial than a single intervention.  
 
Two recent systematic reviews of primary headaches, including both tension-type 
and migraine were completed by Falsiroli Maistrello et al. (2018; 2019). The first 
considered the effectiveness of trigger point therapy in reducing the frequency, 
intensity, and duration of attacks in primary headaches (Falsiroli Maistrello et al. 
2018). The conclusion from the review, comprising five TTH and two migraine 
studies, was that trigger point therapy when compared to minimal active intervention 
was favourable, but the evidence was of low to very low quality. Particular issues 
were highlighted with the heterogeneity of study design, including small sample 
sizes and high risk of bias. The second systematic review (Falsiroli Maistrello et al. 
2019) was specifically of MT in primary headaches, including migraine and tension-
type headaches. The conclusion was that MT when compared to placebo or ‘care as 
usual’ should be seen as an effective approach to improving the quality of life in 
these conditions. However, it also reflected many of the criticisms of previous 
studies highlighting the low quality of evidence and the need for suitable control 
groups and the use of headache specific outcome measures. 
 
Only one recent systematic review was found that specifically examined the effect of 
MT (spinal manipulation) on migraine pain and disability (Rist et al. 2019). In total 
seven studies were included: six migraine and one CM, however due to anomalies 
in the CM study (Cerritelli et al. 2015), it was excluded from the final analysis. The 
results from the remaining studies were favourable for MT, although the effect size 
for reduction in both disability and pain were small (Hedges’ g = - 0.35 [95% CI -0.5, 
-0.16]). The final conclusion was tempered and considered preliminary due to the 
variation in study quality. 
 
Few studies have compared MT as an adjunctive to medication. Bevilaqua-Grossi et 
al. (2016) studied the adjunctive effect of manual therapy (soft tissue, mobilisation 




and traction plus medication) to normal pharmacological treatment in 50 female 
migraineurs. A significant improvement was seen in both groups for headache 
frequency post-treatment but no significant difference was observed between 
groups. At post-treatment there was an 18% greater reduction in mean frequency of 
headaches in physiotherapy plus medication patients compared to control patients. 
Although the active group had a 12% greater reduction than the control during the 
follow-up period, this difference was not statistically significant. However, the global 
perception of change was statistically significantly higher in the combined 
intervention group than in the control. Ghanbari et al. (2015) examined the use of 
trigger point therapy as an adjunctive to medication in a smaller study of 44 
migraineurs. The main outcomes of headache frequency; intensity; duration and, 
medication usage were all reduced in both groups, but with a statistically significant 
difference in favour of the combined MT and medication group.  Although 
improvements were found in the frequency and intensity of migraines, with better 
perceived change and greater satisfaction than in the 'care as usual’ arm, both 
studies either failed to use, or report, standard measures of migraine impact such as 
MIDAS or HIT6. The balance of males to females (54% female) in Ghanbari et al. 
(2015) was also not typical of migraine studies or clinic attendees and may have 
affected the outcomes. 
 
1.6. Current treatment approaches for chronic migraine 
The evidence for current approaches to treating chronic migraine is mixed, with the 
mainstay treatment being medication. A comparison of European and North 
American/Canadian guidelines highlights considerable differences in the 
approaches and the underlying validity of each (European Headache Foundation. 
2020; Charles & Rapoport. 2019). The majority of guidelines suggest the use of 
Sodium Valproate, Gabapentin, Amitriptyline, Propranolol or Topiramate as first line 
prophylactic treatments. However, whilst these have been shown to help to varying 
degrees in episodic migraine, only Topiramate has been subject to randomised 
control trials in chronic migraine.   In recent years OnabotulinumtoxinA (Botox) has 
been the subject of a number of clinical trials in CM and is currently (at time of 
writing, the only product licensed for CM prophylaxis (Diener et al. 2010; Silberstein 
et al. 2013; Aurora et al 2014; Ahmed & Gooriah. 2015; Lipton et al. 2016; Young et 
al. 2019). The current UK NICE guidelines for headaches (NICE.org. 2016) 
recommend the use of Topiramate, Propranolol, or Amitriptyline, and if these 
treatments are not successful then a course of acupuncture.  If this fails, then Botox 




is the recommended option and is the most common treatment in tertiary clinics. 
International guidelines for the use of non-pharmacological approaches in migraine; 
including psychological therapy (CBT, ACT), massage, spinal manipulation 
(chiropractic, osteopathy), acupuncture and exercise are mixed. Some guidelines 
mention psychological approaches e.g. biofeedback and CBT, while others 
recommend physiotherapy as a generalised statement for MT. In the main however, 
specific guidance for multi-modal approaches is sparse (Jensen et al. 2012; Gaul et 
al. 2016). Despite the use and promotion of medications, their limitations were also 
highlighted. Most of the above medications have been developed and licensed for 
other conditions e.g. epilepsy, with use in migraine being “off label”, i.e. without 
license and often with little supporting evidence (Antonaci et al. 2009; Schwedt. 
2014; Schaefer et al. 2015; Al-Quliti and Assaedi. 2016). They are also all known for 
side effects and/or limitations in usage, particularly in women of child bearing age 
(most female migraineurs) sodium valproate is known to cause birth defects, and a 
2014 Cochrane review of gabapentin for the prophylaxis of episodic migraine 
advocated that it “should not be used in routine clinical practice” (Linde et al. 2013); 
Amitriptyline is not recommended for women who are pregnant, trying to become 
pregnant, or breastfeeding or for those with diabetes, heart conditions or serious 
psychological issues (UK NHS. 2021). A systematic review of 58 propranolol studies 
in migraine prophylaxis noted a high dropout rate due to side effects with little 




benefit over placebo (Jackson et al. 2018). Some early studies of Botox showed 
only marginal benefit in terms of the reduction in absolute headache days, and 
reductions in HIT6, with high placebo rates and a high cost mentioned (Aurora et al. 
2011; Aurora et al. 2014; Diener et al.2010; Dodick et al.2010; Frampton & 
Silberstein.2018).  Although Topiramate produces similar reductions, Botox has 
fewer side effects and a better adherence profile. A major factor in the use of 
medications for CM is the impact of side effects and when used for CM, Topiramate 
has been shown to have a drop-out rate of 24% in some studies as a result (Mathew 
et al. 2009, Rothrock et al. 2019).  For women, Topiramate is not recommended if 
pregnant or trying to conceive, and evidence for the use of acute migraine 
medications is uncertain (Cady & Schreiber, 2008, Khalil et al. 2014; Ahmed & 
Gooriah, 2015). Conversely, the side effects of MT are reported as minor in studies, 
normally short-term aches and headaches (Chaibi et al. 2017; Tabelli et al. 2019).  
Diener (2012) concluded that medication alone is not always an effective treatment 
for chronic migraine, and that a multi-modal approach involving neurologists, 
psychologists, and physical therapists is required (Jensen et al 2008; Gaul et al. 
2016; Cho et al. 2017). 
 
1.7. Summary and next steps 
This section outlined the rationale for examining the use of MT in chronic migraine 
by reviewing the pathophysiology of migraine, chronic migraine and the 
commonalities with other chronic pain (and often comorbid) conditions.  It proposed 
two models on which the basis for the use of MT could be argued, the 
neurophysiological model and the allostatic model, with environmental and 
biopsychosocial effectors.  To further build the rationale for a study into the use of 
MT in CM, a summary of findings from studies on the efficacy of MT for non-
migraine headaches and migraine was presented.  One of findings from the 
narrative review was the consistently greater impact, in all domains, of migraine on 
females compared to males and the increased rate of chronification seen in females. 
There was also a greater prevalence of comorbidities including anxiety, depression 
and pain conditions in female migraineurs compared to males, which are thought to 
be affected, in part, by female hormones and play a part in treatment response. 
This level of impact and associated conditions also fitted with my own clinical 
experience.  
 




However, despite the review providing an overall positive basis for further study it 
also highlighted criticisms of the low quality of research. Weaknesses included lack 
of homogeneity in study design, interventions, measurement tools and a lack of 
power calculations. The importance was also noted of focusing studies on specific 
types of headaches. These findings suggested that focusing on one gender and a 
specific headache, in this case CM and females, would provide a more robust study 
design.  
 
Having established a rationale for the study, a systematic literature review was 
undertaken to evaluate the current situation regarding the effect of MT on CM, to 
identify any gaps in research and to provide guidance on the study design. 




CHAPTER 2  SYSTEMATIC LITERATURE REVIEW  
2.1. Introduction 
The background to this study was outlined in Section 1. This discussed the 
theoretical and experimental basis for the use of MT in the treatment of CM using 
studies from pain management, neurology and headache management. Although 
the findings for its use are generally positive, the majority of the studies fail to 
provide high-quality evidence for the use of MT as a standalone therapy (Lozano-
Lopez et al. 2016; Falsiroli Maistrello et al. 2019). 
 
However, this is also the case with existing pharmacological approaches, under 
which some people do not benefit, fail to benefit to the extent expected, or 
experience side effects that reduce adherence (Aurora et al. 2014; Diener et 
al.2010; Dodick et al.2010; Frampton & Silberstein.2018).  This is unsurprising since 
the consensus is that migraine in all of its variants is a syndrome, with multiple 
mechanisms involved in its pathophysiology. This situation lent itself to the 
possibility that the use of concomitant multiple therapeutic options rather than a 
mono-pharmacological treatment may be a better approach (Gaul et al. 2011; 
Wallasch et al. 2012; Grazzi 2013; Burstein et al 2015; Gaul et al. 2016; Grazzi & 
D’Amico, 2019). Thus, rather than treating MT as a replacement to the usual 
pharmacological care of chronic migraine, it was considered more beneficial to 
examine it as an adjunctive intervention. 
 
A systematic review of the literature was undertaken to explore the current situation 
with regard to evidence for the use and effectiveness of MT in the treatment of 
chronic migraine and to provide support for the proposed RCT. Systematic reviews 
provide valid and reliable evidence, enabling rigorous conclusions to be drawn from 
a range of study designs (Bettany-Saltikov, 2010). Although designed to synthesise 
findings from a multitude of primary research sources, one of the strengths of the 
process is its rigour in finding relevant papers and enabling analysis utilising quality 
tools. Systematic literature reviews can also highlight gaps in research despite 
sometimes finding relatively few studies (Glasziou et al. 2010; Yaffe et al. 2012). 
 
Therefore, this systematic literature review aims to summarise what is known about 
the effectiveness of MT as a treatment in conjunction with, or separate to, 'care as 
usual' in chronic migraine.  




2.1.1. Review objective 
Specifically, the review sought to answer the question: 
 
What is the effect of manual therapy on people (females) with chronic 
migraine when added to 'care as usual'? 
 
2.1.2. Participants 
The participants for studies included in this review were drawn from studies of either 
gender over 18 years of age who were diagnosed with chronic migraine. However, 
when reviewing mixed-gender studies an attempt was made to delineate the 
outcomes by gender since the focus of the proposed study is exclusively females. 
This was an important decision as there have been shown to be significant 
differences between males and females in terms of disability from migraine.  Males 
are also thought to respond differently to pain than females and, in migraine, pain 
has been identified as the main determinant of disability in males compared to a 
broader range of factors in females (MacGregor et al. 2011; Scher et al. 2018; 
Sorge & Strath 2018). Moreover, the proposed primary outcome measurement 
instrument is the HIT6, for which Coeytaux et al. (2006) found that males had a 
significantly lower reduction in HIT6 change than females. In a mixed gender study 
these factors potentially skew the results and negatively impact transferability of 
findings in a clinical setting (Peterlin et at. 2011; Buse et al. 2013; Vetvik & 
MacGregor. 2017).  
 
2.1.3. Interventions and comparisons 
Data were extracted from studies that used MT alone or as an adjunct to other 'care 
as usual’ treatments in headaches and migraine to identify its use in chronic 
migraine. MT was defined as any variation of the terms mobilisation, manipulation 
and massage as applied by hands to the musculoskeletal system (Farrell & 
Jensen.1992; Bronfort et al. 2010; Moore et al. 2017). The variations are set out in 
the search strategy below. 'care as usual' was defined as the ongoing/normal 
pharmacological treatment in place and chronic migraine was defined according to 
the diagnosis by the International Classification of Headache Disorders 
(International Headache Society. 2018). 
 





The primary outcome evaluated was the difference in change scores in headache 
impact test 6 (HIT6), which is the most common outcome measure and the only 
instrument validated for all types of headaches. Other validated instrument of 
headache disability e.g. the Migraine disability assessment (MIDAS) and MSQ 2.1 
were also included. The secondary outcomes include impact of migraine-related 
symptoms as measured with validated questionnaires, including patient related 
outcome measures (PROM), reduction in the number of headache and migraine 
days, and changes in medication usage. 
 
2.1.5. Study design 
The review included randomised controlled clinical trials (RCTs), non/quasi-
randomised controlled trials (NRCTs) and cohort studies that together represent the 
highest levels of evidence (Burns 2011).  The study selection was limited to 
literature written in English and those for which full text versions could be obtained. 
The inclusion and exclusion criteria are listed in Table 2.1. 
 
 
Table 2-1. Literature search inclusion and exclusion criteria 
 
Inclusion criteria Exclusion criteria 
Adults aged 18 years or older with 
chronic migraine as diagnosed by a 
consultant according to ICHD 
classification 
Age of participants under 18 years 
Self-diagnosed chronic migraine 
Not chronic migraine 
Studies assessing manual therapy and 
headaches, migraine, chronic migraine 
with definitions as outlined above 
Studies using exercise therapy, 
acupuncture, needling and other non 


















2.2.1. Data sources and search strategy 
The following electronic databases were searched: Web of Science; Medline; 
PsychInfo; Cinahl complete; EMBASE; AMED; Scopus, and the Cochrane database 
of systematic reviews. In addition, platforms including Google Scholar, Open Grey, 
Science Direct and publishers, and Wiley were used to broaden the search. The 
search had date restrictions from 1988 to 2018 on the basis that this period covers 
current studies back to the introduction of modern migraine interventions such as 
the triptans. The search was updated during the writing process to include any new 
studies until January 2020. The first edition of the IHS Classification of Headache 
Disorders was followed in the 1990s with the introduction of the first migraine 
specific medications (Triptans). The general search terms and strategy is shown in 
Table 2.2; the specific search used for Web of Science, Table 2.3, was repeated, 
modified for the other electronic database formats, using MeSH terms whenever 
relevant, e.g. 'headache disorders' and 'musculoskeletal manipulations.'   
   
 
Table 2-2. Generalised search strategy terms  
(headings adapted for individual database format) 
Number  Search Terms 
1.  Migraine*   
2.  Headache*  
3.  Manual therap*  
4.  Chiropract* 
5.  Osteopath* 
6.  Physiotherap* 
7.  Massage 
8.  Spinal Manipulati* 
9.  Mobilis* 
10.  Mobiliz* 
11.  Myofascial 
12.  Trigger point* 
13.  Acupressure  
14.  Physical Therap* 
15.  Kinesiology 
16.  1 OR 2 
17.  3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
18.  16 AND 17 
  







2.2.2. Study records 
The initial screening search results were exported to Endnote referencing software 
and duplicates removed manually based on the titles and abstracts. Studies from 
other sources (e.g. dissertations) were managed manually. This was performed by 
the lead investigator (JO).  Those studies likely to be of interest from the title and 
abstract were examined in more detail for the relevant terms including chronic 
headache, chronic migraine and migraine, when linked to a MT intervention. Those 
studies requiring clarification were extracted for a full text search. Systematic 
reviews were assessed to identify additional relevant studies and avoid duplication 
(Appendix 1). The studies selected as relevant to the systematic review were then 
moved onto the data extraction phase. The study screening and selection process is 
documented and summarised in the PRISMA flow chart (Figure 2.1) and a summary 
of the overall number of studies considered is provided in Appendix 2. 
 
2.2.3. Data extraction 
The lead investigator (JO) performed data extraction on included studies using a 
Microsoft Word template in order to complete the inclusion and quality assessment. 
Data extracted included study design; migraine diagnosis; method; sample size; 
follow up duration; population characteristics; MT intervention(s), 'care as usual' 
intervention; outcome measures, and statistical analysis. In the case of missing or 
unclear details the lead investigator contacted authors for this information.  
 
 
Table 2-3. Web of science search strategy    
#1 (TS = (migraine or headache)) AND LANGUAGE: (English) AND 
DOCUMENT TYPES: (Article) Indexes=SCI-EXPANDED, CPCI-S, ESCI 
Timespan=1988-2018 
#2 TS=(("manual therap*") OR chiropract* OR osteopath* OR physiotherap* 
OR massage OR("spinal manipulat*") OR ("physical therap*") OR mobilis* 
OR mobiliz* OR myofascial OR ("trigger points") OR kinesiology OR 
acupressure ) 
Indexes=SCI-EXPANDED, CPCI-S, ESCI Timespan=1988-2018 
#3 #2 AND #1 
Indexes=SCI-EXPANDED, CPCI-S, ESCI Timespan=1988-2018 




2.2.4. Quality assessment 
Previous headache studies have been criticised for the low quality of methodology 
(Podaski & Ernst 2011; Wanderely et al. 2015; Falsiroli Maistrello et al. 2019). For 
this reason, each included study was assessed using a scoring mechanism 
specifically developed by Fernandez-de las Penas et al. (2006) for headache 
studies (Appendix 3) as well as the “Risk of Bias” tool (Table 2.4) from the Cochrane 
Handbook V.5.1.0.(Higgens & Green, 2011).  This uses factors to classify risk of 
bias as either uncertain, low or high (Table 2-5). This process was cross-checked by 
a professorial collaborator. Any disagreement was resolved by discussion. Level of 
evidence and recommendation are based on the OCEMB (Oxford Centre for 
Evidence-Based Medicine, 2011) criteria. 
 


























of bias  
 
  




 2.3 Results 
A total of 982 studies were identified with their titles and abstracts screened against 
the inclusion and exclusion criteria. In total, 27 studies were included in the full-text 
paper review. Of these 21 were excluded at the outset and four required further 
clarification with requests sent to the original authors for more detail (Appendix 4). 
This left two chronic migraine papers included in the review (Figure 2.1).  
 
 









(n = 726) 
Records identified through 
database searching. 
(n = 981) 
Additional records identified 
through other sources. 
(n =1) 
Records after duplicates removed. 
(n = 753) 
Records screened by 
Title and Abstract. 
Full-text articles 
assessed for eligibility. 
(n = 27) 
Full-text articles excluded 
 (Invalid, n = 21)  
(Awaiting author/full text 
response n =4) 
 See Appendix 4 for 
details
Studies included in 
quantitative synthesis  
(n = 2) 




2.4. Quality of evidence 
Previous research into headache and its management with MT has been criticised 
both for its paucity and low quality (Fernández-de-las-Peñas et al. 2006; Bronfort et 
al. 2010; Podaski & Ernst 2011; Wanderely et al. 2015). There are various indicators 
of quality for RCTs including the Jadad (Jadad et al 1996), PEDro (Sherrington et al. 
2000 and CONSORT (Consolidated Standards of Reporting Trials) (Moher et al. 
2010; Boutron et al.2017). The Jadad is easy to use but limited in scope with scores 
based on the answers to three questions: was the study (1) randomised (2) 
described as double blind and (3) description inclusive of withdrawals and dropouts? 
The PEDro Scale is more comprehensive with 11 questions covering allocation, 
randomisation, blinding, etc (Figure 2.2) but designed for physiotherapy and rarely 
used in headache studies and the most recent option was the CONSORT guidelines 
(including a version for Non-Pharmacological treatments) which is the commonly 
used, and most comprehensive with 25 items on the checklist, to report quality of 
RCTs. However, none of the above were developed for headache studies utilising 
manual therapy.  As such, two eligible chronic migraine studies were checked for 
methodological quality using an approach developed by Fernández-de-las-Peñas et 
al. (2006) specifically for headaches and MT interventions, with which a score of 
above 50/100 is considered good quality. Both studies were considered good to 
high-quality, with Cerritelli et al. (2015) scoring 69/100 and Gandolfi et al. (2017) 
scoring 51/100 (Appendices 5, 5a). In addition, both studies were also assessed as 
low in bias, using the Cochrane Risk of Bias, (Table 2.5), although the small sample 
size in Gandolfi et al (2017) raised ‘other bias’ to uncertain. 
 
 
Figure 2-2. PEDro scale 
 
 





Table 2-5. Cochrane risk of bias – identified studies  
                    Studies 
Cerritelli et al 
et al. 2015 








Allocation concealment   
PERFORMANCE BIAS 











Incomplete outcome data.   
  
REPORTING BIAS 
Reporting bias   
OTHER BIAS 
Other sources of bias 
  
 
Low bias High bias Uncertain bias                   
 
 
2.4.1. Level of evidence 
The overall level of the evidence for MT and chronic migraine in this review was 
established using the OECBM guidelines which provide clinicians with a simple, 
pragmatic measure of evidence for interventions, suitable for use when few RCTs 
exist. They do not give definitive recommendations on use but provide a guide as to 
whether the findings make credible clinical sense (OCEBM, 2011. Appendix 6). 
 
Using the OECBM method in which Level 1 is the highest quality (systematic review 
with homogeneity of RCTs) the level of evidence for this review is considered Level 
2 or 3; single RCTs without narrow confidence intervals; downgraded due to 
inconsistencies, including the lack of homogeneity in studies as a result of 
differences in; patient characteristics, the balance of males to females, intervention 
characteristics e.g. dose and timing, outcome measures e.g. factors and 
measurement instruments and study design.  





2.4.2. Data synthesis 
Both of the studies included focussed on chronic migraine with MT interventions, 
defined as ‘hands on’ techniques which aim to mobilise and manipulate soft tissue 
and joints.  The study of Cerritelli et al. (2015) was a 3-arm RCT and that of Gandolfi 
et al. (2017) was a 2-arm pilot RCT. Sample sizes were 105 and 22 respectively, 
making a total sample size of 127 participants. The participants ranged from 18 to 
66 years of age, with a pooled mean of 40.25 years. The studies included males and 
females with 31% being male. The percentage of females in Gandolfi et al. (2017) 
was higher and more representative of migraine studies (87% female versus 64% 
female in the study of Cerritelli et al.). Both studies took place in Italy and used the 
change in Headache Impact Test (HIT 6) as a disability outcome measure. However 
only Cerritelli et al. (2015) used it as the primary outcome measure. The secondary 
outcome measures included a variety of those recommended by the IHS; change in 
medication usage, headache days and headache intensity (Tassorelli et al. 2018). 
Gandolfi et al. (2017) also used the MIDAS assessment for disability as a secondary 
outcome measure and both studies used diaries to collect this information. Tables 
2.6 and 2.7 summarises the characteristics and outcomes. Gandolfi et al. (2017) 
also collected pain pressure threshold data on the trapezius, temporalis, occipitalis 
and frontalis muscles and data on coffee consumption and dietary restrictions. 
 
The duration of each study was 12 weeks (Gandolfi et al. 2017) and 24 weeks 
(Cerritelli et al. 2015) respectively. Gandolfi (2017) had a post-treatment phase and 
made a final clinical assessment at 12 weeks with an active treatment phase lasting 
four weeks from week four to week eight. Cerritelli et al. (2015) did not have a post-
treatment phase. 
 
Conventional pharmacological care was used in both studies, with Gandolfi et al 
(2017) using Botox in both arms in conjunction with the adjunctive MT treatment, 
whilst Cerritelli et al. (2015) used an unspecified medication regime (‘care as usual’) 
in 2-arms.  
 
Both studies used manipulative techniques designed to improve joint and soft tissue 
mobility. Cerritelli et al. (2015) used osteopathic techniques in an unspecified 
manner based on an initial assessment in the MT arm, whereas Gandolfi et al. 
(2017) specified the cervical spine C0, C1 and the thoracic spine, T3-T7. These 




were treated with low velocity high amplitude manipulation and the cervical spine 
underwent articulatory mobilisations. The study of Cerritelli et al. (2015) had three 
groups: MT plus ‘care as usual’ medication; sham MT plus ‘care as usual’ 
medication: medication ‘care as usual’ only. Gandolfi et al (2017) used 
transcutaneous electrical nerve stimulation (TENS) as a comparative to the MT with 
both groups receiving Botox as ‘care as usual’. 
 
The interventions were applied by six osteopaths in the study of Cerritelli et al 
(2015) and by two experienced physiotherapists, one for each arm, in Gandolfi et al 
(2017).  The MT regime was different in each of the two studies, with Gandolfi et al 
(2017) having four sessions of 30 minutes for four weeks (one per week) from week 
four to week eight, following an initial injection of Botox at week one.  Cerritelli et al 
(2015) used 8 sessions lasting 30 minutes, scheduled one per week in weeks one 
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This systematic review identified only two relevant studies, both of which had 
positive outcomes for MT in CM. This may be seen as too few papers for an RCT, 
however according to Cochrane handbook, “A systematic review attempts to 
identify, appraise and synthesize all the empirical evidence that meets pre-specified 
eligibility criteria to answer a specific research question”.  Whilst the centre for 
evidence-based medicine (CEBM) states the purpose of a systematic review as “to 
provide the best available evidence on the likely outcomes of various actions and, if 
the evidence is unavailable, to highlight areas where further original research is 
required” 
 
To this extent, the quality of the systematic review is not solely contingent on the 
number of papers identified; highlighting gaps in the evidence base may in fact 
support the need for research (Glasziou et al. 2010). There is no set minimum 
number of studies required for a systematic review, with one estimate of zero papers 
in 10% of reviews, which will often be the case in new or immature areas (Yaffe et 
al. 2012), whilst another study gave the median number of papers as six 
(interquartile range 3 to 12) (Mallett. 2003).  The proposed RCT is in an immature 
area and as such a systematic review with two papers was considered a valid 
outcome and consistent with other authors (Chaibi and Russell. 2014; Cerritelli et al. 
2016; Moore et al. 2017; Rist et al. 2019) who identified a lack of research in this 
area. Whilst the number of papers in itself was not seen as a weakness of process, 
the Cochrane approach to systematic reviews suggests that two people are involved 
in screening the relevant papers to avoid selection bias. Unfortunately, in this case 
the resources in a Doctoral PhD did not permit this.   
 
In addressing the impact of potential selection bias and the limitations imposed by 
only having two papers, it may be useful to revisit the primary aim of this systematic 
review.  It was not, as is usually case, to provide evidence for guidance on the role 
of MT in CM for clinical purposes but rather to identify the state of current research 
and provide guidance on the development of the protocol. Thus, the exclusion any 
papers would have served no useful purpose. 
 
 Bettany-Saltikov (2010) suggest that part of the systematic review process is to 
provide a critical review of the evidence, enabling rigorous conclusions to be drawn 
from a range of study designs. In this case, whilst the limited number of papers did 




reduce the depth of the conclusions to be drawn it did raise issues that were fed into 
the development the protocol. However, from a quality standpoint, apart from the 
lack of two people screening the papers, all other components of the process were 
completed according to the PRISMA guidance. 
 
2.5.1. Risk factors 
Both of the studies failed to address the impact of any modifiable risk factors for 
chronification e.g. stress (Scher et al. 2008).  Although Gandolfi et al (2017) 
measured dietary restrictions and coffee consumption, no analysis was presented. 
Gandolfi et al (2017) suggested in the discussion that future studies should consider 
the impact of risk factors on therapeutic response. 
 
2.5.2. Outcomes 
Both studies used the validated HIT6 as an outcome measure, although only 
Cerritelli et al (2015) used it as the primary outcome measure. Gandolfi et al. (2017) 
presented a non-significant change in HIT 6 score between groups of -3 [95% (CI -
5;3)], whilst Cerritelli et al (2015) produced statistically significant differences in 
changes (p<0.001) of -8.74 for the Osteopathic group (MT+'care as usual') 
compared to 'care as usual'. There was also a difference between (MT+'care as 
usual') and Sham (MT + 'care as usual') of -6.62; with a non-significant change of     
-2.32 for Sham (MT+'care as usual') compared to 'care as usual'. Cerritelli et al 
(2015) used a difference of 5 between groups and 27 within groups to power at 90% 
(p= 0.05) between baseline and post-treatment HIT6 scores. This resulted in a 
sample size of 35 per group although no calculations were provided of underlying 
assumptions on standard deviation in HIT6. However, the small sample size of 
Gandolfi et al (2017) study made the finding less powerful. Gandolfi et al (2017) also 
used MIDAS, another validated measurement of migraine disability, as a secondary 
outcome. However, unlike HIT 6, a minimal clinical difference had not been 
calculated for MIDAS.  
 
The majority of recent pharmacological studies into chronic migraine used 
responder categories as outcome measures, despite a lack of consistency in the 
definition and use of responder rates. The IHS guidelines (Tassorelli et al. 2018) 
define responder rates as either:  
1. The number of headache days with moderate or severe intensity 
2. The number of migraine days  




3. The number of migraine episodes.  
 
The IHS has suggested a reduction of ≥30% in any of the above measures as 
clinically meaningful (Tassorelli et al. 2018). Cerritelli et al (2015) also used 4-point 
Likert scales to assess the severity of pain on headache days and functional ability, 
whereas Gandolfi et al (2017) used a visual analogue scale (0 = no pain 100 = worst 
ever). Although these scales were included in the headache diary and are easy to 
use, it was difficult to correlate the results with changes considered important to the 
patient. Gandolfi et al (2017) concluded that the primary outcome had been met as 
the study was successful in terms of attendance for treatment and pain scores 
before and after each session. All patients completed the study and no significant 
differences between pre and post-treatment pain scores (VAS) were found (Table 
2.7). 
 
Medication use was reduced in both studies although usage was measured 
differently: Cerritelli et al (2015) used the number of people taking medications in 
addition to 'care as usual', whereas Gandolfi et al (2017) the consumption by type 
(Total, Triptans and NSAIDS). The results were statistically significant at p<0.001 
and p<0.009 (Table 2.7) for Cerritelli et al (2015) and Gandolfi et al (2017) 
respectively in MT groups. However, in Cerritelli et al (2015), the sham MT+'care as 
usual') and ('care as usual') groups failed to show any significant reduction in 
medication use. In this case it was difficult to compare the results apart from noting 
the significant decreases in both. 
 
2.5.3. Gender differences 
Whilst both studies included males and females in proportions generally consistent 
with the population studies of gender and migraine, they did not stratify the results. 
This limited any discussion on gender differences, despite CM being more prevalent 
and more disabling in females (Buse, 2012).  An important difference that may have 
influenced the results was the significant variation in the proportion of males in each 
group in Cerritelli et al. (2015).  The (MT + 'care as usual') group had 50% fewer 
males compared to the 'care as usual' group and 40% fewer than the Sham 
(MT+'care as usual') group. Coeytaux et al. (2006) found that males had a 
significantly lower reduction in HIT6 change than females and females are theorised 
to feel pain differently to men (Scher et al. 2018; Sorge & Strath 2018). 
  




 2.5.4. Side effects 
Side effects from MT were collected using a diary, with neither study reporting 
significant side effects. This was consistent with other MT studies despite concerns 
about the risk and side effects of MT. However, neither study used HVLA cervical 
rotation manipulations which have often been the focus for attention with regard to 
stroke (Carnes et al. 2010; MacPherson et al. 2015; Vaughan et al. 2016). 
 
2.5.5. Intervention and process 
The TiDier (Template for Intervention Description and Replication) checklist was 
developed to improve the descriptive reporting of interventions, in part to help 
clinicians to implement useful interventions, and for other researchers to replicate 
and build on research (Hoffman et al. 2014). 
 
Both studies provided detail on the intervention in line with the TiDier checklist 
(TiDier summaries Appendix 7). Although Cerritelli was less prescriptive than 
Gandolfi in the MT intervention itself, the type and manner of MT was well described 
in both. However even given the detail in Gandolfi, the exactness of the delivery of 
intervention will always come down to the manual therapist themselves. Gandolfi et 
al (2017) also had a planned and actual assessment of adherence – since this was 
one of the study objectives. Cerritelli et al (2015) on the other hand made no 
mention of adherence, although all participants completed the study. What is 
unknown is whether any switched groups. Cerritelli also failed to record any change 
(modifications) in the care as usual (medication) group regime, which was an 
important consideration given the impact a change in medication could have on 
outcomes.  
 
Cerritelli et al (2015) used MT and sham MT as an adjunctive intervention whilst 
Gandolfi et al (2017) used TENS in one arm as a comparator and MT in the other. 
The structure of the intervention process also varied with Gandolfi et al (2017) 
having a four-week run in, a four-week treatment and a four-week phase out 
compared to Cerritelli et al (2015) with a 24-week treatment phase. Clinical 
assessments were taken by Gandolfi et al (2017) at the start and end of the MT 
therapy treatment phase with the Botox being injected at week 0 and again at week 
12. Cerritelli et al (2015) made clinical assessment at the start and end of the 24 
weeks, concomitant with pharmacological ‘care as usual’ (triptans).  




There are no set protocols established for trials of this type although the IHS 
guidelines (Tassorelli et al.2018) recommend a minimum of 12 weeks for 
prophylactic migraine studies involving medication with a post-treatment follow up 
period. 
 
The number and frequency of treatments differed in each study. Cerritelli et al 
(2015) had 8 out of 24 weeks weighted towards the start whereas Gandolfi et al 
(2017) had 4 sessions equally spread over 4 weeks. There are no defined or 
recommended approaches to treatment protocols and other headache studies vary 
in approach often with no stated rationale. Cerritelli et al (2015) used a “needs-
based" protocol, appraised by the osteopathic evaluation, to determine the MT 
therapy treatment required in each session and used random light touch as the 
sham treatment. Gandolfi et al (2017) however used a pre-planned approach to 
using MT therapy and TENS. The issue of a pre-planned protocol and clearly 
identifying the location of intervention has been cited in the past as a weakness in 
MT studies, however one of the strengths of the ‘pragmatic’ approach, as adopted 
by Cerritelli et al (2015), is the similarity to real life clinical situations including the 
adjustment to each patient (Loudon et al. 2015, Forden & Norrie. 2016). 
 
The issue of tailoring the intervention was not constrained to MT in migraines and 
headaches, but also to pharmacological and psychological interventions where the 
need to produce a personalised approach is highlighted in medical literature (Belvis 
et al 2014; Probyn et al. 2015; Antonuci et al. 2016; Agostini et al. 2019). There is 
therefore an argument to say the best intervention protocol is one that has a broad 
evidence-based approach, within which individual pragmatic tailoring is used, based 
on clinical experience and observation.  
 
2.5.6. Limitations 
Despite the overall positive primary and secondary outcomes of the studies 
included, limitations were noted in both approaches. Firstly, blinding of practitioners 
or participants to allocation is difficult in MT which can add an increased placebo 
effect. Cerritelli et al (2015) attempted to address effect of placebo with the use of 
blinded sham treatment. Another way of reducing the placebo effect is to limit 
patient interaction to taking necessary clinical information. However, placebo is also 
large in medication and non-pharmacological interventions, with estimates of 
between 20%-50%, and thus may not be the comparative issue imagined (Speciali 




et al. 2010; De Groot et al. 2011).  The diary data were self-reported and no clinical 
records were used to verify co-morbidities, which are common with migraine, 
although this is part of a pragmatic approach and endorsed in the IHS guidelines 
(Tassorelli et al. 2018). 
 
Each study used a different design, 2-arm versus 3-arm, and although there is no 
consensus on which is better, there is a view that an intervention arm should be 
compared to a ‘real’ control.  For example, using only Botox or other intervention as 
a control (Silberstein et al. 2008) with a third sham arm, as in Cerritelli et al (2015), 
would enable more accurate calculation of the placebo effect and strengthen the 
validity of the results. The issue of sex- based studies is also a limitation, since 
neither study focussed on females nor stratified results by sex or gender. This opens 
the question up as to whether the results are equally applicable to both sexes 




In attempting to answer the question on the effect of MT as an adjunctive therapy to 
'care as usual' in chronic migraine, the narrative literature review identified a gap in 
research with a lack of studies on MT and headaches generally and chronic 
migraine specifically.   
 
Gandolfi et al. (2017) commented that one of the limitations was the lack of a 
comparison to a control (a group using 'care as usual') and added that there is value 
in examining MT as an adjunctive to (rather than a replacement for) pharmacological 
care in chronic migraine. The majority of systematic reviews commented that more 
high-quality studies are needed to establish the role of MT, and experts within the 
field suggest that multi-modal approach to a multifactorial disease is the best 
solution (Jensen et al 2008; Gaul et al. 2016; Cho et al. 2017).  
 
Although this systematic literature review confirmed the need for more high-quality 
studies into MT and chronic migraine, it also identified a lack of studies that used a 
pragmatic approach. Patsopoulos (2011) defined this as, “trials designed to evaluate 
the effectiveness of interventions in real-life routine practice conditions”.  Although 
Cerritelli et al. (2015) seemed to be undertaken in clinical practice it was difficult to 
assess if this was the case, and it was not described as a pragmatic trial.  Gandolfi 




et al. (2017) on the other hand, was not designed to be a pragmatic study. The 
analyses confirmed the use of HIT6 as a suitable primary outcome measure, and 
the value of responder group analyses.  
 
This review did show that good quality studies into MT and chronic migraine were 
possible and, in the process, informed the methodology proposed for the planned 
RCT research study, in the following areas: 
 
- The need to check against the methodological quality screen to ensure a good 
quality approach was taken, wherever possible using guidelines, e.g. CONSORT. 
-  To ensure the manual therapy protocol was adequately described (TiDier) 
-  To take into account the risk factors in the chronification of migraine when 
collecting and analysing data. 
-  To consider the basis of sample size calculations




CHAPTER 3  METHODOLOGY AND STUDY DESIGN 
3.1. Introduction 
The literature review highlighted, that whilst many randomised controlled trials 
(RCTs) exist on the topic of migraine and headaches, there are relatively few 
investigating the combination of manual, as distinct from physical therapy, and 
migraine. In particular, there is a paucity of RCTs that involve both MT and chronic 
migraine (CM). This was an important finding given that CM is the most problematic 
migraine variant, both for the patient, in terms of symptoms, and the treating 
clinician (in terms of the available treatment options) (Tepper et al. 2017; Becker 
2017; Schwedt 2014). 
 
This chapter describes the methodological approach adopted for a pragmatic RCT 
which explores the use of MT as an adjunctive treatment to 'care as usual' in CM. 
Issues discussed in this chapter include: the type and nature of this study; the 
rationale for choosing a pragmatic RCT; the methods used to collect data, and the 
statistical approaches used for analysis. 
 
My professional expertise and experience as a registered chiropractor, and lecturer 
led me to study the impact of co-morbidities and neck pain in migraine and conclude 
that there is no single solution to the management of migraine. Whilst the presiding 
view of migraine is as a neurological condition (Andreou and Edvinsson. 2019), 
there is mounting evidence is that it is a multi-factorial condition consistent with the 
neurobiological and the allostatic models described in section one (Andrasik et al. 
2005; Gaul et al. 2011; Borsook et al. 2012; Diener et al. 2015; Gaul et al. 2016). 
This helps to explain the known but uncertain relationship between migraine and 
other conditions that appear to involve similar neurological structures and processes 
including anxiety; depression; personality disorders; joint hypermobility syndrome, 
and chronic pain. On this basis, a multi-modal approach to migraine management, 
addressing the multiple effectors that contribute to chronification, seems the most 
appropriate treatment model.  




3.2. Study hypothesis and objectives  
There was extensive empirical evidence as to the benefits of MT for some headache 
types, particularly tension headaches (Espı-Lopez 2013; Chaibi & Russell. 2014; 
Clar et al. 2014; Lozano-Lopez et al. 2016). However, at the time of writing there 
was a lack of RCT studies involving MT for the treatment of headaches, particularly 
migraine and CM (Cerritelli et al. 2016; Moore et al. 2017; Rist et al. 2019). 
 
Both theory and evidence suggest that migraine, with CM being the most refractory 
type (Weatherall 2015; Aurora & Brin. 2016) is a multi-factorial condition and would 
benefit from a multi-modal approach. As such, the overall aim of the study was to 
examine the use of MT as part of a multi-modal approach, rather than to compare 
MT against existing treatments (Gaul et al. 2011; Gaul et al. 2016). 
 
3.2.1. Research questions  
Based on the literature review, the research questions proposed for this study are: 
 
Question one:  Is manual therapy effective as an adjunctive to ‘care as usual’ 
in the treatment of females with chronic migraine? 
 
Question two:  Do female chronic migraine patients exhibit baseline 
characteristics that affect treatment outcomes within and between treatment 
groups? 
3.2.2. Primary objective  
To measure the effectiveness of adding MT to ‘care as usual’ in CM over 12 weeks 
  
3.2.3. Secondary objective 
To explore the association between baseline participant characteristics and the 
effectiveness gained from adding MT to ‘care as usual’ in CM over 12 weeks 
 
3.2.4. Primary outcome measure 
The primary outcome measure is the between-group difference in change scores 
(‘care as usual’ versus ‘care as usual’ and manual therapy) from baseline to the 
end of the 12-week intervention measured using the Headache Impact Test (HIT6). 




3.2.5. Secondary outcome measures.  
These measures include changes over the 12-week study period in: 
x Percentage of participants with a reduction in headache and migraine 
frequency (days per month), 
x Quality of life measure, 
x Number of headache-free days, 
x Number and type of abortive migraine medications, 
x Stress and anxiety levels, 
x Allodynia scores and 
x Patient Global Impression of Change 
 
Details on the instruments used to measure the above outcome changes are 
provided in section 3.4.7. 
 
3.3. Study Design 
 
3.3.1. Basis for pragmatic RCT design 
One of the main criticisms of headaches studies involving all forms of physical 
therapy approaches including manual therapy was the low methodological quality 
(Fernadez-de-las-Penas 2006; Carod-Artal 2014). To address this criticism, an RCT 
design was chosen for this study as this represents the perceived 'gold standard' in 
clinical studies (Jones & Podsolsky. 2015). This section sets out the differences in 
RCT design and explains the rationale for undertaking a pragmatic RCT. 
 
RCTs are positioned to provide support for evidence-based decisions on medical 
treatment; their systematic methodology provides an unbiased comparison between 
groups of participants (Speith et al. 2016). The original systematic approach to 
RCTs is considered to be based on work by Bradford Hill in 1946 (Bhatt 2010). He 
established a foundation of key tenets: randomisation control groups, and the 
blinding of everyone involved and outcome analysis (Kendall 2003; CONSORT. 
2010).  Underlying these tenets is the ability to reduce bias throughout the RCT 
process (Higgins et al. 2011). It is, in essence, a stable and controlled experiment 
that is focussed more on the efficacy of the study rather than the effectiveness. 
Efficacy is defined as the performance of an intervention under ideal and controlled 




conditions, with effectiveness related to the intervention's performance under ‘real 
clinical practice' conditions (Revicki & Frank 1999). 
 
The position of the RCT as the 'gold' standard was enhanced when Guyatt et al 
(1995) brought a sense of quality to the various types of research approach by 
proposing a hierarchy (often illustrated as a pyramid) in the quality of evidence. This 
hierarchy or ‘Levels of Evidence’ established RCTs at the top. This position was 
further consolidated with the development of Evidence-Based Medicine (EBM) 
which grew from the idea that many of the established approaches to treatment 
were often based on poor quality research. Variations of the hierarchy of evidence 
followed, with systematic reviews of RCTs at the top (Fig 3.1.) 
 
Figure 3-1. Hierarchies of evidence 
 
The strict linearity of quality between levels and the hierarchy was challenged by the 
development of the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) framework (Gradeworkinggroup, 2008). This recognised that 
the certainty of evidence of studies was based on more than simply the design and 
reinforced the need to consider other factors, e.g. bias and inconsistency of results. 
Consequently, changes in the hierarchical schema were proposed (Murad et al. 
2016) including “wavy” lines between the types of studies to reflect the movement of 
rating across the domains according to the quality of evidence. Regardless of these 
changes, in the hierarchy of evidence, the RCT is still considered the ‘gold standard’ 
after 70 years, as demonstrated by the growth in the number of studies with RCT in 
the title [Figure 3.2] (LeFevre 2017). 





Image redacted Figure 1 page 411 LeFevre, M., 2017. From Authority- to Evidence-Based 
Medicine: Are Clinical Practice Guidelines Moving us Forward or Backward? The Annals of 
Family Medicine, 15 (5), 410-412. 
Figure 3-2. Number of Medline articles with ‘randomised controlled trial’ as key word.  
(adapted from LeFevre et al. 2017). 
 
A recent study has, however, highlighted the geometric growth in pragmatic RCTs. 
Despite there being only 615 labelled, ‘pragmatic’, between 1977 and 2017, 58% of 
them were published from 2014 onwards, with only 16% involving medicines (Dal-
Ré et al. 2018).  The next section considers the differences between RCT 
methodologies and the rationale for this study’s design. 
 
3.3.2. Choice of Pragmatic RCT 
The choice of a pragmatic design was based on two major tenets. The first, formed 
from personal experience which informed the study aim; the second, founded on the 
theories that underpin the explanatory and the pragmatic RCT designs. 
 
As a manual therapist it was paramount that the outcome of a study should inform 
clinical practice, guiding the approach to the treatment of headache and migraine 
patients in a working clinic, based on the best evidence. These patients are not a 
homogenous group, they are not preselected to fit exact criteria and they will not just 
have one specific intervention, but rather a tailored approach.  As a professional in a 
clinic, the aim is to help reduce patient disability with the tools (interventions) 
available and not to ‘prove’ one way is better than another or which specific MT 
intervention in a multimodal approach makes the difference. This was particularly 
relevant to those with CM, who were most likely already on a ‘care as usual’ 
programme via the or GP or the NHS and thus seeking additional assistance rather 
than a complete replacement.  This situation lent itself to a need to understand the 
study design options available that would enable good practice to be developed 
whilst balancing the need for a robust study and everyday clinical situations. Support 




for the pragmatic approach came from the UK Back pain, Exercise And Manipulation 
(BEAM) trial which was at the time of writing, the largest pragmatic RCT 
investigating the effect of MT interventions in the UK. The BEAM trial was designed 
to examine whether additional benefits accrued over and above best care from GPs 
(Vogel et al. 2005) from combinations of MT and PT. 
 
This next section outlines the thought process that led to the decision to implement 
an adjunctive pragmatic design over the traditional, efficacy based, design. 
 
Despite the success of establishing RCTs as a gold standard, there has been 
criticism of the approach. Many of these criticisms cite: the reliance of the RCT on a 
need for an ideal experimental situation; a set environment; a homogenous group of 
participants; and an exact quantifiable intervention. For many conditions, this does 
not reflect real-life clinical practice (Moeller 2011; Singal et al. 2014). For MT 
specifically, maintaining the quality associated with efficacy-focussed RCTs, 
designed in the main for pharmacological trials, whilst recognising the inherent 
drawbacks and incompatibility with requirements of MT is a balancing act which has 
been suggested as being hard to achieve (Milanese 2011). 
 
Koes and Honig (1999) raised issues with implementing an efficacy-focussed RCT 
approach in physiotherapy, in particular MT. These issues include: 
 
(1) The standardisation of intervention. In pharmacological trials this is 
straightforward, whereas most MT is not applied as a single intervention; 
(2) Blinding. MT interventions can never be double blinded; in all cases the manual 
therapist will know which intervention is being applied even if the participant does 
not know. Without blinding, the potential for an increased placebo effect is 
increased, and 
(3) Sample sizes. The relatively small sample sizes possible in MT studies (often 
fewer than 50 per group) may not affect validity but will influence the precision of 
the outcome measures. 
 
The above issues become more pronounced when working with MT to aid the 
management of headaches. Although headache guidelines existed to maintain the 
quality of pharmacological RCT efficacy-focussed studies, they provided little 
guidance for non-pharmacological/manual intervention studies (Penzien 2005; 




Tassorelli et al. 2018). This led to a question of how research in these areas 
addressed the required demand for higher quality evidence. One development, 
proposed by Schwartz and Lellouch (1967), was the concept of the pragmatic 
effectiveness-focussed trial design to balance the explanatory efficacy-based model. 
This adapted the standard RCT approach to consider the impact of an intervention 
in a ‘real life’ situation, as an alternative to the classical explanatory efficacy- 
focussed design. In the process, this concept addressed some of the limitations of 
the efficacy approach which also applies to fields of medicine, e.g. surgery (Das 
2011). 
 
Table 3-1. Explanatory versus. pragmatic trials: features. 
 
  
Table redacted. Table 1 page 139  MacPherson, H., 2004. Pragmatic clinical trials. 












Adapted from MacPherson, 2004 
 
Following on from this, MacPherson (2004) proposed that pragmatic trials could help 
the manual therapist answer questions on how effective a therapy is when 
compared to an existing, accepted treatment and not a placebo, as typically occurs 
in efficacy RCTs.  
 
It was also proposed that this approach would allow the evaluation of complex, 
multi-modal interventions, and of how well therapies work as an adjunct to 
conventional interventions. However, this approach would not be able to determine 
which parts of the intervention provided the benefits as it evaluates a package of 
care.  
 
Early developments in the pragmatic approach suggested there were distinct 
differences between the explanatory or efficacy-focussed studies and the pragmatic 
or effectiveness-focussed studies (Table 3-1).  In reality, most RCTs fall somewhere 




along the continuum, between the purely efficacy/explanatory and the 
effectiveness/pragmatic study; a situation acknowledged by the development of the 
Pragmatic Explanatory Continuum Indicator Summary, or PRECIS, model (Figure 
3.3). Developed to support researchers’ decision making in trial design (Thorpe et 
al. 2009; Louden et al. 2017), this model comprises nine key domains that are used 
to establish the position of the trial along the spectrum and whether the trial design 
meets the aims. The PRECIS schematic for a very pragmatic trial would be reflected 
by the scores of five for all domains, whilst a very explanatory trial would be 
represented by a small circle in the centre of the wheels shown in Fig 3.3. 
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analyses of randomised trials: a protocol for a cross-sectional methodological review. 
BMJ Open, 7 (9), e017887. 
 
Figure 3-3. PRECIS wheel 




The profile of the current study was mapped using the online PRECIS-2 analysis 
tool (Zwarenstein et al. 2017), and is shown in Figure 3.4. The analysis indicated 
this study is of a more pragmatic than explanatory design and, in accordance with 




MacPherson (2004), is suitable as an adjunctive study. The full PRECIS-2 





Figure 3-4. PRECIS wheel for this trial 
 
3.3.3. Quality and CONSORT statements 
The use of the PRECIS-2 approach helps facilitate avoidance of design decisions 
that were skewed toward the explanatory end of the spectrum when the trial intent 
was pragmatic (Zwarenstein et al. 2017). However, PRECIS-2 did not fundamentally 
address the quality of the methodology. Consequently, a group comprising 
researchers and editors developed the CONSORT (Consolidated Standards of 
Reporting Trials) statements to improve the quality of reporting in RCTs. The 
statements comprised a checklist and flow diagram to be used as a framework for 
reporting an RCT. This approach has now been endorsed by leading medical 
journals and international editors. Since the original statement in 1996, that was 
aimed at purely explanatory RCTs, several extensions have been developed.  
 
These include one designed for non–pharmacological trials (Boutron et al. 2017) 
and another for pragmatic trials (Zwarenstein et al. 2008). The aim of these 
extensions was to provide information to include in reports of pragmatic trials, 




enabling the researcher to decide if the results have validity for their own situation, 
and therefore if the intervention was an acceptable option. They also help trial 
designers to consider these issues when writing the protocol. 
 
3.4. Methodology 
The methodology in this study encompassed issues highlighted in the literature 
review, which included checking the process against a methodological quality 
screen and adhering as closely as possible to CONSORT guidelines and the 
International Headache Society (IHS) recommendations (Tassorelli et al. 2018). 
Specific factors that needed to be included in the trial as a result of this were: 
ensuring relevant details of the MT protocol enacted was available (Appendix 12) 
and using validated instruments to collect information related to the risk factors in 
the chronification of migraine.  By embracing the above points, this study would 
augment the limited quantity of research in the field of MT and CM. 
 
3.4.1. Design 
A single centre, pragmatic RCT was employed. The two groups were designated 
‘care as usual’ (Group C) and ‘care as usual’ plus MT (Group M). The study design 
adhered to the IHS and CONSORT guidelines (Zwarenstein et al. 2008; Boutron et 
al. 2017; Tassorelli et al. 2018).  
 
3.4.2. Participants and Recruitment 
Participants were recruited between August 2018 and the end of November 2018 
from the Salford Royal NHS Foundation Trust Acute Neurology Clinic. The 
neurologist and specialist headache nurse identified potential participants from their 
list of active CM patients.  The initial engagement with potential participants began 
two to four weeks before their next headache clinic appointment by sending a letter 
of invitation from the neurologist (Appendix 9) along with the participant information 
sheet (Appendix 10) and their clinic appointment letter. When the potential 
participants attended their migraine clinic appointment, the specialist headache 
nurse checked receipt of the invitation letter.  
If they had received the letter, and were interested in participating in the study, they 
were offered an initial assessment meeting with the Principal Investigator (PI) 
immediately after their appointment. The full study plan is detailed in Figure 3.5. 
 





Figure 3-5. Flowchart of study plan 
.  
3.4.3. Inclusion and exclusion criteria 
Eligible participants were females aged 18 years or over and diagnosed by their 
neurologist with CM according to the criteria of the International Classification of 
Headache Disorders (ICHD-III).  To mitigate the potential influence of medication 




overuse headache (MoH),  which influences the success of an intervention 
(Schwedt et al. 2017; Rojo et al. 2015), participants were required to have had at 
least two cycles of tertiary care treatment and be on a consistent 'care as usual' 
regime to create a more homologous group (Silberstein et al. 2017). Factors for 









Table 3-2. Inclusion criteria 
 
Female adults over 18 years of age 
A good command of English (to enable informed consent) 
Existing patients with chronic migraine as diagnosed by a clinical interview 
with a neurologist in line with the International Classification of Headache 
Diagnosis criteria (ICHD)  
Undergoing 'care as usual' from the neurologist 
Must have had at least twos cycle of treatment from neurologist and not be a 
new patient 
Table 3-3. Exclusion criteria 
 
Currently having or had manual therapy for neck, shoulder in the last six 
weeks.   
A new patient without any existing management by neurologist 
Having a condition contraindicated for manual therapy including but not limited 
to inflammatory disorders, severe osteoporosis and tumours.  
Identification of any medical ‘red flags’ by the neurologist including: 
x Evidence of any central nervous system involvement e.g.:  
x Facial palsy (presence of ptosis/Horner’s syndrome) 
x Visual disturbance (presence of blurred vision, diplopia, hemianopia) 
x Speech disturbance (presence of dysarthria, dysphonia, dysphasia 
such as expressive or receptive) 
x Balance disturbance (presence of dizziness, imbalance, unsteadiness, 
falls) 
x Paraesthesia (presence, location such as upper limb/lower limb, face) 
x Weakness (presence, location such as upper limb/lower limb) 
x Known major psychiatric or psychological conditions not under control 




 3.4.3.1 Rationale for Inclusion and Exclusion Criteria 
 
x Gender 
The trial included only females for two main reasons. Primarily, CM is much more 
prevalent in females than males, with approximately 70% of CM tertiary care 
attendees being female (Jelinski et al. 2006; Wang et al. 2011), with greater than 
80% representation in trials of CM medication (Silberstein et al. 2014 Silberstein et 
al. 2017; Tepper et al. 2019).  Furthermore, males are thought to respond differently 
to treatment than females, potentially skewing the results and negatively impacting 
transferability of findings to the target population in question (Buse et al. 2013; 
Vetvik & MacGregor. 2017). 
 
x Age 
This study followed IHS guidelines (Tassorelli et al. 2018) for enrolment of 
participants. All were females over 18. Although there are no upper age restrictions 
on participants in a migraine study the suggestion is that age at onset of EM should 




One of the main criticisms of methodology in studies involving headaches/migraine 
and MT, and the reason for exclusion in the earlier systematic literature search, is 
the lack of consistent or formal diagnosis in participants. This trial followed IHS 
guidelines (Tassorelli et al.2018) and only included people diagnosed with CM, by a 
neurologist, after having failed 3 previous prophylactic interventions. 
 
x Medication overuse 
The overuse of acute medications (typically opioids) is a known factor in the 
chronicity of migraine. As this has a significant negative impact on the success of 
interventions (Raggi et al. 2014; Bigel et al. 2010; Scher et al. 2008) participants 
were required to have had a minimum two cycles (approximately six months) of 
intervention, demonstrating CM stability. 
 
x Current or recent MT on head, neck and shoulders 
As an adjunctive investigation, it was necessary to remove any confounding 
influence of past or current MT. Six weeks was considered to be the minimum time 




period for the effects of any intervention to have subsided. There is no set guideline 
for the washout period between MT interventions, as such this was a pragmatic 
decision based upon the period often ascribed to acute injury repair. No new MT 
was allowed whilst participating in the trial for the same reason. 
 
x Contraindications to MT 
The main criteria were based on potential adverse effects of MT on the participant 
(Cambron et al. 2007; Boyle et al. 2008; Church et al. 2016) and red flags for 
conditions which may be reflected by the presence of secondary headaches (Martin 
2010; Schankin & Straube. 2012). To mitigate this, all potential participants on the 
list were reviewed by a neurologist prior to inclusion on the study and were reviewed 
at the start of each cycle by the specialist headache nurse and then by the PI. 
 
3.4.3.2 Alteration and outcome in exclusions criteria 
Early in the recruitment process it became clear that some of those invited to take 
part in the trial had ventral shunts in their skull. This group was then added to the 
exclusion group based on the potential for adverse effects from MT. In all, 17 
potential recruits were excluded at the meeting with the PI (Fig 3.6.).  
 
 









3.4.4. Randomisation and allocation 
 
3.4.4.1. Random sequence generation 
Randomisation is essential in both pragmatic and explanatory randomised control 
trials and is part of the CONSORT model (Boutron et al. 2017). It comprises two 
phases: 
(1) Generation of a random participant allocation sequence; 
(2) Implementing the allocation so the researchers are unaware of the group to 
which potential participants will be assigned. 
 
There are multiple opinions on the best approach to randomisation (Kim & Shin. 
2014) from simple techniques such as putting pieces of paper in a hat and pulling 
them out through to computer generated block and stratified randomisation. The 
“paper in hat technique” is not recommended for RCTs due to the ease of 
compromise, with a computer-generated process generally preferred (Suresh, 
2011). However, if simple randomisation is performed samples of fewer than 100 
have a strong chance of forming unequal groups. This can be addressed with block 
sequences but with the potential drawback that the researcher may guess the next 
allocation (Vickers 2006).  
 
This study employed a randomisation software tool, “Research Randomizer” 
(Urbaniak & Plous. 2015) to create a randomised assignment sequence; this 
process was conducted by an independent research assistant, unattached to the 
project.  Pieces of paper with the group allocation were placed in sealed opaque 
envelopes by the independent research assistant and given to the PI. The master 
file containing the randomisation sequence was placed in a sealed and secure 
envelope by the same research assistant without any involvement from the Principal 
Investigator (PI) or neurology team. With a small sample size, any study is at risk 
from a higher percentage of dropouts/withdrawals and failure to meet the sample 
size required. In a recent study of health care trials, only 56% of RCTs achieved 
their stated sample size (Walters et al. 2017). To mitigate the above issues, the 
initial randomised sequence of 64 participants was implemented and the balance of 
group sizes reviewed on an ongoing basis. When it became clear that the number of 
drop outs and withdrawals would lead to one group not achieving the minimum 
sample size of 29, the existing randomisation sequence was stopped (at n=50). A 
new sequence was implemented by the independent research assistant using the 




Randomiser software with a block balance (2:1) between both groups designed to 
ensure both groups met the minimum number. 
  
3.4.4.2 Allocation 
Those patients who had been screened from the neurology clinic list were sent a 
letter of invitation along with a participant information sheet and attended their 
appointment with the specialist headache nurse as usual (Figure 3.4.1). Once 
assessed by the specialist headache nurse, the participants meeting the inclusion 
criteria were then invited to a meeting with the PI. If this was not immediately 
possible, it was arranged as soon as possible, but no greater than 5 days later 
enabling those who were assigned to the MT group to have treatment in the first 
week, in line with the protocol. 
 
At the PI meeting, potential participants were reviewed again with respect to the 
inclusion criteria and, if still eligible, were informed about the risks, benefits and 
potential adverse reactions to MT. Potential adverse reactions to MT explained to 
the participants included temporary local tenderness, aching and tiredness; the 
potential for higher risk events such as stroke was also explained (Carnes et al. 
2010; MacPherson et al. 2015; Vaughan et al. 2016). Verbal and written information 
about the project was provided to the participants, and written consent obtained 
(Appendix 11). Participants then opened a numbered envelope which contained the 
allocation to either the 'care as usual' group or the MT group. The PI explained the 
process to be followed according to the group to which they were allocated. 
 
3.4.5. Blinding 
The neurologist and specialist headache nurse were blinded as to which group the 
participants were allocated in order to reduce channelling and ascertainment bias 
potential during the study (Jadad. 2002; Pannucci & Wilkins. 2010).  Although it was 
not possible to blind the PI to the MT group, the PI was blinded to the end of study 
survey outcomes before analysis. Another member of the research team re-coded 
the participant reference numbers and stored the key file on a password-protected 









Individuals assigned to the 'care as usual' plus MT group were given a 12-week 
treatment plan as recommended in IHS guidelines (Tassorelli et al. 2018) with 30 
minute sessions in weeks 1, 2, 5, 8 and 12. These weeks were chosen to reflect a 
typical approach in practice and although other studies have used different 
approaches (Table 3.4), there is much commonality, and this trial followed the same 




Each session comprised 20-25 minutes MT and 5-10 minutes admin/write up. Those 
in the 'care as usual' group (group C) were managed by the neurology team and 
reviewed after a period that varied from 12 weeks to 17 weeks. However, final 
primary and secondary data were collected at 12 weeks from all participants. 
 
This trial investigated the adjunctive effect of MT, generally defined as a subset of 
physical therapy (Farrell & Jensen. 1992; Bronfort et al. 2010; Moore et al. 2017) 
which includes the hands-on techniques of mobilisation, manipulation, and soft 
tissue work (MMS). Consequently, those interventions under the broader label of 
physical therapy approaches, e.g. the use of equipment, needles and exercise 
prescription, were not permitted. A pragmatic approach to the MT intervention was 
adopted whereby the PI used MMS interventions deemed clinically appropriate, after 
an initial assessment of, and agreement by, the participant at each session. The PI 
was an experienced chiropractor with over 10 years’ experience and postgraduate 
education and training in headache management, and an author and teacher of soft 
tissue techniques (Sanderson & Odell. 2012).  
Table 3-4. Study intervention schedules and duration 
Study/Headache 
type 
Sessions / week Time 
period 
Session duration 
Chaibi et al. 2017/ 
migraine 
12/1pw 12 weeks 15minutes 
intervention plus 
assessment time 
Gandolfi et al. 
2017/CM 
4/1pw 4 weeks 30 minutes 
Espi et al. 2016 / 
TTH 
4/1pw 4 weeks 30 minutes 
Cerritelli et al. 
2015/CM 
8 / wk 1, 2, 5, 8, 12, 
16, 20, 24 
24 weeks 30 minutes 
Voight et al. 2011 / 
migraine 
5 / 1 per 2w 10 weeks 50 minutes 




Although the key elements of the treatment administered were recorded in the case 
report file (CRF), there was no attempt to specify the exact location of intervention, 
e.g. which specific cervical joint was manipulated or mobilised. This approach was 
taken based on the pragmatic nature of the trial which, as Macpherson (2004) 
noted, would be unable to identify the specific parts of the intervention that provided 
the benefits and because studies of manual therapy have shown that there is little 
specificity when targeting segments of the spine (Ross et al. 2004; Frantzis et al. 
2015). 
 
The outline intervention procedure was as follows (Table 3.5) 
Table 3-5. Manual therapy protocol 
 
1. Assess upper bodya posture in sitting 
2. Assess active and passive neck range of motion 
3. Assess shoulder girdle range of motion by raising each arm 
sideways from side of body up to ear 
4. Assess the temporomandibular joint  
5. Identify areas to treat in sitting position 
6. Administer MT using mobilisation, manipulation and soft tissue 
release in sitting position 
7. Assess patient shoulder girdle, neck and head supine and prone 
8. Administer MT in supine and prone position 
9. Following each session an outline of the MT used will be recorded. 
A total of 30 minutes will be allocated for each participant at these 
consultations 
a Upper body defined as from thoraco-lumbar junction upwards 
     (Details of protocol included in Appendix 12) 
 
Prior to each session participants were asked how they felt after the previous 
session with details of adverse events, no matter how minor, logged in the CRF. 
Participants were also asked how they were feeling in terms of the location of any 
painful areas and headaches. 
 
3.4.7. Data collection  
All participants were asked to complete a structured starting, baseline, questionnaire 
at their first meeting with the PI (Appendix 13). This comprised their demographic 
information and the validated instruments (Table 3-6). The measurement 
instruments were not identified individually in the questionnaire but simply supplied 




as tables of questions in a professionally designed booklet. This was to reduce the 
likelihood of participants recognising the instrument from previous experience, 
particularly HIT6 and HADS, and completing it based on expectation/reward, e.g. a 
belief that HIT6 or other scores determine their continuation with treatment.  The 
structured questionnaire was available in both paper and online formats, for 
completion at either the initial assessment with the PI or at home at the discretion of 
the participant, but had to be completed and returned within 5 days.  
 
Throughout the study, both groups completed a weekly diary either in paper format 
or online which recorded number and intensity of headaches/migraine; any trigger 
factors; perceived levels of stress; measures of allodynia, and overall acute 
medication usage (Appendix 14). After 12 weeks, i.e.at the end of the study, both 
groups completed the final structured questionnaire (Appendix 15) which duplicated 
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3.4.8. Data collection and measurement instruments 
The structured questionnaires at the start and the end of the study comprised a 
number of validated instruments (Table 3.6). All of these questionnaires, excepting 
MSQv2.1, were freely available in the public domain. Permission was given by the 
copyright holders to use the MSQv2.1. All of the instruments had been used in major 
headache studies and validated in the English language. 
 
3.4.8.1 Quality of Instruments  
Given the criticism discussed earlier of the methodologies ascribed to headache 
studies involving MT (Fernández-de-las-Peñas et al. 2006), it was considered 
essential that all measurement instruments used were high-quality, fit for purpose, 
specifically the one used for the primary outcome measure. There are two main 
considerations to assess the quality of instruments used when measuring an 
attribute or behaviours: reliability and validity.  
 
Reliability is reflected by a consistent or stable measurement over time or in different 
conditions for which the results obtained should be the same (Drost 2011). One of 
the most popular measures of reliability, particularly when considering a construct 
such as disability using multiple questions/items, is the internal consistency of the 
instrument. This shows how well multiple items/questions in the instrument work 
together to measure the particular concept /behaviour for which it is designed The 
most accepted measure for this is Cronbach’s alpha(α) which is represented by a 
number between 0 and 1. An acceptable reliability score of approximately 0.7-0.8 is 
considered acceptable although too high (0.9) may indicate the instrument is not 
measuring what it is designed to (Tavakol & Dennick. 2011).  
 
In the migraine setting, the majority of the instruments use multiple questions to 
measure a ‘construct’, for example, disability. The extent to which an instrument 
succeeds in measuring the intended construct is therefore critical. For this reason, 
Cronbach’s alpha(α) was chosen as the main measure of internal consistency  
for most of the instruments; this is often the one most calculated and available in 
order to assess the comparative reliability of proposed instruments.  However, for 
the primary and major secondary outcome instruments other measures such as test-
retest (ICC) reliability, validity and responsiveness (MDC, MCID) were also 
considered to address the ability of the instruments to distinguish between 




subjects, particularly with the HIT6 as the primary outcome measure. Inter-rater 
reliability was not addressed in this study as only one person would be involved, and 
the data would be from self-administered patient reported outcomes. However, it 
would be a major consideration if a future study, with multiple investigators, involving 
interviewer-administered instruments were included (Kimberlin and Winterstein. 
2008; Ranganathan et al. 2017)  
 
Validity is whether an instrument measures what it is designed to measure and how 
accurately the concept under investigation is measured e.g. headache disability 
(Sullivan 2011). There are different components of validity including content validity, 
construct validity and criterion validity (Table.3.7). 
 
Responsiveness is another important component of quality in measurement 
instruments.  There are two ways main ways of reporting responsiveness; the first is 
the minimum detectable change (MDC), which is the change in a patient’s score that 
is greater than measurement error. The second is the minimum clinically important 
difference (MCID) which represents the smallest change in an instrument 
score/outcome that the patient considers beneficial and might bring about a change 
in clinical management (Jaeschke et al. 1989). The MCID has become more 
important as patient-reported outcomes have been used to assess the benefits of 
treatment. Studies have also begun to question the sole use of statistical 
significance when sample sizes are sufficiently large, despite the effect on patients 
being of little consequence (Angst et al.  2017). The next section reviews the quality 
of the instruments used in the study. 
 
3.4.8.2 Measurement Instruments  
 
x Headache Impact Test (HIT 6). 
The primary outcome measurement instrument is the Headache Impact Test 6 a 
well-tested and validated instrument and recommended by the IHS as one of the 
Table 3-7. Components of validity 
 
Components of  validity Description 
Content validity Does the research instrument measure accurately all 
aspects of a construct? 
Construct validity How well does a research instrument measure the 
intended construct? 
Criterion validity How similar is the research instrument to other 
instruments which measure the same construct? 




most valid measures in CM studies (Tassorelli et al. 2018). It comprises six self-
answered questions using one of the following five options: “never”, “rarely”, 
“sometimes”, “very often”, or “always”. These responses are summed to produce a 
total HIT6 score that ranges from 36 to 78. Anything above 60 is classed as having 
a very severe impact on life. Between 56 and 59 is classed as having a substantial 
impact on life, 50 to 55 some impact and less than 49 little impact (Appendix 16).  It 
is generally used to evaluate disability (associated with headaches) over the last 4 
weeks although it has been used for longer periods. It has been validated in multiple 
studies and with different headache types (Appendix 16a). The quality of the HIT6 
has been assessed using a range of measures including internal consistency 
(Cronbach's), test-retest (time stability) and content, construct and criterion validity 
in different headache conditions. 
 
Kosinski et al. (2003) reported an internal consistency (Cronbach's) of 0.9 on 
individuals when tested on general headaches.  A follow-up study in a specialist 
neurology clinic, on a primarily female group (77%), had similar results with internal 
consistency reliability of 0.87 (Kawata et al. 2005). A later, larger (2000 participants) 
validation study in CM came to a similar conclusion with high reliability reflected by  
internal consistency over 3 months 0.87 and 0.92 and test-retest reliability (ICC) of 
0.77 (Yang 2010). The most recent study evaluated HIT 6 in over 1300 CM patients 
(87% female). Over 24 weeks, the internal consistency reliability was calculated at 
0.91 and the ICC test-retest at 0.71, concluding that the findings were consistent 
with other studies (Rendas-Baum et al. 2014). Since its inception HIT6 has been 
used in hundreds of headache studies and translated into at least 27 languages 
(Gandek et al. 2003). Haywood et al. (2017) concluded in a study of patient reported 
outcomes in headaches that “only the HIT-6 has acceptable evidence supporting its 
completion by all ‘headache’ populations.”  
 
The responsiveness of instruments is often measured by the minimal clinical 
important difference (MCID) for either individuals or between groups under 
evaluation. The between- group figure represents the smallest difference in mean 
change score of importance when comparing groups and the individual measure if 
an individual has experienced meaningful clinical change over time (Lipton 2006). 
Coeytaux et al. (2006) investigated four different approaches to evaluate a clinically 
significant change in the HIT6 score in chronic daily headache patients. Using 
modified versions of the anchor method (Jaeschke et al. 1989) and a linear 




regression model, it was concluded that within-person MCID of 3.7 units can be 
used to assess if an individual patient in a clinic setting experiences a meaningful 
change. A MCID of 2.3 units was calculated as the smallest difference in change 
scores between mean HIT6 scores involving two or more groups of individuals over 
time which represented a meaningful clinical improvement.  Castien et al. (2012) 
calculated the individual MCID for chronic tension-type headaches as a change of 8 
points. However, there is currently no MCID for HIT 6 in CM although Smelt et al 
(2014) looked at primary care practices and concluded for migraine the between-
group MCID was 1.5 and within-group between 2.5 and 6 depending on the 
technique used. Despite a lack of MCID’s for CM, the figures from Coeytaux et al. 
(2006) were used in this study particularly as the MCID for Smelt et al. (2014) were 
very similar and covered both chronic headaches and migraine. 
 
x Hospital Anxiety and Depression Scale (HADS). 
HADS (Appendix 17) is a well validated self-assessment instrument. It comprises 14 
questions with a score of between zero and three, seven questions for each 
component (anxiety and depression) with a total score of between 11 and 21 
indicating an abnormal level of anxiety or depression, between 8 and 10 borderline 
levels and between 0 to 7 normal levels (Zigmond & Snaith, 1983; Bjelland et al.  
2002).  It was initially validated by Zigmond & Snaith (1983) for use in a hospital 
outpatient setting and has subsequently been validated for many medical conditions 
and settings. Bjelland et al. (2002) identified 747 studies using HADS and validated 
HADS in a systematic review comprising 22 trials and 13 languages in a variety of 
medical conditions and settings. They concluded that the sensitivity and specificity 
for both anxiety (A) and depression (D) scales were approximately 0.8 with the 
optimum balance between specificity and sensitivity defined by a score of 8 or 
above on both the anxiety and depression scales. The internal consistency, 
Cronbach’s alpha for anxiety and depression was measured as between 0.67 and 
0.9. The construct validity was calculated for both anxiety and depression subscales 
respectively, as between .60 and .80. However, despite its prolific use, some recent 
studies have questioned its bi-dimensional latent structure (measurement of anxiety 
and depression). However, the anxiety scale is considered to be more valid and 
acceptable in studies (Martin 2005; Cosco et al. 2012). In answer to this criticism 
other authors have suggested that whilst there may be some underlying issues with 
the construct which may require reassessment, these are found in all instruments of 
this type and other more recent assessments of the validity of HADS are positive 




(Norton & Sacker. 2012; Bocéréan & Dupret. 2014;). It has also been suggested that 
a total score (combination of anxiety and depression) is used to reflect the level of 
psychological distress on a pro-rata basis to the individual scores hence 0-14 is 
normal and above 21 abnormal emotional distress/instability (Brennan et al. 2010; 
Cosco et al. 2012; Iani et al. 2014). 
 
Whilst taking the above views into account one of the earliest migraine studies using 
HADS to illustrate greater than normal involvement of anxiety and depression in 
migraine was by Devlen (1994). A recent study involving 300 participants with EM or 
CM concluded that it was a useful screening tool for depression with Cronbachs’s 
alpha of 0.89 (Amoozegar et al. 2017). Andree et al. (2010) completed a large-scale 
European study of the burden of primary headaches and concluded that the internal 
consistency of HADS was 0.9 in the UK and 0.91 in Germany with good construct 
validity. Thus, despite some controversy over its bi-dimensional latent structure 
HADS is still a measurement instrument recommended by the IHS for CM studies 
(Tassorelli et al. 2018). However, to date no measures of its responsiveness to 
change as determined by the minimal clinical important difference MCID have been 
calculated for headaches and measures for only a few conditions (COPD, cancer, 
acute respiratory failure (ARF) were available at the time of writing (Table 3.4.7) 
(Chan et al. 2016; Corsaletti et al. 2014; Yost et al. 2011; Puhan et al. 2008). 
 
Table 3-8. Recommended MCID hospital anxiety and depression scale 
(HADS) 






ARF 2.5 2.5 - 
COPD  1.5 1.5 1.5 
Cancer  3-4.5 3-4.5 - 
Smokers 8 6 - 
 
x Migraine-specific quality of life questionnaire, version 2.1 (MSQv2.1).  
MSQ v.2.1 (Appendix 18) is a 14-item, self-administered instrument. It was validated 
for prophylactic migraine treatment by Cole et al (2007) and for CM in subsequent 
studies (Bagley et al. 2011; Rendas-Baum et al. 2013). It has three domains: Role 
Restrictive (RR) which assesses how migraines limit daily social and work-related 
activities. Role Preventive (RP) which assesses how migraines prevent these 
activities and Emotional Function (EF) which reflects physical and emotional 
limitations associated with migraine. The scoring system for each item is based on a 
6-point scale: ‘‘none of the time’’ ‘‘a little bit of the time,’’ ‘‘some of the time’’ ‘‘a good 




bit of the time,’’ ‘‘most of the time,’’ and ‘‘all of the time’’. The score for each 
response is scored between 1 and 6 with raw score summed by factor (RR, RP, EF) 
and converted to a 0 to 100 scale with higher scores indicate better quality of life. 
Bagley et al (2011) estimated Cronbach’s α RP, RR, and EF at 0.90, 0.96, and 0.87, 
respectively.  
 
Rendas-Baum et al. (2013) examined the psychometric properties of the MSQ2.1 in 
CM patients (n=1397) from 2 clinical trials which provide a situational analysis 
appropriate for the current study. The construct validity, its ability to detect clinical 
indicators change between 2 groups of CM patients having prophylactic treatment, 
the convergent and discriminant validity and internal consistency were all measured. 
Cronbach's at baseline was over 0.8 and varied each factor between 0.80 (EF) and 
0.93 (RR) and between 0.83 (EF) and 0.93 (RR) in the 2 studies. It also displayed 
temporal consistency over 24 weeks with Cronbach’s of 0.9. Its convergent validity 
(using HIT 6 correlations) was calculated at between 0.59 and 0.8, well above the 
recommended 0.4 level.  The responsiveness of MSQ2.1 has been estimated for 
group and individual (within-group) change using different techniques (Cole et al. 
2009; Report 2015) (Table 3.4.8). The studies concluded that the MSQ 2.1 is a 
reliable instrument to assess the impact of headache across the range of headaches 
including CM. The MSQ2.1 has been used in many of the large-scale CM studies 






Table 3-9. Minimal Important Differences (MCID/MCID) MSQ 2.1 













Role Restrictive (RR) 3.2 / 5 3.2 / 8.5 5  3.2 
Role Preventive (RP) - / 10.6 4.6  / 9.2 5 - 7.9 4.6 
Emotional Functioning (EF) 7.5 / 10.6 7.5  / 12 8 - 10.6 7.5 
 
MSQ 2.1  Domain  Regression-Estimated MCID (95% CI) 
Domain Within-Group Differences 
Role function – restrictive (RR)  10.9 (9.4 to 12.4) 
Role function – preventive (RP)  8.3 (6.7 to 9.9) 
Emotional function (EF)  12.2 (10.2 to 14.3) 




x State Trait Anxiety Inventory-6 (STAI6). 
The six-item inventory (Appendix 19) was developed from the original larger 40 item 
inventory (Speilberger 1983) and validated by Marteau & Bekker (1992). The short 6 
item inventory measures State anxiety which is a temporary state that reflects how a 
person is feeling at the time (of a specific threat). These feelings exist on a day to 
day basis and reflect the overall daily experiences of people to life. There are six 
questions with four potential answers:  Not at all, Somewhat, Moderately, Very 
Much. Each item is scored between 1 and 4. Positive answers are reverse scored 
and the total score is converted to a score based on Spielberger’s original scoring 
system where 34-36 is considered normal. The 6-item short-form STAI scale 
produced scores similar to those observed with the full scale and has been widely 
used in clinical and basic research with Cronbach’s of the STAI 6 of between 0.74 to 
0.82,(Marteau & Bekker 1992; Macaluso et al., 1996; Tluczek et al. 2009). Recent 
validation studies in different areas have supported its use as an instrument to 
measure anxiety (Bayrampour et al. 2014; Lucibello et al. 2019). At the time of 
writing, there were no published findings on the responsiveness of STAI6. Despite 
few clinical studies in headache using the STAI-6 to measure State Anxiety it was 
selected for this study due to its short length as way to minimise survey fatigue.   
 
 
x Brief Cope. 
The Brief Cope (Carver 1997) is a self-report questionnaire to assess the extent of 
different coping behaviours and thoughts a person may have in response to specific 
situations (Appendix 20). It has 14 subscales:  self-distraction, active coping, denial, 
substance use, use of emotional support, use of instrumental support, behavioural 
disengagement, venting, positive reframing, planning, humour, acceptance, religion,  
and self-blame. The relevant situational specific scenario is placed prior to the 
questions (in this case migraine specific). There are 28 coping behaviours and 
thoughts (with 2 items for each subscale) which rated on the perceived use by the 
participants. The scale comprises 1 (I haven‘t been doing this at all) to 4 (I‘ve been 
doing this a lot). Cronbachs D for the 14 subscales range from 0.57-0.90 (Carver 
1997), and similar results (D= 0.54-0.93) from Benson (2009). The wording was 
modified (as is suggested by Carver) for this study to reflect the participant 
population and their challenges. Brief Cope has been translated into multiple 
languages and validated across a range of conditions (Brasileiro et al. 2015). Garcia 
et al. (2015) calculated Cronbach's alpha for each subscale as between 0.53 and 




0.82 and the overall scale at 0.6. Monzani et al. (2015) examined the latent structure 
with respect to personal goal commitment and progression and concluded that the 
14-factor structure was a suitable instrument to evaluate coping responses to 
specific events.  Brief Cope has been used successfully in large scale(n=5417 and 
n=1534) studies involving migraine, CM and chronic daily headache patients (Radat 
et al. 2005; Radat et al. 2008) and smaller more focussed studies in migraine (n=50) 
in which reliability of subscales ranged from 0.50 to 0.90 (Chan & Consedine. 2014). 
At the time of writing, there were no reports of figures for minimal clinical important 
differences (MCID) for Brief Cope. 
 
x Perceived Stress Scale (PSS-10). 
The PSS-10 (Appendix 21) is designed to measure perceived stress the preceding 
month (Cohen et al. 1983). It is one of the most widely used psychological tools for 
ascertaining the degree to which one’s personal life’s events are perceived as 
stressful based on how unpredictable, uncontrollable, and overloaded respondents 
find their lives. There are two subscales: one, a negative subscale items 1, 2, 3, 6, 
9, and 10 and the other a positive subscale items 4, 5,7, and 8. A five-point Likert 
scale scored from 0 to 4 is used, with a higher summed score indicating higher 
perceived stress. The unidimensionality of the PSS has been open to question 
recently and whilst Denovan et al. (2017) concluded the PSS was a short and easy 
to understand unidimensional stress measure there was a need to test it on a wider 
audience rather than students. It was originally validated by Cohen et al (1983) and 
since been validated in multiple chronic headache, tension-type headaches and CM 
studies around the world (Lipton et al. 2014; Moon et al. 2017; Andreeva et al. 
2018). Cronbach’s coefficient of this scale ranges from 0.82-0.89 (Lee 2016). Its 
test–retest reliability was .85 in students after 2 days and 0.55 in a community 
sample after 6 weeks and its convergent validity confirmed with strong association 
among the PSS10 total score and the STAI Score.  At the time of writing no studies 
were found that provided minimal clinical difference in headaches and only two 
linked to other conditions, one was a validation study in a Danish population on 
work-related stress concluded that 11 points and 28% for absolute and relative 
change scores were the minimal clinical important change (Eskildsen et al. 2015). 
The other, in Systemic Lupus Erythematosus (SLE) posited the minimal clinically 
important difference as 0.5*SD or 4.0 points (Plantinga et al. 2016). 
 
 




x Allodynia Score Checklist (ASC). 
Cutaneous allodynia (CA) is a marker for central sensitisation and is usually 
assessed with quantitative sensory testing (QST) which requires special equipment 
that is not easily available in a clinical situation and is sometimes complicated to 
use. The ASC (Appendix 22) was developed and validated by Lipton et al (1983) to 
measure CA in migraineurs with an easy to use, self-reported measure that reflected 
the three main types of CA measured by QST: thermal, dynamic mechanical, and 
static mechanical allodynia. It comprises 12 statements with options – does not 
apply to me, never, rarely, less than half the time and more than half the time with 
scoring of 0,0,0,1,2 respectively. Summation scores of 0-2, 3-5, 6-8, >9 represent 
none, mild, moderate and severe allodynia respectively. Cronbach’s has been 
calculated at between 0.76 and 0.8 in studies around the world (Ashkenazi et al. 
2007; Lipton et al. 2008; Florencio et al. 2012; Yalin 2017). The ASC has been used 
extensively in studies of central sensitisation and in particular with migraine and CM 
(Bevilaqua-Grossi et al. 2016; Benatto et al. 2017; Young et al. 2019). 
 
x Patient Global Impression of Change Scale (PGIC). 
The PGIC (Appendix 23) was developed from earlier patient-reported outcome 
scales although it was Hurst & Bolton (2004) who quantified the clinical change 
needed in scores rather than the normal statistically significant change. The PGIC is 
recommended by the IHS as valid measures of patient-centred change in migraine 
studies. It has seven statements, describing how the patient feels after treatment, 
which are scored by the participant (0):  No change (or condition has gotten worse) 
(1) Almost the same, hardly any change at all (2) A little better, but no noticeable 
change (3) Somewhat better, but the change has not made any real difference (4) 
Moderately better, and a slight but noticeable change (5) Better and a definite 
improvement that has made a real and worthwhile difference (6) A great deal better 
and a considerable Improvement that has made all the difference (7).   A score of 
>=5 is considered a significant change. However, despite its use and 









3.5. Statistical analysis. 
The primary analysis used the Intention to Treat (ITT) method rather than per 
protocol (PP) or as assigned (AS) as it reduces potential bias, promoting a higher 
level of evidence for clinical research. However, all approaches have their 
advantages and disadvantages. The PP approach analyses results excluding all 
participants who did not follow the protocol, did not adhere to the treatment, 
changed group, or missed required sessions. The AS analysis uses data based on 
the treatment participants received, even if they changed group/treatment. Both of 
these approaches are thought to provide a good measurement of efficacy of 
treatment, in an ideal situation but both lose the benefits of randomisation required 
in an RCT (Sainani. 2010). One of the major downsides to excluding the results of 
participants who failed to complete treatments is that the measure of treatment 
effect will be exaggerated and will not accurately reflect the outcomes in clinical 
practice and potentially miss implications for the treatments used, for example, side 
effects. 
  
The principle of ITT is that all participants in a randomised study should be 
analysed in their original treatment group, whether or not they stayed in that group 
or actually received treatment at all. The concept of ITT is founded on two main 
tenets: firstly, to maintain the benefit of randomisation whereby the baseline factors 
are balanced between treatment groups and, secondly, that the approach estimates 
the treatment effect in real-world clinical practice which was an important aspect 
given the pragmatic design of this study. The first of the above is particularly 
important when participants can self-select treatment and the second issue when 
they do not adhere to treatment. In practice, the ITT approach has difficulties 
(Armijo-Olivo et al. 2009; Sainani. 2010) and although initially recommended by the 
CONSORT guidelines (Moher et al. 2010) a subsequent update (Moher et al. 2012) 
replaced the requirement with “a clear description of exactly who was included in 
each analysis”. 
 
In this study, since participants could not ‘change groups’, as all adhered to their 
treatment, none withdrew during treatment and all provided complete primary data, 
the as-assigned and as-received treatment effects could be assumed to be the 
same regardless of analysis approach. Secondary endpoint/outcomes from the 
baseline and final questionnaires were analysed on ITT basis without issue since 
the conditions were the same as with the primary outcome (Ten Have et al. 2008).   





However, analysis of the secondary outcomes based on the diary data used a 
modified ITT (mITT) basis. In this case mITT refers to dealing with missing data and 
although the approach to take is not defined by any current standards, the use of 
multiple imputation is considered the most suitable (Bell et al. 2014). In this study 
any participant who completed over 6 weeks’ worth of data for an outcome was 
included using multiple imputation methods to calculate missing values. (Further 
detail on handling missing data is provided in section 3.5.3). 
 
Full details of statistical approaches and rationale are provided below with a 
summary of the main statistical hypotheses and approaches in Table 3.5.2. 
3.5.1. Data variable decisions 
In medical and many health care RCTs there is often confusion over how to handle 
the mix of data produced from the measurement instruments. Many of the 
instruments used to measure complex attitudinal or affective constructs are based 
on multiple Likert scale items (e.g. MSQoL 2.1, HIT6) others rating scales include 
adjectival (e.g. PGIC), visual analogue (VAS) and numerical rating (NRS) scales 
(e.g. pain rating) along with categorical data, both simple and as an output from a 
Likert based instrument (e.g. ASC) (Carifio & Perla. 2008; Harpe 2015).  The 
confusion is often over how to treat the output from such instruments. Some authors 
have contended that Likert scales are ordinal data and require non-parametric 
statistics and the use of mean and SD is inappropriate (Jamieson 2004). However, 
others have completed substantive studies demonstrating that ordinal data and 
Likert scales in particular can be analysed with parametric approaches (Norman 
2010; Willits et al. 2015). For example, HIT6 has a minimum value of 36 and a 
maximum of 78 but not every value in between is possible and it is designed in 
categories (section 3.4.8.2).  However, in many major headache studies it is treated 
as a continuous variable (Buse et al. 2011; Lipton et al. 2019). VA and NR scales 
are also prone to the same arguments as to whether analysis should use parametric 
or non-parametric given the apparent ordinal basis of the design. Some authors 
adhere to the simple construct that they are ordinal and must be analysed with non-
parametric approaches (McCrum-Gardner 2008) others suggest that VAS/NRS are 
suitable as a one-off measure (e.g. pain) but cannot be used to measure change 
unless transformed to interval data (Kersten et al. 2014).  
 




However, an alternative midway view proposes that normally distributed results can 
use parametric tests and skewed situation requires non-parametric approaches 
(Heller et al. 2016; Kim 2017). Dworkin et al. (2008) in Interpreting the Clinical 
Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT 
Recommendations support the use of NRS in pain trials and make suggestions for 
clinically important changes which do not rely on distribution-based statistics. 
 
 In this study data variable analysis involved a review of current thinking followed by 
evaluation of 1. How other headache/pain studies had handled the same outcome 
measures (or similar if an exact evaluation did not exist), 2. The approach 
recommended by the questionnaire designers, 3. Confirmation of proposal by the 
medical research statistician involved at the NHS trust (Table 3.10). 
 
Table 3-10. Study variable definitions 
 
Variable Design and type of 
data 
Example measures 
comment / references for 
supporting information 
Headache impact test score - HIT6 Likert type scale 
Continuous and 
categorical data 
Mean (SD) valid although 
analysis of proportions in 
HIT6 categories valid 1,2,3 
Perceived Stress - PSS10 Likert type scale 
Continuous data 
Mean (SD) valid,1,2,4 
State Trait Anxiety - STAI6 Likert type scale 
Continuous l data 
Mean (SD) valid 1,2,5 
MSQ 2.1 scores Likert type scale 
Continuous data 
Mean (SD) valid (on total and 
sub scales) 1,2,6 
Hospital Anxiety and Depression 
Scores - HADS 
Likert type scale 
Continuous data and 
categorical 
Mean (SD) valid (on total and 
sub scales) also analysis of 
proportions in categories 
also valid 1,2,7 
Allodynia Symptom Checklist - 
ASC 
Categorical Analysis of proportions in 
ASC categories valid 1,2,8 
Brief Cope scores (SD) - BCope Likert type scale 
Continuous 
Mean (SD) valid for sub 
scales 1,2,9 
Mean body mass index  BMI Categorical and 
continuous data 
Mean (SD) valid although 
analysis of proportions in 
BMI categories valid 1,2 
Patient Global Impression of 
Change Scale (PGIC) 
Likert Item 
Categorical 
Proportion by category 1,2,10,11 
Stress measure from diary Numerical rating scale 
Continuous data 
Mean (SD) valid 1, 2,12 
Headache pain from diary Numerical rating scale 
Continuous data 
Mean (SD) valid 1,2,12 
1 (Harpe 2015), 2 (Norman 2010), 3 (Usai et al. 2008), 4 (Moon et al. 2017), 5 (Marteau & Bekker 
1992),6 (Wang et al. 2012), 7 (Lantéri-Minet et al. 2005), 8 (Lipton et al. 2008), 9 (Pozzi et al. 
2015) 10 (Perrot and Lantéri-Minet 2019) ,11 (Hurst & Bolton 2004), 12 (Wang et al. 2011) 




3.5.2. Normality testing  
Study data were analysed for normality using visual assessment of the frequency 
distributions, skewness and kurtosis, the Kolmogorov-Smirnov test (KT) and the 
Shapiro-Wilks test (ST) within excel or SPSS as appropriate. Significance levels of 
p>0.05 in these tests were considered to be normally distributed and parametric 
tests appropriate. If this was not the case and significance was ≤0.05 then non-
parametric tests were used. Quantile-Quantile (Q-Q) normality plots were also 
generated within SPSS and visually assessed. A quantile-quantile (Q-Q) plot 
compares the quantiles of actual data distribution with the quantiles of a theoretical 
standardized distribution. The basic normal Q-Q plot should be a straight line of fit 
between the two distributions. Any variation from these indicating a non-normal 
distribution and the need for non-parametric tests (Das 2016).  
 
3.5.3. Missing data 
Although various approaches are available for coping with missing data some are 
considered more appropriate than others according to the situation, depending on 
whether the data are missing completely at random (MCAR), at random (MAR) or 
not at random (MNAR) (Kang 2013). Opinions vary as to the most appropriate 
approaches and rules of thumb exist to support each (van Ginkel et al. 2020). One 
rule of thumb is if data represents fewer than 5% of total cases then ignore it, whilst 
other authors disagree (Jakobsen et al. 2017). For all missing data the simplest 
approach is to remove the participant from analysis, although this is not compatible 
with the ITT approach.  It also reduces the sample size and power in MCAR data 
and introduces biases in the MAR and MNAR. To test if data is MCAR  
then Little's test can be used, although authors differ on the validity of this approach 
(McCleary 2002). Although this study could have used a simple approach for 
missing data, e.g. single imputation including last observation carried forwards 
(LOCF) partly because it was missing only in a small proportion and considered 
monotone (simple). However, the single imputation, LOCF approach can add 
significant bias and is not recommended in many journals (Jakobson et al. 2017; Li 
and Stuart. 2019). Multiple imputation (MI) is an accepted approach for missing data 
in RCTs although it has been suggested that using MI separately with each 
randomised group is a better approach than with the whole sample (Bell et al.2014)  
As the missing data was only in the diaries the limitation of MI on PROMS with 
subscales was not an issue where a large (>100) sample size is required (Rombach 
et al. 2018). The main limitation to implementing MI is its complexity, however with 




SPSS this now an automated function. Therefore, in this study it was decided to use 
Little's test and multiple imputations if the results were MCAR or MAR (which they 
were in all diaries returned). If MNAR then no methods of replacing are available for 
the data collected in the diaries and data from the participant was removed before 
any analysis (for example if a diary was not returned). The final analyses used 27 
diaries from each Group M with any weekly data missing from included diaries being 
replaced using multiple imputation using SPSS (c) version 25 (2018).  The range for 
mean number of imputation points per group over 12 weeks was between 1 and 3.3. 
The final percentage requiring imputation in any of the outcomes was between 
0.01% and 4% percent, so less than the 5% cutoff. This represents a small 
proportion that was considered not to add to a significant error or bias. 
 
 
3.5.4. Baseline differences  
The use of statistical significance tests in RCTs to identify differences between 
groups at baseline was considered an “ubiquitous error" in RCTs of the 1970's 
according to the New England Journal of Medicine. This ‘error’ fell to 38% of RCTs 
in 2007 (de Boer et al. 2015) although other authors have suggested 50% of RCTs 
adopt this unnecessary approach (Assmann et al. 2000). However, for many years it 
has not been considered necessary or useful to produce this analysis as good 
randomisation should eliminate the issue (Senn 1994). The CONSORT guidelines 
(Moher et al. 2010) specifically state that significance testing for baseline differences 
is unwarranted and suggest the preferred approach is to tabulate baseline 
characteristics with the mean and standard deviation (SD) for normally distributed 
data and median with interquartile ranges (IQR) for non-normal distributed data. 
However, it is accepted that when comparing outcomes, particularly the primary 
outcome, it is good practice to adjust for baseline difference using ANOVA 
techniques (Egbewale 2015; European Medicines Agency. 2015) but also to provide 
unadjusted figures (Saquib et al. 2013). 
 
3.5.5. Correlation and effect sizes 
Correlation is used to assess the strength of association and direction of 
relationships between two or more variables. Typically, it is a linear relationship 
measured by the Pearson Correlation Coefficient (r) with a value of between -1 and 
+1.  The most common approach to interpreting the strength or magnitude of these 
associations is to use Cohen’s (1988) guidelines in which r ≥0.10 indicates a weak 




association, r ≥ 0.3 a moderate, r ≥ 0.5 a strong association. These figures were set 
arbitrarily but are established and understood, although Rosenthal (1996) proposed 
and additional category of r ≥ 0.7 as very strong. In clinical environments effect size 
is a term often conflated with Pearson's correlation coefficient when a difference in 
understanding is required. Kerry and Preacher (2012) define effect size as a 
"quantitative reflection of the magnitude of some phenomenon that is used for the 
purpose of addressing a question of interest" and suggest there are different 
categories: a) a statistic, e.g. odds ratio, relative risk, (b) a standardized value, such 
as Cohen’s d (c) the actual numerical value of the statistic or (d) the relative 
interpretation as small, medium, or large. For continuous variables the Cohen’s d 
and the correlation coefficient is a common choice and for categorical variables, the 
relative risk, the odds ratio, and rate ratio are used.  However, for ANCOVA there is 
not an official effect size. A suggested approach to calculate an equivalent Cohen’s 
d is to use the difference between means divided by the square root of the mean 





In other studies (Levine & Hullett. 2002) it is recommended to use Eta2 for 
ANCOVA. The basis for comparing the Cohen’s d effect size with the r (Eta effects 
sizes used in this study were based on figures in Lenhard (2016). In pragmatic 
studies, the smallest effect size which would be considered important is sometimes 
referred to as the minimal clinical important difference (MCID) (Angst et al. 2017; 
Fleischmann & Vaughan. 2019). The CONSORT (Moher et al. 2010) reporting 
approach recommends the use of effect sizes with confidence levels and makes 
clear that this can include risk and odds ratio, risk difference and, for continuous 
data, the difference in means.   
 
3.5.6. Multiple test corrections 
In this study, the secondary hypotheses are related to the potential impact of 
participant characteristics, e.g. levels of depression, on the primary outcome. It also 
considered the impact of the interventions on secondary outcomes (changes in 
medication, etc). This involved multiple analyses using the same data from both 
groups to examine the difference between the means. To minimise the potential for 
identifying effects (statistically significant results) when none exist (Type 1 errors) a 




correction to level of p (normally 0.05) is required.  One of the most common 
adjustments is the Bonferroni correction, which reduces the stated statistical 
significance (p) to p divided by the number of tests undertaken. For example, if 20 
tests were undertaken the standard 0.05 significance would be reduced to 0.05/20 
giving a new significance level of 0.0025.  
 
However, its use is not universally agreed for a number of reasons, including the 
potential increase in type 2 errors at the expense of the reduction of type 1 and the 
lack of consistency in definition of the situations for its use, as it was not designed 
for the evidence in clinical studies (Perneger 1998).  There is an argument that 
corrections are not needed with small sample sizes; an a-priori hypothesis and, 
when relatively few comparisons are undertaken and that it may actually penalise in 
these situations (Armstrong 2014; VanderWeele & Mathur. 2018). The CONSORT 
guidelines (Moher et al. 2010) do not mention Bonferroni but do state that multiple 
analysis correction should be applied when needed.  In this study it was decided to 
present both the corrected and uncorrected p values to keep consistency with the 
only comparative headache study (Cerritelli et al. 2015) which used Bonferroni 
correction and to allow for consideration of the uncertainty around the necessity 
given this study's design. 
 
3.5.7. Summary statistical analysis methods 
Between-group differences were measured using either the unpaired student's t test 
or the analysis of covariance (ANCOVA) with adjustments for baseline or the 
median values with the Mann-Whitney U test depending on data distribution 
Nominal and categorical data used the chi-squared test. Continuous data, e.g. 
stress level, from the diaries collected over the 12 weeks, were treated as repeated 
measures and analysed using the repeated measures mixed ANOVA. Linear 
regression models were used to evaluate the impact of baseline variables on the 
outcome measures. For binary outcomes, logistic regression was used to examine 
the relationship between explanatory variables. All statistical analyses used a 
probability of <0.05 (two-tailed) as criteria for statistical significance. Bonferroni 
correction was used when appropriate and presented alongside with uncorrected 
figures. Numerical data were described by means, standard deviations (SD), 
standard error of the mean (SE) and 95% confidence intervals (CI) as appropriate 
and assessed for normal distribution using the Shapiro-Wilks tests.  
 




Table 3-11. Summary statistical analysis 
 
Descriptive Proposed Statistical Measures 
 Primary Endpoints 
Differences in migraine-related disability, 
as measured by the patient-reported 
Headache Impact Test instrument (HIT6) at 
end of intervention (12 weeks) between 
groups 
Mean, standard deviations 
Group comparison of change using: 
Significance testing (P values) 
α =0.05 has 80% power to detect a mean difference 
of 3.7 points in HIT6 before and after treatment 
ANCOVA 
Effect sizes: small (0.2–0.5), medium (0.5–0.8) or 
large (>0.8).  
Multivariate linear regression, ordinal logistic 
regression to assess the secondary endpoints 
relationship with changes in primary end point while 
adjusting for baseline parameter levels 
Secondary Endpoints  
Change in Migraine Specific Quality of Life 
Questionnaire Score  
Change in percentage of participants with 
reduction in headache frequency (days per 
month) of greater than 50% and 30% 
Change in number of headache free days  
Reduction in number and type of abortive 
migraine medications  
Change in stress and anxiety levels  
Patient global impression of change scores 
Allodynia checklist scores 
Means, standard deviations 
Between group comparison of change in secondary 
outcomes 
Students T, Ancova 
(Mann–Whitney) will be conducted in case of non-
normal distribution outcome measures and ordinal 
data 
Correlation measures between secondary outcomes 
using Pearson’s coefficient or partial gamma 
coefficient 




3.5.8. Sample size calculation. 
A pooled standard deviation (SD) for the Headache Impact Test (HIT6) was initially 
calculated from the analysis of nine major studies in CM involving a total of 4629 
participants and 19 measures of SD (Yang et al 2010; Suh et al. 2012; Aurora et al. 
2014; Baum et al. 2014; Negro et al. 2015; Berra et al. 2015; Cerritelli et al. 2015; 
Rojo et al. 2015; Silberstein et al. 2017). This resulted in a pooled SD of 4.9 for HIT6 
in CM. Consequently, this study required 29 participants in each arm to ensure that 
a two-sided test with α=0.05 has 80% power to detect a mean difference of 3.7 
points in HIT6 before and after treatment. However, some SD’s in these studies 
were outliers (>8). Subsequently, a second calculation was made without outliers, 
involving eight studies and 17 measures of SD with 4400 participants, which gave a 
pooled SD of 4.7.  On this basis the study required 29 participants in each arm to 
ensure that a two-sided test with α=0.05 has 80% power to detect a mean difference 
of 3.5 points in HIT6 before and after treatment The project aimed to recruit a 
maximum of 32 participants into each group to allow for dropout from the study, but 
also to increase the power to detect a difference in HIT6 of 3.35 (Appendix 24). 




3.6. Ethical approval 
The online University ethics procedure was initially completed in October 2017. As 
this project involved an NHS site, a Regional Ethics Committee (REC) submission 
was required. This took place in February 2018 and was subject to review which 
resulted in a resubmission in April 2018. The study was given final approval by the 
UK Heath Research Authority (IRAS 228901), Bournemouth University ethics panel, 
and R&D at Salford Royal NHS Foundation Trust (SRFT) in June 2018 (Appendix 
25) The Declaration of Helsinki was adhered to during this study. All data were 
anonymised and participants provided written informed consent. Insurance was 
provided through Bournemouth University. The procedure for withdrawal from the 
study was in line with the HRA non-CITMP study protocol. Severe adverse events 
were reported to the CI or the neurologists and resulted in participant withdrawal 
and appropriate referral to their General practitioner or neurologist. The study was 
open to monitoring in accordance with SRFT’s R &D department's standard 
operating procedures to ensure compliance with GCP and the Research 
Governance Framework 2005. All trial-related documents were available upon 
request for monitoring by R&D monitors. Any changes to the protocol were 
communicated in accordance with HRA guidelines.




CHAPTER 4  RESULTS 
4.1. Introduction 
This chapter presents the main study results. The Methodology section introduced 
the approaches taken with statistics. This section will build on the methodology 
where necessary when presenting the results. Data from the initial and final 
questionnaires were used to provide participants' demographics and baseline data 
for the primary outcome analysis. Secondary outcomes were evaluated using both 
the initial and final questionnaires along with data from the diaries and the case 
report file. The project flow, baseline demographics and participant characteristics 
are presented first. This is followed by the results of the primary and secondary 
outcome measures and analysis of the differences within and between groups. 
Finally, correlation and regression analysis are presented.  
 
4.2. Recruitment. 
Participants were enrolled between August and November 2018.  In total, the 
neurology clinic sent letters of invitation together with the participant information 
sheet to 213 patients diagnosed with CM. Of those invited, 124 (58%) declined to 
take part at the initial screening at the nurse-led appointment; a further 17 (8%) at 
initial screening with the PI, with 10 (5%) being withdrawn before the end of the 
study. This resulted in 62 (29%) reaching final analysis stage (Figure 4.1). 







 Figure 4-1. Study recruitment process 




4.3. Baseline demographics and clinical measures 
The baseline demographics and characteristics data were collected from the initial 
questionnaire (Appendix 13) and measurements made at the time of the PI interview 
and entered in the case report file (CRF) together with diary data collected at the 12 
weeks (Table 4.1).   
 
Table 4-1. Baseline demographics and characteristics  
 
Characteristics Mean (SD) Manual Therapy 








Participants, n 32 30   
Age, years   43.9 (11.2) 45.6 (13.8) IQ (32,30) 0.73$ 
Body mass index  28.2 (6.0) 28.5 (7.3) C (32,30) 0.86$ 
Mean number cycles onabotulinum 








Currently in work/college/retired 
(%) 
28 (88) 28 (93) IQ (32,30) 0.5a 
In relationship (%) 24 (75) 23 (77) IQ (32,30) 0.86a 
Age first migraine ≤18 years (%) 19 (59) 16 (53) IQ (32,30) 0.63a 
     
n: number of participants,  
%: percentage,   
SD: Standard Deviation from the mean  
Data sources: IQ – Initial questionnaire; C – Case report file; D – Diary data PR = Patient 
records 
































Table 4-2. Baseline clinical measures  
 
Clinical Measure or patient 
reported measure Means (SD) 
Manual Therapy 









Number medication days per week 
over last 6 weeks  
3.75 (2.2) 4.4 (2.5) IQ(32,30) 0.28 
Number of headaches per month & 17.2 (8.9) 17.5 (9.8) D (27,27) 0.13 
Headache impact test score-HIT6  66.4 (4.7) 62.1 (7.0) IQ (32,30) 0.006* 
% HIT 6  score >60 (severe) 94 60 IQ (32,30) 0.0015* 
Perceived Stress - PSS10 20.9 (8.3) 19.3 (7.2) IQ (32,30) 0.42 
State Trait Anxiety - STAI6 52.9 (11.2) 46 (12.7) IQ (32,30) 0.03* 
MSQ 2.1 scores   IQ (32,30)  
Role Function Restriction 49.5 (13.2) 57.5 (20) 0.07 
Role Function Prevention 58.2 (16.6) 64.6 (25.4) 0.24 
Emotional Function 46 (19.8) 57.6 (26.3) 0.04* 
Hospital Anxiety and Depression 
Scores - HADS 
  IQ (32,30)  
Anxiety 10.6 (3.2) 10.6 (2.9) 1.0 
Depression 9.4 (1.9) 8.6 (2.2) 0.13 
Total HADS Emotional Distress 20.0 (3.5) 19.2 (4) 0.20 
Allodynia Symptom Checklist - 
ASC 
8.0 (4.1) 7.2 (5.3) IQ (32,30) 0.51 





Self-distraction 5.28 (1.7) 4.93 (1.9) 0.44 
Active coping 5.3 (1.8) 5.1 (1.5) 0.63 
Denial 3 (1.60) 2.8 (1.5) 0.61 
Substance use  2.8 (1.5) 2.6 (1.2) 0.57 
Use of emotional support 5 (2.1) 4.3 (1.6) 0.15 
Use of instrumental support 3.6 (1.2) 3.4 (1.3) 0.53 
Behavioural disengagement 4 (2) 3.1 (1.6) 0.056 
Venting 4.3 (1.8) 3.2 (1) 0.005* 
Positive reframing 3.8 (1.7) 4.3 (2) 0.29 
Planning 5 (1.9) 4.5 (1.9) 0.31 
Humour  3.8 (1.8) 4.3 (2) 0.34 
Acceptance 6.3 (1.3) 5.9 (1.5) 0.27 
Religion 2.8 (1.2) 2.6 (1.6) 0.57 
Self-blame  4.5 (1.9) 3.8 (2.1) 0.17 
Data sources: IQ – Baseline questionnaire; C – Case report file; D – Diary data PR = Patient 
records 
& Baseline was taken as end of month 1 after start of intervention 
$ Chi square   * significance p ≤0.05.  
 

























Table 4-3. Diary data 
Additional triggers by total times reported (number participants reporting)  
Total reported  Trigger 
12 Shoulder pain (4)  
11 Busy life (5) 
10 Botox (6), Anxiety (4) 
9 Heat/Cold (6) 
8 Alcohol (7), Wearing glasses (3), Chocolate (2) 
7 Diet (5), Low mood (3), Skin sensitivity (2) 
5 Weather (4), Family issues (4), Travel (3) 
4 Perfume (2) 
3 Dehydration (3), Driving (1), Smoking (1) 
2 Darkness (1), Allergies (1) 
1 Sun (1), Dental pain (1) 
 
 
Figure 4-4. Percentage adverse events (AE) in Group M 








Figure 4-5. Number of adverse events by duration in Group M 
 
 
Figure 4-6. Geographic spread of participants 




4.4. Adverse events (AE) 
The detailed analysis of adverse events was limited to Group M as all participants 
were experienced users of ‘care as usual’ and presented immediately after their 
injections with mild discomfort, considered a normal response. In Group M, a total of 
57 adverse events were reported across the 12 weeks. All were of a mild non-
serious nature with 77% lasting 48 hours or less, 78% of participants had a 
maximum of 2 events over the 12 weeks with the majority (92%) being attributable 
to some degree to the treatment. All were typical of after-effects commonly 
associated with MT. The most commonly reported were short-lived muscle 
soreness/aches (54%) followed by headache (18%). 
 
4.5. Research questions and objectives 
The research questions proposed for this study were: 
 
Question one:  Is manual therapy effective as an adjunctive to ‘care as 
usual’ in the treatment of females with chronic migraine? 
 
Question two: Do female chronic migraine patients exhibit baseline 
characteristics that affect treatment outcomes within and between 
treatment groups? 
  
4.5.1. Research question one. Primary objective  
To measure the effectiveness of adding manual therapy to ‘care as usual’ in CM by 
(1) the change in migraine-related disability (HIT6) at the end of the 12-week 
intervention and (2) by the proportion of responders at 12 weeks. 
 
Question one:  Is manual therapy effective as an adjunctive to ‘care as usual’ in the 
treatment of females with chronic migraine? 
 
Question 1, Null hypothesis one: H1(0) There is no difference in the between-
group difference in change scores (‘care as usual’ [group C] versus ‘care as usual’ 
and manual therapy [group M]) from baseline to the end of the 12-week intervention 
measured using the Headache Impact Test (HIT 6). 




The a-priori outcome measure was the absolute difference between the group 
change scores from baseline in HIT 6 scores (gain scores) after 12 weeks.  Data 
were tested for normality using SPSS v 25 ©: Q-Q plots were produced and test for 
normality calculated with Shapiro-Wilk test. These indicated that HIT 6 pre and post 
for both groups was normally distributed. 
 
4.5.1.1 Absolute within and between group differences in HIT 6 
The absolute changes in HIT6 score (Table 4.4) show that group C had a 
statistically significant increase in HIT6 score compared to a marginally non-
significant reduction (p=0.059) in group M.   The between-group difference however 
was statistically significant at p=0.006; the difference in between-group change 




4.5.1.2. Between group differences adjusted for baseline HIT 6 score 
An ANCOVA determined the effect of adding MT to ‘care as usual’ (Groups M, C) on 
post-intervention HIT6 outcomes, controlling for baseline HIT6 measures.  
Assumptions of linearity, homogeneity, residuals, homoscedascity and outliers were 
checked and violations noted with the analysis (Laerd Statistics 2017). After 
adjustment for baseline HIT6 scores, there was a statistically significant difference in 
post-intervention HIT6 scores between the Groups (M, C), F(1, 59) = 4.77,  p = .033, 
partial η2 = .075. Post hoc analysis was performed with a Bonferroni adjustment.  





Effect size C 
 
(n) Group C 
(30) 
Group M (32) Difference in gain score B 
Group M – Group C (95% CI) 
Mean Hit 6 Pre  
(SD) 






Mean Hit 6 Post 
(SD) 







 (-0.73, 3.45) 
P value (P ≤ .05) 0.034** 0.059 0.006** 
a paired t-test      B independent t test c cohens d 
*MCID for HIT 6 between groups 2.3 (Coeytaux et al. 2006) 
CI: confidence intervals 
** significant  p<0.05 




Post-intervention HIT6 scores were statistically significantly lower in Group M versus 
Group C with a mean difference of - 2.86 (95% CI, -5.12 to -0.22 p = .033) and 





4.5.1.3. Question one, null hypothesis two: H2(0) there is no difference 
in HIT6 responder rates between groups 
 
Table 4-6. HIT6 responder rates  
 
Group (n) C (30) M (32) Difference 
proportion 





10 40.6 0.30 0.11 – 0.50 0.006** 
b difference of proportion test (chi square of homogeneity) 
*MCID for HIT 6 within person = 3.7  
CI: confidence intervals 
** significant <0.01 
 
The responder rate in this study is defined as the proportion in each group that 
achieved a reduction of greater than 3.7 in their HIT6 score (within person minimum 
significant clinical difference) from their base line. In the Group M, 40.6% had a 
change of more than 3.7 compared to 10% in the Group C. The difference in 
proportions test (chi square test homogeneity) was statistically significant (p=0.006) 
indicating a higher response in Group M (Table 4.6).  The difference in proportion 
was 0.3 (CI.95% 0.106 – 0.496.) Using a post-hoc fisher test based on response 
rates this study was powered at 78% with p=0.05. Thus, for every 100 patients in 
the population an additional 30 might be expected to achieve the minimal clinically 
significant change if they were treated with MT and ‘care as usual’ (Grissom & Kim. 
2012).  We can therefore reject the null hypothesis H2(0). 
Table 4-5. Means and variability for post intervention HIT 6:  
unadjusted and adjusted. 
  Unadjusted Adjusted              Mean Difference          
Adjusted CI 95% 
 N Mean SD Mean SE 
[-5.12]  to  [-.224] Group M 32 64.7 5.8 63.01 0.83 
Group C 30 63.9 7.4 65.87 0.85 
Effect size 0.13* ~0.6c 
N = number, SD = standard deviation, SE = standard error,  * Cohen’s d calculated from 
difference in means, c Cohen’s d calculated from η2     




4.6. Research question one: Secondary objectives 
The secondary objectives resulting from research question one in the study included 
the post intervention changes in other patient reported outcomes that reflect the 
disability felt by those with CM. This included Patient Global Impact of Change Scale 
(PGIC) and the Migraine Specific Quality of Life (MSQ2.1), frequency and intensity 
of headaches, use of rescue/acute medication and the change in allodynia. The 
hypothesis for each is listed above the results. 
 
4.6.1. Patient Global Impression of Change 
Question one, null hypothesis three: There is no difference in the PGIC outcomes 
between the ‘care as usual’ and the ‘care as usual’ with manual therapy groups 
 
 
A score of 5 or above was a positive change (Hurst & Bolton. 2004). The Chi square 
test homogeneity (for two proportions) was used to analyse the final outcomes: 19 
patients (59%) in the MT group had an improved PGIC classification compared to 2 
patients (6%) in the ‘care as usual’ group with a statistically significant difference in 
proportions of .53, p = .002. We can therefore reject the null hypothesis H3(0). 
  
Figure 4-7. Patient Global Impression of Change Scores (PGIC) 
 




4.6.2. Migraine Specific Quality of Life (MSQ2.1) 
Question 1, null hypotheses four, five: H4(0), H5(0) There is no difference 
between the MSQ2.1 outcome in the ‘care as usual’ and the ‘care as usual’ with 
manual therapy groups for domains and responder rates. 
 
An ANCOVA determined the effect of being in each group on post-intervention 
MSQ2.1 domain score after controlling for the baseline measure as a covariate. The 
data were assessed for linearity and homogeneity of regression; normality; 
homoscedasticity; homogeneity of variance, and outliers using SPSS © v.25. Any 
violations were noted alongside results (Laerd Statistics, 2017). 
 
The unadjusted pre and post scores and change in pre and post scores with the 
group difference compared to the MCID are shown in tables 4.7 and 4.8 
respectively.  
 
Table 4-7. Mean MSQ 2.1 scores 
 
 Domain  Pre scores (SD)  Post scores (SD) 
 Group M  Group C  Group M Group C 
Role Function 
Restriction 
49.5 (13.2) 57.5 (20) 53.1 (18.2) 54.3 (20.6) 
Role Function 
Prevention 
58.2 (16.6) 64.6 (25.4) 62.8 (19.7) 64.7 (25.7) 




Table 4-8. Differences in mean change from baseline in domain score 
 
Domain Group M@ Group C@ P value* Difference between 
mean group change $ 
Role Function 
Restriction A +3.6 - 3.2 0.046 6.8 
Role Function 
Prevention B +4.6 +0.1 0.115 4.5 
Emotional 
Function C +5.6 - 0.9 0.05 6.5 
$ MCID: minimal clinical important difference between groups  A =3.2, B= 4.6, C=7.5,  
@ MCID: minimal clinical important difference within groups  A= 5, B=8, C=10 
* P value determined by Mann Whitney U test 
 
The differences in RR and EF mean changes were statistically significant with 
Group M positive (i.e. improved HRQoL) as opposed to Group C in which they were 
negative.   The difference in RP mean change between groups was not statistically 
significant although Group C was only marginally positive.  




Despite none of the within-group mean changes exceeding the within-group MCID 
the between group mean differences for RR exceeded the MCID, RF was borderline 
with EF less than the between group MCID. 
 
4.6.2.1. MSQ2.1 Domain Analysis  
An ANCOVA determined the differences in pre and post domain scores between the 
groups adjusted for baseline. There were some violations to the assumptions for 
ANCOVA.  With Role Restriction there was one outlier at +3.04 (SD) which was 
ignored due to the robust nature of ANCOVA to these violations. Role Prevention 
did not meet the normality assumption for Group C using Shapiro-Wilk test p=0.032 
(C), p =0.3 (M). The Emotional Function domain did not meet the assumption of 
normality for Group C with Shapiro-Wilk test p=0.02(C).   Levene's homogeneity of 
variances was also significant (p=0.042).  However, as the above deviations were 
due to a few extreme (but acceptable scores) and close to the critical p=0.05, they 
was ignored on the basis that ANCOVA is robust to deviation from normality and 
slight deviations for homogeneity of variances particularly with similar sample sizes 


















In contrast to the unadjusted scores there were no statistically significant differences 
between the group post domain scores when adjusted for differences at baseline. 





Mean (SE) adjusted 





 F (1, 59) =2.1 
p=0.15,   
partial η2 <0.036 Group C (n=30) 54.3 (20.6) 
50.92 (2.5),  
[45.8 - 56 ] 




 F (1, 59) 
=0.56, p =0.46, 
partial η2 = 0.009. 
 
Group C (n=30) 64.7 (25.7) 62.15 (2.89),  [56.4 - 67.9] 




 F (1, 59) = 
0.78, p =0.38, 
partial η2 =0 .013. 
 
Group C (n=30) 56.49 (25.7) 51.89 (3.18),  [45.5 - 58.3] 
Group M (n=32) 51.56 (23.5) 55.87 (3.01),  [ 49.7 - 62.0] 




4.6.2.2. MSQ 2.1 Responder rates 
The responder rate was defined as the proportion of participants in each group who 
had a change in the MSQ2.1 domain greater than the within groups MCID (Table 
4.10). For RR the MCID within group has been calculated as a change greater than 
5, for RP the MCID greater than 8 and for EF greater than 10 (Cole et al. 2009). 
 
 
There were consistent proportions of responders in Group M for each domain, 
although only RR had a significant difference from Group C after the application of a 
Bonferroni correction in EF. 
 
As a result, we can neither accept nor reject H4(0) and H5(0) for the difference 
between groups in the MSQ2.1 domain and for the responder rates respectively.    
 
4.6.3. Frequency of headaches 
Question one, null hypothesis six: H6(0) There is no difference between the 
frequency of headaches outcomes in the ‘care as usual' group (Group C) and the 
‘care as usual’ with Manual Therapy' group (Group M). 
 
 A two-way mixed ANOVA was completed using the data from the diaries (n=54) to 
examine any differences between groups over the 12-week period. Responder rate 
analysis in each group was also undertaken using changes from baseline of a 30% 
and 50% reduction. The assumptions associated with ANOVA were tested. The 
assumption of sphericity was violated for the two-way interaction, χ2 (65) = 189.7, p ‹ 
.005. As a result, the Huynh-Feldt correction (epsilon, ε = 0.702) rather than 
Mauchly's test was used to interpret the results. 
 
Table 4-10. MSQ2.1 responder rates 
MSQ 2.1 Domain Proportion of Responders Significance* 
 Group M Group C  
Role Restriction 46.8% 16.7% p= 0.011$ 
Role Prevention 46.9% 30% p= 0.17 
Emotional Function 46.9% 20% p =0.025& 
*Chi square test of proportions,  $ significant  P<0.05  with bonferroni correction, & not significant with 
bonferroni correction  




There was no statistically significant interaction between the group intervention and 
time on frequency of headaches, F(7.7,401.8) = 0.62, p=0.75, partial η2 =0.012.   In 
other words, there was no difference in effects of the group interventions (C or M) on 
mean headache frequency over time. The main effect of group showed that there 
was no statistically significant difference in mean headache frequency between 
intervention groups F(1, 52) = 0, p =0.99, partial η2 = 0.0.  The marginal mean (SE) 
for Group C score was 4.056 (0.45) and 4.052 (0.45) for Group M, with a statistically 
non-significant mean difference of 0.003 (95% CI, 1.28 to 1.286), p = .996. 
 
The main effect of time however resulted in a statistically significant difference in 
mean headache frequency at the different time points, albeit with a small effect size 
(0.053) F (7.7, 401.8) = 2.93, p = .004, partial η2 = .053. The significant changes 
were seen in the period between the first and fourth week. The changes in the mean 




4.6.4. Headache responder rate 
Question one, null hypothesis seven: H7(0) There is no difference between the 
headache responder rate outcomes in the ‘care as usual' group (Group C) and the 
‘care as usual’ with Manual Therapy' group (Group M). 
 
 
 Figure 4-8. Mean headache frequency   




The responder rate is the percentage of participants experiencing a certain 
percentage reduction in headache frequency from baseline. There is no 
standardised figure for responder rate analysis although the IHS guidelines for CM 
(Tassorelli et al. 2018) suggest a 50% and 30% reduction in headache frequency 
with a focus on headaches classed as moderate to severe. This study analysed the 
results for headaches classed as moderate to severe headaches and those mild to 











Of the 27 participants in each group, for whom diary data were recorded, a chi 
square test was run to compare the 50% and 30% responder rates headaches 
between groups for both mild to moderate and moderate to severe headaches.  
There was no statistically significant difference in proportion between groups in 
either the 50% or 30% improvement levels (0.037, p=0.75 and 0.074, p=0.48).  
(Table 4.11). We fail to reject H7(0). 
 
 
4.6.5. Intensity of headaches 
Question one, null hypothesis eight: H8(0) There is no difference between the 
mean intensity of headaches outcomes in the ‘care as usual' group (Group C) and 
the ‘care as usual’ with Manual Therapy' group (Group M) 
 
A total of 53 (M= 27, C=26) participants completed data for headache intensity. If 
the participant indicated that they had no headaches, headache intensity was listed 
as zero. A mean of the weekly headache intensity was calculated for each 
participant and used in two-way mixed ANOVA to compare the response between 
groups over the 12-week period.  There were some violations in the test 
assumptions. There were 6 outliers as assessed by boxplot but all were within 
Table 4-11. Headache frequency responder rates.  









>30% reduction 0% 0% ns 
> 50% reduction 4% 0% ns 
Mild to Moderate 
Headaches 
(NRS≤4)  
>30% reduction 26% 30% ns 
>50% reduction 15% 22% ns 
ns= not statistically significant 




normal values - these were ignored due to the robust nature of the ANOVA to 
outliers. The -data were normally distributed in 6 of the 24 distributions, as assessed 
by Shapiro-Wilk's test of normality (p > .05) although box plots indicated this was the 
result of a few outliers. There was homogeneity of variances as assessed by 
Levene's test of homogeneity of variances was met in all except week 2 
(p=0.0).Mauchly's test of sphericity indicated that the assumption of sphericity was 
violated for the two-way interaction, χ2(65) = 92.7, p = .14 therefore the 
Greenhouse-Geisse correction was used to calculate the results.  As both groups 
had similar distributions, skewness at each time point, and were of similar size the 
above violations were ignored based on the robust nature of ANOVA in these 
circumstances (Tabachnick & Fidell, 2007).  
 
There was no statistically significant interaction between the groups and time on 
headache intensity: F(8.5, 433)=0.546  p=0.832  partial η2 = .011. The main effect of 
time did not show a statistically significant difference in mean headache intensity at 
the different time points: F(8.5, 433) = 1.65, p =0.103, partial η2 = .031.  
 
The main effect of group showed that there was not a statistically significant 
difference in mean headache intensity between groups (Fig. 4-7): F(1, 51) = 2.2, p = 
.14, partial η2<0.042 
The marginal mean (SE) for Group C score was 4.71 (0.452) and 5.4 (0.33) for 
Group M, with a statistically non-significant mean difference of 0.715 (95% CI, -
0.241 to 1.67), p= 0.14. We fail to reject H6(0). 
 
Figure 4-9.  Mean headache intensity 
 




4.6.6. Use of rescue medication 
Question one, null hypothesis nine: H9(0) There is no difference between the use 
of rescue/acute medication outcomes in the 'care as usual' and the 'care as usual' 
with Manual Therapy groups. 
 
A two-way mixed ANOVA was run to compare the medication usage between 
groups at monthly time points, m1, m2 and m3 from the start of the study (Fig.4-10). 
There were some violations to the test assumptions with 3 outliers but as all were 
within normal measures, these were ignored due to the robust nature of the ANOVA 
to outliers. The data were not normally distributed, as assessed by Shapiro-Wilk's 
test of normality (p > .05) although box plots indicated this was the result of the few 
outliers. As both groups had similar distributions and skewness at each time point 
this violation was ignored based on the robust nature of ANOVA in these 
circumstances. Mauchly's test of sphericity indicated that the assumption of 
sphericity was violated for the two-way interaction, χ2(2) = 7.09, p = .029, as result 
the Greenhouse-Geisser correction was used to calculate the results. There was no 
statistically significant interaction between the groups and time on medication 
usage; F(1,77, 90.1) = 0.295, p = .72, partial η2 = .006,   ε=0.833.  
 
The main effect of time did not show a statistically significant difference in mean 
medication usage at the different time points, F(1.77, 90.1) = 2.08, p =0.136, partial 
η2 = .04. The main effect of group showed that there was not a statistically 
significant difference in mean medication usage between groups M and C; F(1, 51) 
= 0.13, p = .91, partial η2<0.001   Consequently we fail to reject H8(0).  
 
 
Figure 4-10. Mean monthly use of acute medication  




4.6.6.1. Medication Overuse  
The ICHD guidelines (Tassorelli et al 2018) define medication overuse headache as 
headache occurring on 15 or more days/month in a patient with a pre-existing 
primary headache and developing as a consequence of regular use over 3 months 
of one or more: 
1. Triptans on 10 ≥ days/month  
2. Opioids on ≥10 days/month  
3. NSAIDs (other than acetylsalicylic acid) on ≥15 days/month  
4. Non-opioid analgesics on 15 ≥ days/month  
5. Combination-analgesic medications on ≥10 day/month 
 
Analysis of the 12-week diary data showed that of the 53 total useable responses 
31% could be classed as having medication overuse headache:  26% of Group C 
(n=27) and 37% (n=24) of Group M. A test of proportions found no significant 
difference between groups with X2 (1, N = 53) = 0.791, p = 0.374. 
 
The most commonly used medications by participants were NSAIDS (71%), Triptans 
(65%), miscellaneous (51%) and Opioid (16%). Twenty one (40%) of the 52 
participants who supplied data used a single medication with a triptan the most 
common (17%) followed by Naproxen and Ibuprofen (6% each). Twenty participants 
(38%) used 2 medications in a regular combination, 7 (13%) used three medications 
with 2 (4%) on 4 and 1 (2%) on 5 and 6 medications respectively. The most 
common dual combination was triptan/paracetamol (29%) followed by naproxen/ 
Ibuprofen (14%) with triptan/aspirin, naproxen/paracetamol and 
paracetamol/ibuprofen combinations each on 10%. 
 
4.6.7. Allodynia checklist scores (ASC) 
Question one, null hypothesis ten: H10(0) There is no difference in the allodynia 
score outcomes between the ‘care as usual' group (Group C) and the ‘care as usual’ 
with Manual Therapy' group (Group M). 
 
Analysis of the ASC (used as a measure of central sensitisation) between groups 
was completed using two approaches: The first used the difference in the proportion 
by severity (none, mild, moderate, severe) between groups and the second the 
difference in those reporting allodynia (Score > 2) or not. Figure 4.11 illustrates the 
change in ASC category distribution between categories pre and post intervention 
and figure 4.12 highlights the movement between the categories. 





















Chi square test was completed on the above category proportions post intervention 
which was not statistically significant (p=0.86) indicating there was no difference 
between the balance of categories in the groups after intervention. However, an 
analysis of the movement between the categories (Figure 4.12) highlighted that a 
 
 
Figure 4-11. Pre–Post ASC category by group 
 
 
Figure 4-12.  Movement between ASC categories 
 




higher percentage of the severe category moved into the mild group in Group M 
(n=6) compared with Group C (n= 1 (35% versus 9%). 
 
Conversely the percentage moving from the severe to moderate category was 
higher in Group C (n=4) compared to M (n=4) (36% to 24%) whilst 12% of the Group 
M moved from the severe to none category compared to 0% in Group C. No 
statistical tests including the test of proportion, chi square or Fisher’s exact test were 
suitable to analyse the difference in movement between groups due to the 
population size and test assumption conditions. The proportion of those in each 
group experiencing allodynia (ASC score > 2) after the intervention was assessed 
using a test of proportions. The findings were not significant (p= 0.81) with 73.3 % 
(n=30) of Group C having allodynia compared to 75% (n=32) of Group M. However, 
given the other findings this meant that H10(0) can be neither rejected nor failed to 
be rejected. 
 




4.7. Research question two   
Do female chronic migraine patients exhibit baseline characteristics that 
affect treatment outcomes within and between treatment groups?  
 
Previous studies have demonstrated the potential for participant characteristics at 
baseline (e.g. level of depression) to influence patient reported outcomes and in 
some cases to be influenced themselves by interventions. The generic null 
hypotheses for research question two can be summarised as follows: 
 
H(0) Treatment outcomes are not affected by baseline characteristics 
H1(0) The probability of being a responder is not affected by baseline characteristics 
 
This next section presents an analysis of differences in characteristics, within and 
between groups, pre and post and, in the case of diary data longitudinally, as a 
precursor to examining the results of their influence on the primary outcome(s).   
 
4.7.1. Brief Cope (BC) 
The non-parametric Mann-Whitney U test was used to examine the distribution of 
change scores between groups for each variable in Brief Cope and then for the 
French four factor variables. The full results can be found in Appendix 25. The only 
individual variable in Brief Cope with a statistically significant difference (p=0.036) in 
scores pre and post between groups was Behavioural Disengagement. In Group C 
the mean score increased whilst decreasing in Group M.  
This can be interpreted as those in Group C becoming more likely to shy away from 
difficult situations compared to those in Group M. The effect size, η2 =0.07 is 
equivalent to a moderate effect when converting to Cohen's (d ~0.55) (Lenhard & 
Lenhard, 2016).  The French four factor version of Brief Cope (Baumstarck et al. 
2017) groups the individual variables in four composite factors as shown in table 












Table 4-12. French four factor cope 
  
Original Brief Cope variables French four 
factors variables 
T-test results  
(p= 0.05) 
Self-distraction Avoidance  t(60)=1.473 p=.146 
Mean Diff = 2.72 
95% CI (0.97, 6.4) 
Denial 
Substance use  
Behavioural disengagement 
Self-blame  
Use of emotional support Seeking social 
support  
t(60)=0.689 p=.493 
Mean Diff =1.02 
95% CI (1.93, 3.97) 
Use of instrumental support 
Venting 
Religion 
Humour  Positive thinking  t(60) =-1.178 p=.243 
Mean diff = -1.6  
95% CI (-4.32, 1.12) 
Acceptance 
Positive reframing 
Planning Problem solving  t(60) =-1.089 p=.281 
Mean Diff = -1.18 




There were no statistically significant differences in the change in factors scores 
between groups when using the French four factors variables. 
 
4.7.2. Perceived Stress Scale (PSS 10) 
Table 4-13. Perceived Stress Scale 10 ANCOVA 
 
 Mean pre (SD) Mean post (SD) 
unadjusted 
Mean post (SE) adjusted for 
baseline: [95% CI] 
Group  C (n=30) 19.3 (7.2) 19.2 (6.59)  19.83*(.865)  [18.10, 21.56] 
Group  M (n=32) 20.9 (8.3) 19.6 (8.37) 19.03*(.837)  [17.36, 20.71] 
*Covariates appearing in the model are evaluated at the following values: Pre PSS = 
20.1613 
The norm for females =13.7 (Dietrich et al. 2008) 
 
 
The difference between the post PSS scores for the groups was calculated with 
ANCOVA adjusted for the baseline score. There were 2 minor violations of 
assumption for the test: Group M did not meet the Shapiro Wilks condition for 
normality (p<0.05) and there was one outlier. These two violations were ignored on 
the basis of the robust nature of the ANCOVA. 
 
After adjustment for baseline perceived stress, there was no statistically significant 
difference in post-intervention PSS score between the Groups C and M, F(1, 59) = 
0.443, p = 0.51, partial η2 = .007.    
 




4.7.3. Hospital Anxiety and Depression Scale (HADS) 
A one-way ANCOVA test was run on the HADS for each of the following factors: 
anxiety, depression and the total score (which is seen as a measure of emotional 
stability) with the baseline score of each acting as the covariate. However, the data 
failed the assumptions of homogeneity of regression and thus it was decided to use 
a two-way mixed ANOVA on the grounds that the baseline figures between each 
group were similar and that the covariance error would be small in the between 
group differences. A Bonferroni correction was applied to the three ANOVA tests (p= 
0.05/3 = 0.016). A Chi square test of homogeneity was also used to compare the 
proportions in each category between Group M and C post intervention. If the 
assumptions were not met then the Fishers exact test was used. 
 
4.7.3.1. HADS:  Anxiety 
Table 4-14. HADS anxiety Score* 
 
 Mean Pre (SD)  Mean Post (SD) Difference  Significance 
Group C  
(n=30) 
 10.57(2.9) 9.8 (2.46) - 0.77 p= 0.27 
Group M 
(n=32) 
10.56 (3.2) 10 (2.26) -0.56 P=0.42 
* Score 0 - 7 Normal, 8 -10 mild , >10 severe 
 
Assumptions for the mixed ANOVA were performed. There was one outlier, as 
assessed by boxplot and the data were normally distributed, as assessed by 
Shapiro-Wilk's test of normality (p > 0.05) except for a slight variation in the pre-C 
score (p=0.03). These variations were ignored due to the robust nature of the 
ANOVA.  Mauchly's test of sphericity indicated that the assumption of sphericity was 
not met for the two-way interaction, χ2(0) = 0, p< 0.00, resulting in use of the 
Greenhouse-Geisser correction. There was no statistically significant interaction 
between the groups and time on anxiety, F(1, 60) = 0.02, p = 0.89, partial η2 < .001 
(Table 4.14). 
The main effect of time did not show a statistically significant difference in mean 
anxiety score at the pre and post time points, F(1, 60) = 1.68 , p = 0.2, partial η2 < 
0.02.  The main effect of group showed that there was no statistically significant 
difference in mean level of anxiety between intervention groups F(1, 60) = 0.017, p = 
0.89, partial η2 < 0.001. 
 




The data for anxiety was tested using a Fisher exact test. There was no significant 
difference between the two groups in the proportion of categories for anxiety 
(p=0.182) (Figure 4.13). 
 
4.7.3.2. HADS:   Depression 
 
Assumptions for the mixed ANOVA showed there was one outlier, as assessed by 
boxplot which was ignored based on the resilience of the test to this condition.  
Box's M test assumption was violated (p=0.007) and on this basis the Anova was 
continued but without an analysis of interaction simply the difference between 
groups. The main effect of group showed that there was no statistically significant 
difference in mean level depression between intervention groups at the end of the 
study F(1, 60) = 2.064, p = 0.16, partial η2 < 0.033 (Table 4.15). A chi square of 
homogeneity was run to compare the proportions in each category for depression 
(none, mild, moderate-severe). The results showed there was no statistically 
significant difference in proportions between groups. χ2(2) = 3.24, p = 0.198. 
 
Figure 4-13. Anxiety categories 
 
Table 4-15. HADS depression score* 
 Mean Pre (SD)   
Mean Post 
(SD)    Difference Significance 
Group C (n=30) 8.63 (2.19)  9.07 (2.51) 0.44 P = 0.47 
Group M (n=32) 9.44 (1.88) 9.31 (1.57) -0.13 p = 0.76 
* Score 0 - 7 Normal, 8 -10 mild, >10 severe 





Figure 4-14. Depression categories 
 
4.7.3.3. HADS Total Score 
The total score is considered a measure of emotional stability (or distress) with a 
higher score being more unstable and any score ≥ 16 considered abnormal. 
The mixed ANOVA assumption tests found two outliers, although both were 
acceptable scores, as assessed by boxplot. The data were normally distributed, as 
assessed by Shapiro-Wilk's test of normality (p > .05) except in the case of the post 
total score in Group C. These violations were ignored due to the resilience of Anova 
to minor deviations. Mauchly's test of sphericity indicated that the assumption of 
sphericity was not met for the two-way interaction, χ2(0) = 0, p< 0.05 necessitating 
the use of the Greenhouse-Geisser correction.  
There was no statistically significant interaction between the groups and time on the 
Total_HADS score, F(1, 60) = 0.113, p = 0.74, partial η2 = .002 . The main effect of 
time did not show a statistically significant difference in mean Total_HADs score at 
the pre and post time points, F(1, 60) = 0.58 , p = 0.45, partial η2 = 0.01. The main 
effect of group showed that there was no statistically significant difference in mean 
Total_HADS score between intervention groups F(1, 60) = 0.967, p = 0.329, partial 
η2 < 0.016 (Table 4.16). 
Table 4-16. HADS Total score* 
 Mean Pre (SD)   Mean Post (SD)   Difference Significance 
Group C (n=30) 19.2 (3.96)  18.93 (3.63) -0.27 p=0.78 
Group M (n=32) 20 (3.45) 19.3 (2.46) -0.7 p=0.35 
*Score ≥16 is cut off for emotional instability/distress 




A test of 2 proportions was used to compare the groups for the proportion of total 
scores over the cut off score (16) which showed no statistically significant difference 








The level of stress was recorded weekly for each of the 12 weeks using the diary 
using a NRS scale (Figure 4.16). A two-way mixed measure ANOVA was run using 
the 12-week data. The assumptions for ANOVA were checked and found to be 
violated for outliers. However, these are within normal values and given the robust 
nature of the ANOVA to outliers they were included. The assumption of sphericity 
was also violated and therefore the Greenhouse-Geisser correction was used. 
There was not a statistically significant interaction between the interventions and 
time on stress, F (7.2, 376) = 1.3, p = 0.243, partial η2 = 0.025. The main effect of 
time showed did not show a statistically significant difference in mean stress at the 
different time points, F (7.2, 376) = 0.944, p =0.474, partial η2 = 0.018. The main 
effect of group (M, C) showed that there was not a statistically significant difference 
in mean stress between intervention groups F(1, 52) = 0.19, p = 0.667, partial η2 = 
0.004 
                                                                          






4.7.5. Body Mass Index (BMI) 
The body mass index (BMI) was recorded for each participant at the start of the 
study (Figure 4.17.). In total 64.5% of all participants were overweight or obese. A 
chi square test showed no statistically significant difference between groups in the 
proportion of participants in each BMI category. χ2(2) = 2.68, p =0.26. 
                              








Figure 4-17. Body mass index by group  





To determine if any baseline factors correlated with the primary and secondary 
outcome measures (change in HIT6 and PGIC score) correlation analyses were 
completed between the continuous variables (Appendix 27) using the Pearson's 
coefficient (r) bivariate matrix for both groups.  
 
4.8.1. Continuous patient reported outcomes measures by group 
Analysis of each group highlighted differences in the correlation figures for the 
outcome results. Group C had statistically significant correlations between the 
change in HIT6 score and the baseline variables: Substance abuse (r=-0.404 
p=0.027) positive reframing (r=0.367 p=0.046), planning (r=0.439 p= 0.015). Group 
M had no statistically significant correlations between the change in HIT6 and the 
baseline variables.The secondary outcome measure, the PGIC was correlated with 
baseline variables in both groups. Group M was significantly correlated with 
Emotional support (r =0.363 p=0.04), Instrumental support (r =0.469 p=0.007), 
Behavioural disengagement (r =- 0.384 p=0.03) and Planning (r =0.488 p=0.005). 
Group C had statistically significant correlations between PSS10 (r =0.466, 
p=0.014), Denial (r =0.362 p=0.049), Behavioural disengagement (r = 0.37 
p=0.044), Acceptance (r = - 0.464 p=0.01) Religion (r =0.41 p=0.024), Self blame (r 
= 0.496 p=0.005) and ASC (r =0.458 p=0.011). 
 
4.9. Baseline variable response predictors 
Two approaches were employed to identify potential relationships between baseline 
characteristics and outcomes. The first approach considered baseline variables that 
have been shown in previous studies to be associated with chronicity or treatment 
response outcomes (Mathew et al. 2007; Schwedt et al. 2014; Schiano di Cola et al. 
2019; Dominguez et al. 2019). The second evaluated between groups outcomes 
using t-tests on all baseline variables, in the HIT6 and PGIC responder groups, to 
identify significant differences as an indicator for predictive variables (Tables 4.17, 
4.18). Hierarchical linear regression was used to examine the baseline relationships 
with the change in HIT6 scores and multinomial logistic regression with the PGIC 
outcome.  Due to the limited sample size, a maximum of four variables (where n=62) 
were chosen when the outcome was a continuous variable (Tabachnick & Fidell. 
2001).  




Binomial logistical regression was used to evaluate the relationship between mixed 
categorical and continuous baseline variables and dichotomous responder the 
responder/non responder outcomes for HIT 6 and PGIC.  Finally, to evaluate the 
potential impact of abnormal levels of baseline variables the proportions of 
responders/non responders of these baseline variables were also examined using 
the chi square test. 
                                                                                                                          
Table 4-17. Baseline characteristics between HIT 6 responder groups  
                  Responder 
Group Y N 
Within group variables 
with significant mean 
differences 
Significance 
M (n=32) 13 19 Planning,  Emotional support 
P= 0.06 
P=0.07 



























Table 4-18. Baseline characteristics between PGIC responder groups  
 
































































4.9.1. Hierarchical linear regression 
 
4.9.1.1. Headache impact test  
The initial regression equations for the change in HIT6 were examined based on 
variables identified in previous studies as factors likely to impact treatment 
outcomes. These included substance abuse, medication overuse, levels of anxiety, 
depression, coping and stress (Biaggianti et al. 2014; Schwedt et al. 2014; Probyn 
et al. 2017; Bottiroli et al. 2018). Prior to conducing a hierarchical regression, the 
assumptions of this statistical analysis were checked. A sample size of 62 was 
deemed adequate given four independent variables (IV) to be included in the 
analysis (Tabachnick & Fidell. 2001).  Since substance use accounted for a 
statistically significant variation in the change in HIT6 a regression process was 
used that maintained the maximum number of additional variables at 2 per group, or 
3 for the combined groups, to evaluate other variables as potential predictors. The 
assumptions of linearity, independence of residuals, homoscedasticity, 
multicollinearity, studentized deleted residuals greater than ±3 standard deviations, 
leverage value greater than ~0.33 (3k/n, k = number factors, n = sample size), 
Cook's distance above 1 and assumption of normality were checked with violations 
highlighted with each model. 
 
4.9.1.2. Final hierarchical models 
In Group C 40% of variation in the change in HIT6 was accounted by the variables, 
substance use, planning and Total_HADS. The full model was statistically 
significant, R2 = 0.43, F(3, 26) = 7.45, p = 0.001, adjusted R2 = 0.40. There were a 
few high centred leverage values, however removal of these cases did not affect the 
model significantly. In contrast, in Group M, no individual variables or models were 
found that could be regressed to account for a statistically significant variation in the 
change in HIT6. The same model as Group C above was statistically insignificant, 
R2 = 0.14, F(3, 28) = 1.5, p = 0.231, adjusted R2 = 0.039.When the combined groups 
(C and M) were regressed using the same model as above only substance use entry 
was significant which accounted for 6.2% of variation in the change in HIT6.  R2 = 
0.078, F(1,60) = 5.05, p = 0.028, adjusted R2 = 0.062. The optimum model for the 
combined group, accounting for 20% of the variation in the change in HIT6 score 
comprised substance use, planning, active coping and intervention (dichotomous 
variable). R2 = 0.25, F(4, 57) = 4.85, p = 0.002; adjusted R2 = 0.20. 




4.9.2. Multinomial logistic regression 
 
4.9.2.1. PGIC category outcomes 
The PGIC categories for perception of change (1-7) were regrouped as: None 
(score 1, 2) Little (score 3, 4) Moderate (score 5) Much (score 6, 7). Multinomial 
regression was used to identify those baseline factors that produced the optimum 
predictive model. Assumptions were checked and violations noted with summary. 
Two models were constructed to identify those factors which best predicted the 
positive categories, Moderate (=5) and Much (>5) into which responders are likely to 
fall based on baseline factors when compared to no change (none) category. Given 
the relatively small sample size these models were taken as a guide for discussion. 




The main predictors of gaining “Moderate” improvement were:  MT therapy plus 
'care as usual' (Group M), Denial and Behavioural disengagement score.  The 
predictors in the model for "Much" improvement were: MT therapy plus (Group M), 
Planning and ASC. 
 
These results (Table 4.19) suggest that participants in Group M were statistically 
significantly more likely to be in the Moderate PGIC group compared to Group C, 
with almost no increase in the probability of being in the moderate category in Group 
C.  With increasing denial score there was a significantly more likely probability 
(137%) of participants being in the Moderate category compared to the no change 
(None) category.  
Table 4-19. Predicting PGIC ‘Moderate’ change versus ‘No’ change category  
Base =  
No change  
B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 







Intercept 0.13 1.25 0.01 1 0.92       
Denial 0.86 0.35 6.19 1 0.013 2.37 1.20 4.66 
Behavioural 
disengagement 
-0.59 0.31 3.67 1 0.055 0.56 0.31 1.01 
[MT_Y=.00] -4.90 1.51 10.52 1 0.001 0.001 0.00 0.14 
[MT_Y=1.00]a 0b     0         
a = group M b = redundant as is comparator 




Although just over the significance level (p=0.05) an increase of one unit in 
behavioural disengagement decreased the odds of the participant being in the 
Moderate compared to the No change (none) category by ~45%. This model 
successfully predicted 75% of the Moderate category, 11% of the Much, 20% of the 
Little and 84% of the No change category outcomes and had an overall success rate 
of 61.3% for all categories. 
 
The best model for predicting the participants being in the PGIC "Much change" 
compared to the "No change" (none) category (Table 4-20) suggested that those 
participants in Group C had a significantly less (almost zero) probability of being in 
the “Much change” category those in Group M.  The model also suggested that for 
each unit change in Planning and ASC there was an 87% and 38% greater 
probability respectively of being in the "Much change" compared to the "No change" 
category. This model predicted 56% of the Much change, 67% of Moderate change, 
0% of the Little and 87% of the No change categories successfully and had an 
overall predictive rate of 64.5%. 
 
4.10. Binomial logistical regression 
The probability of predicting the outcome of treatment on a responder basis used 
binomial regression with the baseline characteristics as the variables. Variables 
were selected using a combination of evidence of impact on outcome from previous 
studies and the differences identified in Tables (4.21, 4.22). Assumptions for the 
regression included:  A linear relationship between the continuous independent 
variables and the logit transformation of the dependent variable. No substantial 
multicollinearity and outliers, high leverage points or highly influential points. Any 
violations and how handled are listed with the model. 
Table 4-20. Probability of PGIC ‘Much’ change versus ‘No’ change category  
Base = None  B Std. 
Error 
Wald df Sig. Exp(B) 95% Confidence 





Much Intercept -5.75 2.23 6.64 1 0.01       
Planning 0.63 0.30 4.48 1 0.034 1.87 1.05 3.33 
ASC 0.32 0.15 4.71 1 0.030 1.38 1.03 1.84 
[MT_Y=.00] -4.63 1.56 8.81 1 0.003 0.01 0.00 0.21 
[MT_Y=1.00]a 0b     0         
a = Group M b = redundant as is comparator 




4.10.1. HIT6 responders combined group  
 A binomial logistic regression for HIT6 responders found that a model comprising 
treatment group, self-distraction, ASC and baseline HIT6 score affected the 
likelihood of being a HIT6 responder. A Bonferroni correction to p=≤ 0.05 was not 
applied in the model (Tabachnick & Fidell. 2014) as these findings were to be taken 
as a guide and correcting at this level may have removed potential important 
predictors. There was one standardized residual with a value of 2.3 standard 
deviations, which was kept in the analysis. The logistic regression model was 
statistically significant, χ2(4) = 17.4, p = 0.002.  
 
The model explained 36% (Nagelkerke R2) of the variance in responder group and 
correctly classified 77.4% of cases. Sensitivity was 89.1%, specificity was 43.1%. 
The baseline HIT 6 score was the only variable not to add significantly to the model 
(Table 4.21).  
 
The odds of being responder decreased by 83% by being in Group C compared to 
Group M, whilst a unit increase in ASC decreased the odds of being a responder by 
17% and a unit increase in self-distraction increased the odds of being a responder 
by 67%. The area under the ROC curve was .837 (95% CI, .738 to .936) (Figure 
4.18.), which is an excellent level of discrimination (Yang & Berdine. 2017). 
 
Table 4-21. Logistic regression predicting likelihood of being HIT6 responder  




HIT6_base 0.09 0.06 1.89 1 0.17 1.09 0.96 1.24 
MT_(Group C) -1.79 0.81 4.88 1 0.03 0.17 0.03 0.82 
ASC - 0.19 0.09 3.97 1 0.046 0.83 0.69 0.99 
Self_distraction 0.51 0.24 4.73 1 0.03 1.67 1.05 2.65 
Constant -7.65 4.41 3.00 1 0.08 0.00     
 








4.10.2. Patient global impression of change (PGIC) responders  
A binomial logistic regression found that a model comprising treatment group, 
behavioural disengagement and denial affected the likelihood of participants being 
in a PGIC responder group. A Bonferroni correction to p=≤ 0.05 was not applied in 
the model (Tabachnick & Fidell. 2014) as these findings were to be taken as a guide 
and correcting at this level may have removed potential predictors. There was one 
standardized residual with a value of 2.2 standard deviations, which was kept in the 
analysis. The logistic regression model was statistically significant, χ2(3) = 35.7, p < 
0.001.  
 
The model explained 61% (Nagelkerke R2) of the variance in responder group and 
correctly classified 85.0% of cases. Sensitivity was 80.1%, specificity was 88.1%. 
The three predictor variables were all statistically significant (Table 4.22).  
  
Figure 4-18.  ROC curve HIT 6 responders 






The odds of being a responder if in Group C decreased significantly by a factor of 
0.01 compared to Group M. A unit increase in denial increased the odds of being a 
responder by 112%, whilst a unit increase in behavioural disengagement decreased 
the odds of being a responder by 38%. The area under the ROC curve was .91 
(95% CI, .83 to .98) (Figure 4.19), which is an outstanding level of discrimination 
(Yang & Berdine. 2017).       
 
 




Table 4-22. Logistic regression predicting likelihood of being PGIC responder  
 





-4.94 1.43 11.85 1 0.001 0.01 0.000 0.119 
Denial 0.75 0.32 5.50 1 0.02 2.120 1.132 3.972 
Behavioural 
disengagement 
-0.48 0.24 4.19 1 0.04 0.617 0.389 0.979 
Constant 0.19 1.06 0.03 1 0.85 1.215     




4.11. Baseline characteristics outside normal range 
A number of baseline variables when present at above normative levels have been 
shown to be associated with poor treatment outcomes in migraine studies (Mathew 
et al. 2007; Schwedt et al. 2014; Schiano di Cola et al. 2019; Dominguez et al. 
2019). These include depression, anxiety, medication over-use, allodynia and 
stress.  Test of proportions or Fishers exact tests were used to compare the 
proportion of these variables in HIT6 and PGIC responder groups. 
 
There were no statistically significant differences in the proportion of scores above 
normative values in the PGIC responder/non responder groups for any of the 
variables (Table 4.23). 
 
In table 4.24 only medication overuse had a statistically significantly difference in 
proportions between HIT6 responder groups with less probability of being a 
responder if MO was present.
Table 4-23. Combined groups:  PGIC Responders 
Base line variable / Responder  
 
Y N Chi square test of proportions (*Fishers 
exact test) 
HADS_Depression  
Score (>10)             
Y 6 8 *p =0.33 (n=62) N 14 34 
HADS_AnxietyScore 
 (>10) 
Y 7 17 p =0.68 (n=62) N 13 25 
Medication Overuse  
Present (Y/N) 
Y 5 11   p =0.646 (n=53) N 14 23 
Allodynia (ASC)  
Score (>2) 
Y 16 35 * p=0.735 (n=57) N 4 7 
Stress (PSS10) 
Score (>13.7) 
Y 16 33 * p =1 (n=62) N 4 9 
Table 4-24. Combined groups:  HIT6 Responders 
Baseline variable /Responder  
 
Y N Chi square test of proportions (*Fishers 
exact test) 
HADS_Depression  
Score (>10)             
Y 2 12 *P=0.322 (n=62) 
N 14 34 
HADS_Anxiety 
 Score (>10) 
Y 8 16 *P=0.374 (n=62) 
N 8 32 
Medication Overuse (MO) 
Present (Y/N) 
Y 13 29  
*P=0.017 (n=53) N 8 3 
Allodynia (ASC)  
Score (>2) 
Y 11 40 *P=0.151 (n=57) 
N 3 3 
Stress (PSS10) 
 Score (>13.7) 
Y 15 34 *P=0.154 (n=62) 
N 1 12 






Table 4-25. Summary hypotheses 
 
Outcome 
Question one:  Is manual therapy effective as an adjunctive to 






There is no difference in the between-group 
HIT6 change scores from baseline in the ‘care 
as usual’ (Group C) and the ‘care as usual’ with 
manual therapy' group (Group M)  
Rejected 
2 
There is no difference in HIT6 responder rates 
between Group C and Group M 
Rejected 
3 
There is no difference in the PGIC outcomes 
between Group C and the Group M 
Rejected 
4 
There is no difference in the MSQ2.1 domain 




There is no difference in the MSQ2.1 responder 
rate outcome between Group C and Group M  
Inconclusive 
6 
There is no difference in the frequency of 




There is no difference in the headache 




There is no difference in the mean intensity of 




There is no difference in the use of 
rescue/acute medication outcomes between 
Group C and Group M 
Not rejected 
10 
There is no difference in the allodynia score 
outcomes between Group C and Group M  
Inconclusive 
Question 2: Do female chronic migraine patients exhibit 
baseline characteristics that affect the treatment outcomes 





1 Treatment outcomes are not affected by 
baseline characteristics 
Rejected 
 2 The probability of being a responder is not 
affected by baseline characteristics 
Rejected 
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CHAPTER 5 DISCUSSION 
5.1. Introduction 
The original idea for the study evolved from extensive professional experience 
working in the field of musculoskeletal therapy with people who had headaches and 
migraines. It became increasingly evident that the outcomes for people with certain 
headache types were consistently good, whereas with other types the results varied 
without an obvious reason. Those with migraine, particularly uncontrolled episodic or 
chronic migraine, experienced the least predictable response. 
 
Prior to undertaking this study, a narrative literature review explored the current 
state of research in the area of MT and headaches both generally and, more 
specifically, chronic migraine (Chapter 1). This review provided evidence that there 
was both a biopsychosocial and pathophysiological basis for investigating the use of 
MT in the treatment of chronic migraine. This evidence suggested migraine is a 
neurological condition with multiple-factorial drivers and consequently likely to 
benefit from a multi-modal approach to treatment including physical therapy and 
psychotherapy (Nicholson et al. 2007; Gaul et al. 2011; Diener et al. 2015; Gaul et 
al. 2016). Following this, a systematic literature review was undertaken that 
identified a limited base of existing research. No studies of MT and CM had 
attempted to assess the effect of ‘care as usual’ i.e. Botox and adjunctive MT, 
compared to Botox alone, and none had focussed solely on the primarily affected 
population, i.e. females.  
 
Only two studies describing MT as an adjunctive intervention with chronic migraine 
were identified: a three-arm RCT (Cerritelli et al. 2015) and a two-arm pilot RCT 
(Gandolfi et al. 2017). Neither study reflected current clinical practice in the UK, 
where most CM patients in tertiary care are managed with the existing ‘gold 
standard’ treatment, i.e. Botox. Despite receiving Botox, the outcomes in these 
patients can be extremely variable, with a significant proportion remaining severely 
affected (Silberstein et al. 2014; Ahmed & Gooriah. 2015; Sarchielli et al. 2017). 
This may have been due to the multi-factorial nature of chronic migraine and the 
limited use of multi-modal interventions. Since both CM studies identified in the 
literature review demonstrated positive results in the use of adjunctive MT, the 
question raised was whether the outcomes from the ‘care as usual’ intervention (i.e. 
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Botox) might be improved with the use of adjunctive MT rather than MT as an 
alternative competing mono-therapy. 
 
As a result of the narrative literature review highlighting the low quality of many MT 
and headache studies, this study was designed as an adjunctive RCT methodology 
to mitigate some of the quality issues e.g. heterogeneity of participants, lack of detail 
on interventions, missing sample size calculations (Fernadez-de-las-Penas 2006; 
Carod-Artal 2014). The design comprised a pragmatic methodology, reflecting 
normal clinical practice and followed CONSORT and IHS guidelines (Boutron et al. 
2017; Tassorelli et al. 2018). It recruited only female CM participants undergoing 
Botox treatment from a specialist tertiary headache clinic, representative of the most 
affected group of migraine patients (Jelinski et al. 2006; Buse et al. 2012; Dodick et 
al. 2016; Deneris et al. 2017). For the purpose of this study, ‘care as usual’ in this 
study was treatment with OnabotulinumA (Botox (R)) given as per the PREEMPT 
protocol (Appendix 12a): this is currently the gold standard for CM in the UK 
(NICE.org. 2020). Manual therapy was defined as a hands-on approach utilising 
mobilisation, manipulation and soft tissue work singly or in combination (Bronfort et 
al. 2010). 
 
Accordingly, this study’s methodology used outcome measures recommended by 
the IHS guidelines, reflecting those used in major CM studies (Tassorelli et al. 2018) 
and recruited participants with CM being treated with a defined intervention (Botox) 
in a tertiary clinic setting. 
 
The research questions addressed in this study are: 
  
Question one:  Is manual therapy effective as an adjunctive to ‘care as 
usual’ in the treatment of females with chronic migraine? 
 
Question two:  Do female chronic migraine patients exhibit baseline 
characteristics that affect treatment outcomes within and between 
treatment groups?  
 
The terms ‘the study’ or ‘this study’ in this chapter refer to the data collected as part 
of this RCT and reported within this thesis.  
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This chapter begins with a discussion of the baseline characteristics of the two 
groups in the context of successful randomisation, moves on to explore differences 
between this and other studies, and follows with a discussion of the findings in 
relation to the research questions and their null hypotheses (for a reminder of the 
hypotheses, see Chapter 4, section 4.12). The chapter concludes with implications 
for clinical practice, challenges and the strengths and limitations of the study.  
 
5.2. Group characteristics 
One of the reasons for an RCT is to achieve a balance in participants’ 
characteristics between treatment arms at baseline, facilitating more accurate 
comparisons of outcomes between groups and with similar studies (Efird 2010; 
Spieth et al. 2016). 
 
This study differs to other CM studies by involving only females whereas the 
majority of CM studies have a small proportion of between 10% and 20% male 
participants (Lipton et al. 2016; Tepper et al. 2019). This typical balance was 
reflected in Gandolfi et al. (2017), but differed significantly from Cerritelli et al. 
(2015), in which the male proportion varied between 23% and 43% in the three 
groups. This is an important difference, as males are thought to differ from females 
in presentation and responses to migraine and other pain conditions (Buse et al. 
2013; Sorge & Strath. 2018). As such, the outcomes of mixed-sex studies may not 
be generalisable to either sex and may explain some of the differences in outcomes 
between studies (Peterlin 2011). 
 
The average age of the participants in this study was 44.7 years, typical of the 
majority of chronic migraine studies where mean ages vary between 41 and 51 
years (Lipton et al. 2016; Washington State Health Care Authority. 2017; Tepper et 
al. 2019; Ahmed et al. 2019). This age range was expected since the majority of 
migraine sufferers are often initially misdiagnosed (Dougherty & Silberstein. 2014) 
and consequently not diagnosed with CM until they are in their mid 20’s, after which 
they must wait several years to access to the ‘gold standard’ of the time (Dodick et 
al. 2016). However, in Cerritelli et al. (2015), the average age was less than 40 
years; this difference in average age may have been a contributing factor in 
outcome variations between this study and Cerritelli et al. (2015). 
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In this study, there was a statistically significant difference at baseline between the 
control, Group C, and the intervention, Group M, in the proportion of participants in 
the HIT6 severe category. Despite this, both groups had a high proportion in the 
severe category and were typical of the majority of people recruited to CM studies 
with Botox as an intervention (Frampton & Silberstein. 2018; Lipton et al. 2019). 
However, in people using Botox for the first time there is often a 30% reduction in 
the proportion of those in the severe category, with further reductions in cycles two 
and three of the Botox intervention, until a stable level is reached (Silberstein et al. 
2014; Guerzoni et al. 2017). All of the participants in this study had between three 
and 20 (median nine) cycles of Botox treatment and thus confirmed that participants 
were in a stable treatment state, as intended in the methodology. Furthermore, the 
participants were also representative of the most refractory migraineurs with 
potentially unidentified and/or unaddressed underlying biopsychosocial co-
morbidities that may limit further improvement (Schiano di Cola et al. 2019; Ozge et 
al. 2018; D’Antona & Matharu. 2019). Therefore, any change in HIT6 score 
/response was likely linked to the intervention.  
 
There were two important baseline outcome variables with a statistically significant 
difference between the two groups: HIT 6 score and Emotional Function (MSQ2.1).  
 
The mean baseline HIT6 scores in groups M and C (66.4 and 62.1) respectively 
indicated that Group M was slightly more disabled than Group C. However, while 
both group scores were in the severe HIT6 category, consistent with major 
pharmacological studies of CM (Washington State Health Care Authority. 2017), 
they were not consistent with the participants in Cerritelli et al. (2015). The mean 
HIT6 scores in the Cerritelli groups range from 58.5 to 59.9 which is not in the 
severe HIT 6 category, suggesting that the participants were not in the same 
refractory state as those in this study, highlighting another potential reason for 
differences in outcomes. In contrast, the HIT 6 scores of 62 (severe category) in 
Gandolfi et al. (2017) were similar to this study.  
 
The greater similarity of Gandolfi et al (2017) HIT6 scores to this study may have 
been due to Gandolfi following IHS guidelines on inclusion and exclusion criteria, as 
did this study, whereas Cerritelli et al (2015) did not appear to have done so. This 
highlights the importance of following guidelines in future studies to enable useful 
comparisons. 
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The MSQ2.1 sub domain of Emotional Function had a marginal statistically 
significant difference between groups, indicating that Group M was slightly more 
disabled than Group C as a result of feelings of frustration and helplessness linked 
to their migraine.  However, these baseline factor measures were consistent with 
large CM studies and represented substantial disability (Blumenfeld et al. 2010; 
Bagley et al. 2011; Rendas-baum et al. 2012; Dodick et al. 2015; Lipton et al. 2016).  
 
In summary, despite the slight baseline differences, the characteristics of both 
groups were relatively balanced and both groups comprised severely disabled 
participants consistent with a wide range of previously published CM studies.  The 
relatively small sample size may have had an impact on the final balance between 
the groups' baseline characteristics but overall, the outcome demonstrated that the 
randomisation process worked well. 
 
5. 3. Clinical effectiveness: Primary outcome 
 
RQ1: Is manual therapy effective as an adjunctive to ‘care as usual’ in the 
treatment of females with chronic migraine? 
 
5.3.1. Change in HIT6  
The primary outcome measure was the between group difference in HIT 6 change 
scores with an initial hypothesis H1(0) that there was no difference between the two 
groups. 
 
Although the HIT6 outcomes were positive for Group M, and the statistical power 
approximately 80%, some authors consider that the evaluation of treatment effect in 
clinical studies should examine the effectiveness of a treatment based on a broader 
evaluation. This includes clinical significance, effect size and confidence intervals 
rather than simply a-priori power and statistical significance (Sullivan & Feinn. 2012; 
Page 2014; Nahm 2017).    
 
In this study the between-group difference in HIT6 change score was greater than 
the MCID, with the point estimate and confidence interval in favour of Group M 
(Figure 5.1) and a moderate effect size.  This result is also of the same order as the 
Botox PREEMPT 1 and 2 studies in CM that reported smaller positive differences in 
change scores in HIT6 between Botox and placebo but with smaller confidence 
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intervals, as a result of a much larger sample (Aurora et al. 2010; Diener et al. 
2010).  A recent systematic review also reported statistically significant differences 
in HIT 6 change scores with migraine and other primary headaches that 
favoured MT in line with this study, although caution was noted due to the low 
quality of evidence (Falsiroli Maistrello et al. 2018) (Figure 5.1). 
 
This result suggests that being in Group M is moderately more beneficial than being 




The only adjunctive MT study into CM for which a direct comparison can be made to 
this study is Cerritelli et al. (2015); although Gandolfi et al. (2017) used an 
adjunctive treatment approach and reported a non-significant change in HIT6 it did 
not have a 'care as usual' comparator.  Cerritelli et al. (2015) reported much greater 
difference in change score for HIT6 between the ‘care as usual’ control group, and 
the MT plus ‘care as usual’ in favour of the MT (Fig 5.1).  
 
The significantly greater difference in the HIT6 change between groups reported in 
the Cerritelli et al. (2015) study raised questions as to why it was much greater than 
Figure 5-1. CM studies. HIT6 change differences (with 95% CI) 
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both this study and major pharmaceutical studies against placebo. Risk et al. (2019) 
also questioned the extent of the effect size found in the Cerritelli et al. (2015) study 
in their systematic and meta-analysis review of SMT and migraine, and decided to 
exclude it from their final analysis during peer review. Some of the differences 
between Cerritelli et al. (2015) and this current study, which may provide an 
explanation for these substantial differences, will now be explored, including the 
participant characteristics, the study design and the method of analysis.  
 
Firstly, the HIT6 MCID is normally calculated on the absolute difference in change 
(gain score) between groups (Deiner et al. 2010) whereas Cerritelli et al. (2015) 
chose to use ANCOVA, adjusting for multiple baseline covariates except, unusually, 
the baseline HIT6 which is recommended by the CONSORT guidelines (Boutron et 
al. 2017). This approach answers a different statistical question about “the 
difference between final measures, based on starting at the same theoretically 
calculated baseline” (adjusted for covariates). If the standard approach, used in the 
majority of CM studies, had been used this would have reduced the difference only 
slightly to 8.3 (Royale et al. 2011). 
 
One argument is that ANCOVA is statistically more valid than an absolute gain 
score in a randomised trial (Fitzmaurice 2001), another is that experimental design 
and research question matter more in terms of the test used (Petscher & 
Schatschneider. 2011; Smolkowski 2019).  However, the importance here is that it 
highlights the need for guidelines on how data are collected; results analysed and 
presented for comparative purposes in future MT headache studies. In this study, 
both the absolute and ANCOVA results were provided and demonstrated a 
statistically and clinically significant difference with both analytical approaches, 
highlighting the stability of the outcome. 
 
Other factors that may have influenced the difference in HIT6 outcome measures in 
this study, when compared to both Cerritelli et al. (2015) and the PREEMPT CM 
Botox studies (Aurora et al. 2010; Diener et al. 2010; Lipton et al. 2016), include the 
study duration, participant selection, medication/dosage and intervention frequency.  
 
Both this study and Gandolfi et al. (2017) were of 12 weeks duration (one Botox 
cycle) compared to Cerritelli et al. (2015) and the PREEMPT (Aurora et al. 2010; 
Diener et al. 2010; Lipton et al. 2016) studies which were 24 weeks. The CM 
PREEMPT studies used naïve participants and two cycles of Botox, 24 weeks, i.e. 
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potentially benefitting from the early stage repeated dose effect. An inclusion 
criterion for Cerritelli et al. (2015) was that the acute or prophylactic intervention had 
to be stable for only four weeks, thus the longer study period of 24 weeks may have 
also enhanced the repeated dose/temporal effects that have been shown to exist for 
CM medications over the initial cycles (Silberstein et al. 2014; Silberstein 2016; 
Guerzoni et al. 2017). 
 
This current study involved the most refractory CM participants thus limiting the 
potential for change; the participants in Cerritelli et al (2015) were generally less 
disabled and younger, suggesting some may not have CM or had a strong 
component of cervicogenic or tension-type headache, which have shown to be 
amenable to MT (Clar et al. 2014; Wandereley et al. 2015; Espi-Lopez et al. 2016; 
Ferragut-Garcias et al. 2017).  
 
The composition of the groups in Cerritelli et al (2015), having higher than typical 
proportion of male participants, may have also influenced the group outcomes. The 
current consensus is that males and females experience pain differently, including 
headaches, although the mechanisms and factors involved have yet to be fully 
elucidated (Popescu et al. 2010; Buse et al. 2013; Scher et al. 2018; Sorge & Strath. 
2018). No studies could be found that reported how males and females differ in 
outcomes to treatment with MT or Botox regardless of having CM. However, two 
studies involving physical and psychological therapy identified that males were less 
likely than females to benefit from interdisciplinary programmes for chronic pain 
(Burns et al. 1996; Racine et al. 2019).  Coeytaux et al. (2006) also found that males 
had a significantly lower reduction in HIT6 change than females when comparing 
'care as usual' and 'care as usual' combined with acupuncture. This may explain 
why the control group in Cerritelli et al (2015) with 42% males performed worse than 
the MT group with only 23% males and potentially increased the HIT6 difference 
outcomes. The gender difference in treatment effect is an area that warrants further 
investigation.  
 
Cerritelli et al. (2015) further increased the potential differences for change between 
groups compared to this study and that of Gandolfi et al. (2017) by not presenting 
the medication or regime used in the groups. This meant that each group potentially 
had different medications, with those in the worst performing groups possibly on the 
least effective medications, and more in the MT group on the gold standard, 
including topiramate and Botox. In addition, unlike this study and that of Gandolfi et 
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al. (2017), Cerritelli et al. (2015) allowed the control group to change their 
medication regime throughout the study as directed by the physician whereas the 
MT group were not. This introduces a potentially significant confounder to the 
Cerritelli et al. (2015) study outcomes, as the control group may not have benefitted 
from the long-term effect of medications and may have been negatively impacted by 
the changes, thus artificially increasing the reported differential benefit of the MT 
group. 
 
Cerritelli et al. (2015) also excluded participants with medication overuse headaches 
and significant psychological signs on examination. There is no specific detail 
whether this meant anxiety, depression or other common comorbidities or how they 
were evaluated by the physician. The PREEMPT studies (Aurora et al. 2010; Diener 
et al. 2010; Lipton et al. 2016) also exempted those overusing opioids and anyone 
with a score ≥ 24 on the Beck depression inventory or with fibromyalgia.   
 In contrast, neither this pragmatic study nor Gandolfi et al. (2017) screened 
participants for any common comorbidities (except known severe uncontrolled 
psychiatric conditions) or medication overuse prior to randomisation as the study 
was designed to examine treatment response in patients attending a typical tertiary 
clinic, and likely to be most chronic and least responsive to existing treatments. This 
is important; a relationship between medication over-use and psychological co-
morbidities has been proposed, with them both independently and jointly established 
as risk factors in chronification and reduced treatment response (Negro & Martelletti. 
2011; Riederer et al. 2013; Biagianti et al. 2014; May & Schulte. 2016; Bottiroli et al. 
2017; Seng et al. 2017).  
 
This study used one chiropractor compared to Cerritelli et al. (2015) which involved 
six osteopaths. Importantly, no details were provided on variations in outcomes 
between osteopaths in each group. Whilst this study had less participant contact 
than Cerritelli et al. (2015), the frequency of five MT sessions in 12 weeks versus 
eight in 24 weeks, was higher than Cerritelli et al. (2015). However, Pasquier et al. 
(2019) concluded that, whilst further study is required, the frequency of spinal 
manipulative therapy (SMT) did not significantly influence the clinical outcomes 
during or following SMT treatment period. The effect of treatment dose with MT 
therapy in CM is an area for future research.  
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In summary, the greater between group differences in HIT6 mean change seen in 
Cerritelli et al (2015) when compared to this study can be explained by a number of 
factors, although both studies favour MT an adjunctive intervention in CM. 
 
5.3.2. HIT 6 responder rates 
The secondary group of hypotheses in research question one considered the 
outcomes of the within-individual changes or responder rates. 
 
The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials 
(IMMPACT) group emphasised that the interpretation of results of randomised trials 
of treatments for chronic pain involve two components: interpreting the clinical 
importance of both group differences, and the individual patient improvements. Part 
of the rationale for responder analysis is that the change in group means downplays 
individual patient improvements and, to really understand the therapeutic benefit 
associated with a treatment, a broader overview should be taken. The responder 
rate analysis for all outcome measures requires an MCID and there are also 
differences in the values of MCID at the group mean difference level and at the 
individual level responder level (with-in individual) which require different 
calculations to establish clinical benefit of one treatment over another. However, 
neither identifies which participants are likely to benefit more from each treatment as 
each group was only exposed to a single intervention.  Conversely, reporting only 
the difference in proportions responding can also be misleading since it may be 
possible that many of the responders needed only a small improvement to tip over 
the MCID.  There is also the question of the value of the dichotomised variable i.e. 
the cut off from non-responder to responder.  In the absence of a validated MCID for 
a measurement instrument the value may be arbitrary and not clinically significant. 
Therefore, the balance was struck by presenting each group means difference 
outcomes against MCID and individual outcomes against MCID to gauge overall 
statistical and clinical patient benefit. (Snapinn and Jiang. 2007; Dworkin et al. 2008, 
2009; Moore et al. 2009; Cates & Karner. 2015) 
 
The within-individual MCID for HIT6 used was as 3.7 (Coeytaux et al. 2006) and can 
be used to assess if an individual participant has experienced a meaningful 
improvement in their headache condition. In this study the figure used was ≥ 4 as 
the HIT6 change results were expressed as a whole number.   
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However, in Lipton et al. (2014), the proportion of responders decreased after the 
first and second cycle of Botox until only 7.5% responded by cycle three, leaving 
almost 25% as non-responders. Other studies have also concluded that there are 
approximately 30% non-responders to Botox after approximately four cycles 
(Cernuda-Morollón et al. 2014; Matharu et al. 2017; Parrales Bravo et al. 2018). 
Given the high proportion of participants in this study categorised, by the HIT6 
score, as severely affected, it is probable that the majority of the were poor 
responders to Botox since the median number of cycles of Botox was nine, with a 
minimum of three in Group M and four in Group C. A similar effect may have 
accounted for the small mean change in HIT6 in Gandolfi et al. (2017) where the 
median number of Botox cycles was six with a range of three to ten. Thus, the 
participants in both this study and that of Gandolfi et al. (2017) could be classed as 
having refractory chronic migraine, and consequently less likely to benefit from 
ongoing treatment (Guerzoni et al. 2017; D’Antona & Matharu. 2019). This situation 
would also suggest any difference in this study was treatment effect. 
 
The results in this study demonstrated a statistically significant 30% difference in 
proportion of responders in Group M compared to Group C (Table 4.6). It was not 
possible to compare this result with Cerritelli et al. (2015) or Gandolfi et al. (2017) as 
neither presented HIT6 responder figures, and a meaningful comparison to other 
Botox studies in CM was confounded by their use of an MCID of ≥5 which is not a 
recognised MCID and would favour CM patients who are naïve to Botox rather than 
long term users. 
 
The difference between Group M and Group C responder rates was not only 
statistically, but clinically, significant as it represented a change in a group of 
patients that are likely to have been classified as non-responders in much larger 
Botox studies. However, as with the change in HIT6 score, there was the likelihood 
that responder rate outcomes were due to the placebo effect which is known to be 
high in all headache studies (de Groot et al. 2011; Hougaard & Tfelt-Hansen 2016).   
The exact mechanism of placebo in headache is unknown, although it has been 
postulated that there are three components of treatment effect (Speciali et al. 2010).  
One is the specific effect on the mechanism of headache, the second a placebo 
effect linked to the idea of having had the known treatment and finally a non-specific 
psychological covert intervention, such as empathy, listening, understanding.  
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 An aspect of all MT interventions often cited as a source of placebo, is physical 
touch despite the evidence in headache studies being inconclusive (Autret et al. 
2012; Benedetti. 2014; Meissner et al. 2013 
 
Consequently, to minimise the potential differential placebo effects, this study 
attempted to reduce the difference between the groups in social interaction and the 
project team by making weekly contact with all participants for data collection. This 
was helped by all participants having a strong relationship with the headache nurse, 
built over a number of years with an expectation of benefit from Botox every 12 
weeks.  Schwedt et al. (2007) highlighted factors associated with increased placebo 
in migraine prophylaxis treatment that included younger age, lower severity and 
being male (odds ratio of placebo response 5.8 times that of females).  
 
Although the relative values of these factors in this study should have decreased the 
placebo effect compared to Cerritelli et al. (2015), and minimised it in overall terms, 
the exact extent of the placebo effect in either study cannot be ascertained. 
 
Whilst a ‘novel’ or new treatment is thought to increase the placebo effect, the 
novelty or newness itself is not the factor in question, it is the construct of the 
novelty which drives the expectations of the participant. For example, a new 
procedure with a dramatic delivery (injected, sham surgery or involving more 
complexity) is likely to create a greater placebo effect than a new drug with a normal 
delivery (Hedges and Burchfield. 2005; Lipton et al. 2020). 
 
In this study the participants were all aware of MT and some had tried it before and 
so although the ‘newness’ factor was not high; the expectation factor may have 
added to the effect. However, since there was little difference between groups for 
many of the common outcome measures, such as headache frequency and 
intensity, this would tend to suggest a limited additional placebo effect over and 
above that of the botox injections.  
 
However, whilst one view is that placebo controlled trials establish whether a new 
intervention is better than ‘care as usual’ by more than a placebo, there is an 
alternative view: If adding a new intervention to ‘care as usual’ is better than ‘care as 
usual’ alone - even if the element of placebo cannot be measured - then is it right to 
withhold the treatment from patients that it may benefit, particularly if few other 
options are available and risks are low (Avins et al. 2012)? 
Discussion                                    5.4. Research question one: Secondary outcomes 
                                              
158 
 
In this study, the participants fitted the criteria for the most affected, refractory, 
chronic migraine patients and consequently most resistant to treatment with few 
other options. The difference in HIT6 responder rates was statistically and clinically 
significant in favour of Group M. In summary these results suggest a potentially 
beneficial treatment effect for those females most severely affected by CM with the 
use of MT as an adjunctive therapy to Botox. 
 
5.4. Research question one: Secondary outcomes   
Guidelines for CM studies (Tassorelli et al. 2018) recommend the use of a number 
of outcome measures that reflect the change in disability felt by those with CM, and 
consequently, the success of an intervention. In this study the main outcome 
measures included Patient Global Impact of Change (PGIC); the Migraine Specific 
Quality of Life (MSQ2.1); frequency of headaches; use of rescue/acute medication 
and change in allodynia.  
 
As such there are hypotheses to be considered for each outcome (section 4.12). 
The generic null hypothesis H(0)n: There is no difference between the 
[measurement] outcomes for ‘care as usual', Group C and  ‘care as usual’ with 
Manual Therapy, Group M. 
 
5.4.1. Patient Global Impression of Change (PGIC) 
The proportion of much or very much improved PGIC outcomes (responders) in 
Group M was 59%, equalling the best of the new calcitonin gene related peptide 
(CGRP) medications (Lipton et al. 2019) and significantly higher than Group C, at 
10%. The PGIC is a well validated instrument for examining the patient's perception 
of how they have improved after an intervention. It has been used in a wide range of 
chronic pain studies, is recommended by IMMPACT (Dworkin et al. 2008) for clinical 
trials in chronic pain and was recommended in the latest CM trial guidelines as a 
secondary outcome (Tassorelli et al.  2018).  Despite this, in the original literature 
search, the author was unable to find the PGIC used in any major CM or migraine 
study, whether or not MT was involved, against which to compare the outcomes of 
this study.  In a subsequent search, one recent trial of Eptinezumab, a new 
calcitonin gene related peptide (CGRP) for CM (Lipton et al. 2019), was found to 
have used the PGIC. This was a large study, involving 92 sites around the world 
with 1072 participants. The PGIC responder rates for the medication and placebo 
were 59% and 32% respectively. 
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As with all patient reported outcomes, the placebo effect is a consideration and, 
although a completely different study to this one, some aspects of the Lipton et al 
(2019) design were reported to have increased the chances of a higher responder 
rate due to the placebo effect. These included; the novelty and administration of the 
treatment, with evidence suggesting that a more dramatic intervention increases the 
placebo effect (Meissner et al. 2013; Dodick et al. 2019); and importantly, 54% of 
participants were naïve to the treatment and may have had CM for only one year, 
which provided the opportunity for greater expectancy from a new medication, 
reinforced by the higher early phase response (Guerzoni et al. 2017). There was 
also intensive patient contact with migraine experts during the trial that included 
supervised intravenous administration and frequent contact by telephone and face 
to face. Additionally, the PGIC was recorded every 4 weeks rather than once at the 
end of the 12-week intervention period, as in this study, and potentially increased 
the placebo response through learning mechanism (Bishop et al. 2016). 
  
These reported effects are not as relevant to this PhD study and consequently 
suggest that the 59% responder rate in this current study may have benefited less 
from placebo effect than the Eptinezumab study.   
 
As a comparative, the difference between placebo and the Eptinezumab responder 
rates was 27% compared to 49% in this study, assuming an additive model of 
placebo (Enck et al. 2011).  Therefore, taking into account a placebo response, the 
PGIC outcomes in this study were consistent with existing, albeit limited, findings 
from large clinical studies and in favour of MT as an adjunctive to Botox.  
 
5.4.2. Migraine Specific Quality of Life (MSQ2.1) 
The MSQ2.1 measures how migraine impacts on the participant's life using 3 
domains: Role restriction (RR): Do migraines reduce involvement in social and work 
activities; Role prevention (RP): Do they prevent these activities, and Emotional 
freedom (EF): How emotions are involved with migraines. A higher score (range 0-
100) reflects a better the quality of life. Cerritelli et al. (2015) did not use the MSQ2.1 
so a comparison cannot be made, although many Botox studies have used MSQ2.1 
and can provide a comparison to the differences between groups M and C to 
evaluate the study outcomes. 
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The mean baseline domain scores (RR, RP and EF) for both groups in this study 
were consistent with initial MSQ2.1 validation studies, CM-Botox studies and the 
latest CRGP studies (Bagley et al. 2012; Rendas Baum et al. 2013; Tepper at al 
2019) and female only studies (Talarska et al.  2014).  The mean within-group 
changes from baseline were small compared to the major Botox studies (Frampton 
2012; Silberstein et al. 2013; Aurora et al. 2014) suggesting a negligible benefit for 
both groups. However, difference between group means for role restriction (RR) 
exceeded the clinically meaningful difference, and placebo differences in recent 
studies of new CM medications (Detke et al. 2018), in favour of Group M. 
 
These results were surprising as the expectation was that Botox alone (Group C) 
outcomes would improve the MSQ2.1 score, as was the case in almost all studies of 
Botox referenced above.  One explanation is that it may reflect both the stable and 
refractory nature of the participants. This is supported by long term studies of Botox 
in which the difference in MSQ2.1 change between Botox and placebo in all 
domains is insignificant after 4 to 5 cycles (Aurora et al. 2013) despite having started 
with large change differences. This suggests that the MT did have a small positive 
effect over and above Botox on Group M participants' daily social and work-related 
activities (RR). 
 
However, conversely, the long-term reduction in difference between groups (Aurora 
et al. 2013), did not appear to be true of the MSQ2.1 responder rate. The proportion 
of responders (those exceeding the with-group MICD) was almost 50% for each 
domain in Group M; statistically significantly different to a responder rate of 
approximately 20% for RR and EF domains in Group C.  
 
Although this type of responder analysis is often completed for HIT6, figures for 
MSQ2.1 are rarely reported which limits any comparison to other studies.  In a 
systematic review involving 35 studies associated with CM, no examples of this 
analysis could be found (Washington State Health Care Authority. 2017) and the 
latest Botox studies failed to produce comparative or placebo MSQ2.1 responder 
rates (Blumenfeld et al. 2015; Young et al. 2019; Ahmed et al. 2019).  Why this is 
the case is unknown, but it identifies an area for consideration in future analysis, 
given that MSQ2.1 is widely used and has validated within and between group 
MCIDs (Tassorelli et al. 2018). However, the MSQ2.1 responder rates in this study 
tend to support the view that the quality of life was improved clinically and 
statistically in a greater proportion of Group M participants than Group C. 
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5.4.3. Medication usage  
A reduction in use of acute medication is recommended in the IHS guidelines 
(Tassorelli et al. 2018) as a secondary outcome measure. The monthly medication 
usage from the diary was analysed to identify whether there was a change between 
groups in the use of acute medications and to calculate medication over use 
headache (MO) in participants. 
 
The analysis showed a non-significant drop in usage of acute medication in both 
groups with no statistical difference between groups. This was consistent with 
Gandolfi et al. (2017) but could not be accurately compared to Cerritelli et al. (2015) 
as only the number of participants using medications was recorded in their study. 
 
However, even on this basis, the result of this study appeared to differ markedly 
from Cerritelli et al. (2015) in which 80% of the MT group stopped using acute 
medication altogether compared to none of the ‘care as usual’. The Cerritelli et al. 
(2015) result for the MT group was also far superior to the pooled analysis of three 
major Botox studies which reported a non-significant reduction in both acute 
medication and change from placebo (Washington State Health Care Authority 
2017). It also differed to a study comparing MT to amitriptyline, in which there was a 
reduced usage overall but no significant difference between groups (Nelson et al. 
1998). The reason why the MT group in Cerritelli et al. (2015) differed so much from 
its own control and sham groups, as well as from this current and other studies, 
cannot be ascertained exactly. However, it is likely a combination of the differences 
in participant characteristics between studies and between groups in Cerritelli et al. 
(2015) and also a failure to record how many days and what type of medication was 
used, as recommended in CM trials (Tassorelli et al. 2018). Other potential 
explanatory factors include an overall lower disability in Cerritelli et al. (2015) and 
therefore less dependency on acute medications (Mehuys et al. 2012), a lower 
percentage of males (in MT) which would tend to decrease the likelihood of 
medication over use (Schwedt at el. 2018), and the exclusion of participants with 
psychological signs, who tend to use more medication and be more dependent 
(Bendtsen et al. 2013; Kristoffersen et al. 2015). The results of this current study are 
consistent with Botox studies and did not provide support for the view that adjunctive 
MT reduces acute medication use over and above the use of Botox alone. However, 
the differences between Cerritelli et al. (2015) and other studies highlights the need 
for future MT studies to follow guidelines to enable better comparison of outcomes. 
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5.4.4. Medication over use headaches (MoH)  
The diary data were also used to calculate the presence of MoH which is considered 
one of the risk factors in the chronification and poor treatment response in CM (May 
& Schulte. 2016; Vandenbussche et al. 2018). Overall, a third of participants were 
classed as having MoH with no significant difference between groups. These 
findings were consistent with other studies of CM which have suggested that 
between a third and two thirds of those with CM have MoH (Natoli et al. 2010) and 
even after detoxification between 20% and 40% of CM patients have MoH (Biagianti 
et al. 2014). 
 
Some studies have proposed that Botox reduces the use of acute medications, both 
in those with MoH and in those without (Silberstein et al. 2013), whilst others’ views 
are that it does not help any more than placebo when MoH is present (Olsen 2012; 
Pijpers et al. 2019). Although Chiang et al. (2017) highlighted the heterogeneity in 
design and reporting between MoH studies as a cause for the differences, there is 
agreement that in the long term (>2 years) a cohort of patients still exhibit MoH 
regardless of withdrawal therapy, the use of Botox, or a combination. Although a 
small study, Schiano di Cola et al. (2019) concluded that after 3 cycles of Botox 
almost half of the participants still had MoH. In this study the presence of medication 
overuse was also the only single baseline factor that reduced the probability of 
participants being a HIT6 responder regardless of intervention which concurs with 
existing CM Botox studies as to its effect on outcomes. 
 
The findings from this analysis suggested that the participants in this study were the 
most refractory to Botox treatment (Negro et al. 2015) and that there was no 
adjunctive benefit from MT, for long-term users of Botox, in reducing the proportion 
classified as having MoH.  
 
5.4.5. Headache days 
The IHS guidelines (Tassorelli et al. 2018) for CM trials recommend the change in 
number of headache days per month be used as a primary outcome measure and if 
not, then as a secondary outcome along with the responder rates based on change 
in intensity of headaches. In this study, diary data over the 12 weeks collected mean 
headache frequency and intensity, from which responder rates were calculated. 
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There was no statistically significant difference in the change in mean headache 
frequency per week between groups and, although the frequency decreased and 
remained lower than baseline in both groups, there was not a statistically significant 
change over the 12 weeks.  
 
There was no significant difference between this study and Gandolfi et al. (2017) in 
the baseline frequency of headaches days per month. In contrast, Cerritelli et al. 
(2015) reported significantly higher baseline monthly frequencies of migraine days in 
the MT and control groups than the headache days in both groups in this study. The 
author could find no CM study that reached the mean number of migraine days per 
month cited in Cerritelli et al. (2015). This level of migraine day frequency was also 
at odds with the mean HIT6 scores reported by Cerritelli et al. (2015), which were 
lower than all major CM studies investigated, Gandolfi et al. (2017) and this study.  
 
However, regardless of migraine or headache days, in the MT group there was a 
surprisingly large, 70%, reduction in days per months down to 7 migraine days per 
month at week 12 and 95% reduction to 1.2 days per month in 24 weeks (Cerritelli 
et al. 2015). In comparison this study had approximately seven percent reduction in 
headache days for groups M and C over 12 weeks, with less than one percent 
reduction reported by Gandolfi et al. (2017).  The reduction in Cerritelli et al. (2015) 
was also significantly greater than those reported by major Botox CM studies where, 
despite high baseline migraine days, the reduction was only 36% over 24 weeks for 
headache days (Blumenfeld et al. 2018) and 40% over 12 weeks (Pijpers et al. 
2019). A systematic review reported that the mean change with Botox compared to 
placebo was only three headache days per month over 12 weeks (Herd et al. 2019).  
One longer term CM Botox study produced similar reductions to Cerritelli et al. 
(2015) but over 36 weeks and in a group of known responders which added a large 
selection bias (Vikelis et al. 2018). 
 
Although it was possible that the mode of MT in Cerritelli et al. (2015) had a much 
greater effect on the number of headache and/or migraine days than the MT in this 
study, or than medications in pharmacological interventions for CM, there are other 
possible explanations for these large differences in both baseline and change.  The 
definition of migraine days given to, or used by, the participants may have been 
subject to recording error with participants recording a mixture of headache and 
migraine days, which has been the subject of discussion (Tassorelli et al. 2018). 
Also, the lower mean HIT6 baseline scores in Cerritelli et al. (2015) was suggestive 
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of participants with episodic migraine and/or mixed headaches (Buse et al. 2011). 
These, by their nature, would have altered in the 24 weeks, and may have shown a 
greater response to MT and or medications. In addition, no details on the ‘care as 
usual’ intervention were provided which may have been a major confounder. 
However, some of the differences between this study and Cerritelli et al. (2015) 
might reflect a smaller sample size. These potential explanations raise the issue of 
consistency, clarity of measurement and reporting in CM studies to enable accurate 
comparisons between studies. 
 
Whilst the changes in outcomes of this study were less than the major CM studies, 
this was not surprising since these larger Botox CM studies have the greatest 
reduction in headache and migraine days during the first two cycles of treatment. 
This study comprised participants with long term Botox use, a group in which 
stabilisation has occurred, with a non-significant change from one cycle to the next 
after 6 cycles/18 months (Guerzoni et al. 2017; Vernieri et al. 2019; Pijpers et al. 
2019).  
 
Both groups in this study had the most significant drop in headache days between 
weeks one and four, with the decrease in Group M marginally statistically greater, 
albeit with a very small effect size.  This is consistent with other studies where the 
largest reduction in number of headache days was seen over the first four weeks 
(Dodick et al. 2010; Blumenfeld et al. 2018; Pijpers et al. 2019). Some authors have 
concluded this is a placebo effect (Aurora et al. 2010; Cernuda-Morollon et al. 
2015). If this was the case, then it was an interesting outcome as it would seem to 
indicate that the Group M did not have a significant additional placebo effect over 
and above that of Group C, which conflicts with some theories of placebo in MT but 
is consistent with the PGIC responder placebo theory posited earlier in this study 
(Autret et al. 2012; Benedetti.2014; Meissner et al. 2013). 
 
The findings in this study were consistent with existing long-term Botox studies and 
Gandolfi et al. (2017). The overall reduction in headache days supports a view that 
MT as an adjunctive to Botox does not reduce headache days in female, long-term, 
users of Botox. 
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5.4.6. Headache frequency responders  
A CM participant is generally a responder if they have a 50% reduction in migraine 
days or in overall and severe to moderate headache days, although a 30% reduction 
commonly used (Bendtsen et al. 2018; Tassorelli et al. 2018). The NICE guidelines 
consider a reduction of 30% in moderate to severe headache days per month, after 
two cycles, as a responder (NICE.org. 2016).  Many CM studies use both 
recommended IHS (Tassorelli et al. 2018) percentages although few specify if a 
headache is moderate or severe in the analysis, preferring to simply use the 
reduction in days per month (Khalil et al. 2015; Blumenfeld et al. 2018; Stark et al. 
2019; Young et al. 2019). In this study, mild to moderate severity was a score of less 
than or equal to four, using a NRS, with moderate to severe severity a score greater 
than four. However, issues in comparison between studies occur because there is 
no consistency in agreed percentage figure, nor what constitutes a severe and 
moderate headache if an VRS or NRS scale is used (Sjaastad et al. 2002; Tassorelli 
et al. 2018). There is also no official guidance for responder rates in adjunctive 
studies or MT studies, which makes comparative analysis with this study difficult. 
There was no significant difference in responder rates between groups in this 
current study regardless of severity of headache, although overall, approximately a 
third of both Group M and C had a ≥30% reduction in frequency of all headaches 
and a fifth had ≥50% reduction, but almost all were in the mild to moderate severity.  
 
Gandolfi et al. (2017) used a categorical scale and also found a significant reduction 
in the MT plus Botox group in the mild to moderate headache category but failed to 
present any responder rates and was limited by a very small sample size. It was 
difficult to compare this study with Cerritelli et al. (2015) as responder rates were not 
reported. In Botox studies with experienced Botox users the cumulative responder 
rates have been estimated at 70%-85% over more than 3 cycles with the trend for 
fewer participants to achieve a 30% reduction in headache days over more cycles 
(Silberstein et al. 2014; Stark et al. 2018; Schiano di Cola et al. 2019) which again 
suggests the relative lack of  significant change in the headache frequency in this 
study was to be expected. 
 
Although the quantity of data collected in this section of the study was limited, the 
findings were consistent with larger Botox studies of experienced users. The most 
likely rationale for any reduction in headache is the waxing and waning nature of CM 
(Manack et al. 2011) in combination with a placebo effect. The placebo responder 
rates for Botox studies over the same and longer periods have also been estimated 
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at between 30% and 50% (Ahmed & Gooriah. 2015; Frampton et al. 2018). The 
non-significant difference in responder rates in this study also tends to supports the 
earlier view that the MT did not add to the level of placebo over and above Botox 
(Enck et al. 2011). Clinically, it confirms the view of some authors that the definition 
of responder over the long term (e.g. for experienced users of Botox) may need 
revisiting as decisions on stopping the treatment are often based on these outcomes 
(Ahmed & Gooriah. 2015; Santoro et al. 2017; Schiano di Cola et al. 2019). 
 
5.4.7. Allodynia 
Cutaneous allodynia (CA) is considered a measure of central sensitisation (Burstein 
et al. 2000; Landy et al. 2004; Tommaso et al. 2017) and has been identified as a 
risk factor in chronification and refractory treatment response (Louter et al. 2013) via 
changes in two processes: sensitisation of nociceptive structures, and deficiency of 
anti-nociceptive systems in the ascending and descending pain pathways (Filatova 
et al. 2008; Woolf 2011; Su & Yu. 2018).  In this study, the validated allodynia 
symptom checklist (ASC) was used to measure changes from baseline to 
investigate the effect of MT on central sensitisation. No comparison could be made 
between this study and Cerritelli et al. (2105) or Gandolfi et al (2017) as measures 
of allodynia or central sensitisation were not reported. 
 
Both groups had a high proportion of participants in the moderate and severe 
allodynia categories with no statistically significant difference between them.  At the 
end of the study, there was no statistically significant difference between groups; a 
non-significant reduction from baseline in the proportion classified as having CA, 
and three-quarters of participants still reporting a score of two or higher (meaning 
allodynia is present).  
 
This was an expected outcome as participant characteristics in this study were 
similar to those in other studies in which CA was present in 90% of CM patients 
(Mathew et al. 2016; Yalin et al. 2017). Risk factors for CA included being female, 
having depression, a high frequency of headaches (>15 days month), being 
overweight and having had migraine for a long time (Bigel et al. 2008; Lipton et al. 
2008; Tietjen et al. 2009; Benatto et al. 2017).  
 
However, there was an interesting difference between the groups in the movement 
of participants within the severity categories that has not been reported before in 
any previous migraine or CM study. 
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 In Group M over half of the participants moved from the 'severe' category to 'mild' or 
'no allodynia' compared to less than a tenth in Group C, with a third of Group C 
moving to 'severe' to 'moderate' allodynia compared to a quarter in Group M.  
 
The pattern of movement from the severe category to mild and none in Group M 
versus to moderate in Group C suggests that MT added to the effect of Botox. A 
plausible explanation for this additive effect can be made from the similarities 
between the proposed mechanism of Botox in CM, and other musculoskeletal 
conditions, via peripheral nociception (Aoki 2003; Burstein et al. 2014; Do et al. 
2018) and the theories of MT influencing central sensitisation via nociceptive 
mechanisms (Bialowski et al. 2009; Nijs et al. 2010; Vigotsky et al. 2017). This 
finding is also consistent with the allostatic model (Borsook et al. 2012), in which the 
individual effects of Botox and MT might be summated to reduce a common stressor 
(e.g. musculoskeletal pain) in the allostatic load, providing potential for reduced 
chronification and symptoms. However, for some participants the results were not 
positive.  The reason for this is unclear but one possibility is that the intensity/mode 
of MT in some individuals determines whether the effect gained is beneficial via a 
reduction in noxious stimuli, or detrimental via an increase in nociception (Vigotsky 
et al. 2017). Whilst these findings must be taken in the context of a small sample 
size, the results support the use of MT as an adjunctive to Botox in CM to reduce 
signs of central sensitisation in a significant proportion of participants but not all. 
Larger studies to identify modes of MT that most reduce allodynia in this group of 
CM patients could be considered. 
 
5.5. Impact of participant baseline characteristics 
RQ2: Do female chronic migraine patients exhibit baseline characteristics that 
affect the treatment outcomes within and between treatment groups?  
 
Despite Botox being the gold standard for treatment of CM, its mechanism of action 
is still unclear, as is an understanding of which patients will benefit (Matak and 
Lackovic 2014; Schafer 2015; Jaime Kalach-Mussali and Mondlak Algazi 2018).  
Given the cost, the sometimes relatively small benefit over placebo and the 
individual differences in response, the focus of research has turned to identifying 
predictors of response (Lin et al. 2014; Russo et al. 2016; Vikelis et al. 2016; Probyn 
et al. 2017 ; Escher et al. 2017; Domınguez et al. 2018;  Schiano di Cola et al. 2019; 
Parrales Bravo et al. 2019).  
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To explore patient characteristics that might predict treatment response, or identify 
individuals who are more or less responsive to an intervention, baseline 
characteristics were gathered on a range biopsychosocial factors and headache 
characteristics that have been identified as risk factors for chronification and 
reduced treatment response (Holyroyd et al. 2009). 
 
The next section of the discussion starts by addressing correlations between factors 
and outcomes, briefly introducing potential models of mechanism. This is followed 
by a summary review of the results for HIT6 change and PGIC outcomes; the 
responder results for each of these, and an overall discussion that brings together 
common strands in the findings. It is important to note that the sample size is small 
for the type of analysis and therefore these discussions are exploratory and provide 




Initial correlations between baseline variables and outcomes were calculated, to 
establish potential relationships, as a starting point to explain differences between 
groups in the context of current theories and for inclusion in later analyses. 
 
The correlations between baseline variables and change in mean HIT6 differed 
between groups. Group C had moderate positive correlations with adaptive coping 
behaviours but a greater negative correlation with the maladaptive coping 
behaviour, substance use. In contrast, the change in HIT6 in Group M did not 
correlate significantly with any baseline factors. Therefore, this seemed to indicate 
an alteration in the mediation and/or moderation relationships which led to a 
differential effect on the HIT6 change between groups.  
 
The PGIC outcome had significant moderate positive correlations in Group M 
between baseline adaptive coping behaviours whilst Group C had moderate positive 
correlations with stress, allodynia score (ASC) and maladaptive coping behaviours, 
but a negative correlation with acceptance. Interestingly the maladaptive behaviour, 
behavioural disengagement, was the only coping factor that had a statistically 
significant change between groups over the 12 weeks and was negatively correlated 
to Group M, yet positively to Group C. This could be interpreted as those in Group C 
being less likely to engage with difficult actions than Group M and thus reflect a 
possible mediating role for behavioural disengagement in treatment response. This 
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finding is consistent with studies in pain that examined psychological factors 
involved in mediation of treatment outcomes, particularly the role of active 
engagement, reflected by the MT in this study (Leeuw et al.2006; Turk & Wilson. 
2010; Werneke et al. 2011). 
 
Despite the variations between groups, the correlations in this study are consistent 
with previous findings relating biopsychosocial and pathophysiological factors to 
headache disability and treatment outcomes: The ASC score is a measure of central 
sensitisation which has been found to correlate with chronification, poor treatment 
response and increased disability (Burstein et al. 2000; Bigal et al. 2006; Louter et 
al. 2013; Dodick et al. 2019).  Stress (anxiety/depression) factors are also a 
commonly correlated with greater disability in CM studies (González-Quintanillet al. 
2015; Moon et al. 2017; Cha et al. 2017) and coping behaviours, particularly 
avoidance behaviours including substance use, have been linked to CM disability 
and treatment response (Radat et al. 2008; Weiser et al. 2012; Biagianti et al. 2014). 
 
One possibility for the variation in correlations in Group M and C is error resulting 
from a small sample size. However, the differences in PGIC and change in HIT6 
outcomes might also reflect the underlying constructs of the measurement 
instruments, with the PGIC more likely influenced by biopsychosocial factors 
compared to HIT6 (Oh et al. 2014; Das Mahapatra et al. 2015; Scott & McCracken. 
2015). Alternatively, any differences in treatment outcomes between the groups may 
have indicated a difference in the mediation and moderation relationships between 
patient characteristics and treatment outcomes. This proposition will be explored in 
the next section. 
 
5.5.2. Moderation and mediation 
Various authors have described moderators and mediators of treatment effect 
(Baron & Kenney. 1986; Kraemer et al. 2002; Holroyd et al. 2009; Kraemer 2016; 
Hayes & Rockford. 2017). This study adopted the definitions provided by Kraemer 
(2002, 2016). 
 
(a) To be a moderator of effect of intervention (Group M or C) on outcomes, a factor 
must be a baseline characteristic that suggests on whom the intervention choice has 
differential effects on the outcome(s). Predictors are baseline factors that affect 
outcomes but do not change with intervention. 
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(b) A mediator of intervention outcomes changes over time and suggests how or 
why one intervention might be preferred over the other in the population sampled. 
Intervening factors are those that change, or occur, after randomisation but before 
the study outcome and may be independent of, or moderated by treatment 
 
At the time of writing there were no mediation/moderation RCTs with adjunctive 
studies in CM, although there was one of drug and psychological intervention SM 
(stress management) in CTTH. This suggested that presence of mood disorders has 
a mediating effect on headache disability outcomes (Holroyd et al. 2009). Kokonyei 
et al. (2016) also showed increased psychological distress (equivalent 
HADS_TOTAL) in migraine is partially attributed to (mediated by) maladaptive 
avoidant behaviour. 
 
Consequently, this study was the first to explore the potential influencers of 
response to MT as an adjunctive intervention to Botox compared to Botox alone in 
CM. Based on the results, a post-hoc premise was formulated that treatment 
outcomes may be moderated differently by some of the baseline characteristics(s). 
The discussion here must be seen in the context of a small sample size and the 
absence of a standalone MT group and should be viewed as a tentative step for the 













Using initial results, the variables correlated with treatment outcomes could be 
grouped into three themes:  Allodynia (ASC); Stress related; Coping behaviours.  
 
Although there were correlations to baseline variables with differences in outcomes 
between groups, the findings did not provide evidence of causation. However, they 
 
Figure 5-2. Generic mediation – moderation model 
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did demonstrate a consistency with existing studies on the factors that might be 
involved in mediating and moderating CM outcomes (Lin et al. 2014; Russo et al. 
2016; Vikelis et al. 2016; Probyn et al. 2017; Escher et al. 2017; Domınguez et al. 
2018; Schiano di Cola et al. 2019; Parrales Bravo et al. 2019). The next section will 
build on this initial analysis to explore those characteristics that may influence 
outcomes. 
 
5.5.3. Summary outcomes 
This section begins with a brief review of main findings, in the key outcomes of 
interest, before discussing in detail the main themes that emerged from the analysis.  
 
5.5.3.1.  Change in HIT 6 
The change in HIT 6 score is a key outcome in many CM studies (Tassorelli et al. 
2018) and at the time of writing the author could find no studies that investigated 
predictors of change in the HIT6 score. There were significant differences between 
the predictors for Group M and C. In Group C, three factors: substance use, 
planning and the HADS_Total accounted for 40% of the variation in the change in 
HIT6, whereas in Group M, no model could be regressed to account for a 
statistically significant variation in the change in HIT6.  
 
Although the major contributor to variation in groups M and C was substance use, 
the strong influence of HADS_Total in Group C and its absence in Group M was an 
interesting finding given that previous CM studies in Botox have found that 
depression/anxiety (HADS_Total), in association with medication overuse 
(substance use) lead to poorer outcomes (Disco et al. 2015; Schiano di Cola et al. 
2019). It would therefore be expected that these factors should be similar in both 
groups if no effect was involved. The finding in this study indicated that the baseline 
HADS_Total may have moderated the effect of Botox in Group C (Figure 5.3 path 
XA) possibly with other, different/unknown mechanisms, reducing its effect on the 
combined MT and Botox in Group M (Fig 5.3 path YE), and via intervening 
variables. 
  
Medication (substance) use may also have acted as independent intervening 
influencer on outcome regardless of intervention (Figure 5.3 path D), which is 
consistent with the results from this study in which medication overuse was the only 
baseline factor that had a negative impact on the probability of participants being a 
HIT6 responder regardless of intervention.  The role of HADS_Total in this study 
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seemed to mirror studies that concluded: ‘in the presence of mood or anxiety 
disorders’, headache disability was likely mediated by variables including coping 
behaviour (e.g. substance use) (Holroyd et al. 2009; Kokonyei et al. 2016). A more 




5.5.3.2. HIT 6 Responders 
This was the first study to examine HIT6 responder group outcomes and their 
relationship to predictive factors. Binomial logistic regression for HIT6 responders 
produced a model comprising treatment group, self-distraction, ASC and baseline 
HIT6 score that explained 36% of the variance in responder outcome and correctly 
classified three-quarters of cases. The odds of being a responder decreased 
significantly if in Group C compared to Group M, with an increase in ASC score 
decreasing the odds of being a responder substantially, and conversely an increase 
in self-distraction increased the odds of being a responder marginally. The area 
under the ROC curve had an excellent level of discrimination suggesting this could 
provide a useful test for distinguishing the responder outcomes in this group of 
patients (Yang & Berdine. 2017). 
 
5.5.3.3. PGIC category outcomes 
Multinomial logistical regression was used to estimate the predictive factors for 
gaining “Moderate” and “Much” improvement over no change.  For moderate 
improvement the factors were:  being in Group M, denial and behavioural 
disengagement and for much improvement: being in Group M, planning and ASC 
score. The best model for predicting the participants being in the "Much change" 
compared to the "No change" (none) category suggested that those participants in 
 
Figure 5-3. Change in HIT6 potential moderation - mediation model 
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Group M had a significantly greater probability (90%) than those in Group C.  The 
model also suggested that for each unit change in planning and baseline ASC there 
were significant increases in the probability of being in the "Much change" compared 
to the "No change" category. Although these findings must also be seen in the 
context of a small sample size and therefore as a preliminary evaluation, they 
support the secondary outcomes presented earlier on the benefit of MT as an 
adjunctive over Botox alone, providing a basis for future research to investigate the 
effect of baseline variables on patient reported treatment outcomes in CM.  
 
5.5.3.4.  PGIC responders  
A PGIC responder was categorised as having a score of five or higher. The optimum 
model comprised intervention, behavioural disengagement and denial. It explained 
61% of the variance in responder group and correctly classified 85.0% of cases with 
the area under the ROC curve having an outstanding level of discrimination (Yang & 
Berdine. 2017). The odds of being a responder decreased significantly with an 
increase in behavioural disengagement and by being in Group C relative to Group 
M, conversely an increase in denial improved the odds of being a responder. It was 
difficult to say if these results are consistent with any existing research as the PGIC 
has only recently been used for headaches or CM and no previous studies have 
addressed the biopsychosocial factors involved. And despite limiting the number of 
variables used in the model, the results must be considered as only an initial step 
towards larger studies. 
 
5.6. Themes 
The main factors highlighted in the above analyses were cutaneous allodynia (CA), 
stress (depression/ anxiety) related, coping behaviour and intervention. These are 
now discussed in the context of the main research questions.  
 
5.6.1. Central sensitisation (CS) 
Cutaneous allodynia (CA) is believed to be a result of central sensitisation and was 
measured using the allodynia score checklist (ASC). It was no surprise to find CA as 
a main theme in outcomes since the likelihood of having allodynia has been 
associated with factors representative of this study’s participants, including female 
gender, lower age at onset, high frequency of attacks, as well as comorbid 
depression/anxiety and increased medication usage (Bigal et al. 2008; Lipton et al. 
2008; Louter et al. 2013; Mathew et al. 2016; Young et al. 2019). 
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The proportion of participants with CA at baseline was very high in both groups, 
consistent with previous studies (Bigal et al. 2008; Dodick et al. 2019) and neither 
group had a significant change in proportion of participants with CA at 12 weeks. 
However, what did alter significantly was the proportion of participants in each ASC 
category for each group. Group M moved half of participants from severe to mild or 
no CA, compared to less than a tenth in Group C, and both groups moved at least a 
quarter from severe to moderate. 
 
The explanation for this outcome might lay in studies of the mechanisms of Botox 
and MT in pain and migraine. One established theory is that CA results from the 
activation of the trigeminovascular neurons which, over time, leads to sensitisation 
of second-order neurons in the spinal trigeminal nucleus. These can then become 
self-maintaining without the initial noxious sensory input from the internal and 
external neck and head structures, including the muscles, joints and cervical nerve 
roots (Bartsch & Goadsby. 2003; Bigal & Lipton. 2007; Bernstein & Burstein. 2012; 
Tietjen et al. 2019). Therefore, if this pattern of sensitisation can be inhibited, CA 
should reduce and disability along with it. 
 
Two relevant mechanisms of action have been proposed for Botox; one that it 
relaxes muscles by inhibiting acetylcholine (Ach) release resulting from the muscle 
trigger points and the two, that it inhibits nociception in the peripheral 
trigeminovascular system by the reduction of mechanical pain signals to the spinal 
trigeminal nucleus, which begins a cascade of other neurophysiological effects 
(Burstein et al. 2014; Do et al. 2018).  Jakubowski et al. (2006) also concluded the 
success of Botox with migraine pain involves extracranial sensory fibres near the 
injection sites and speculated the involvement of activation of extracranial 
nociceptors of scalp tissues, bone and periosteum. Both of these mechanisms of 
action for Botox have commonality with the proposed mechanisms and potential 
neurophysiological effects of MT in migraine and pain.  
 
Firstly, the relaxation of muscle trigger points and secondly the reduction in 
nociception, via mechanical pain signals, in structures around the head and neck 
(Bialosky et al. 2009; Nijs et al. 2010; Fernández-de-las-Peñas & Dommerholt. 
2014; Bishop 2015; Vigotsky et al. 2017; Falsiroli Maistrello et al. 2018). 
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Consequently, a greater reduction in nociceptive input from the combination of MT 
and Botox may explain the increased benefit over Botox alone in this study, with MT 
adding to the action of Botox (Ghanbari et al. 2015; Gandolfi et al 2017; Kumar et al. 
2018).  
 
However, despite the movement of participants from a higher level of ASC category 
to a lower one, a substantial proportion of participants still exceeded the cut off 
score of two in the ASC, which indicates the presence CA. One explanation may be 
that since Botox and MT are believed to influence just mechanoreceptors, and not 
thermal nociceptors (Burnstein et al.2014; Paterson et al. 2014; Matak et al. 2019), 
the ASC components of thermally induced CA would have been unaffected by either 
intervention and therefore potentially limit the ability of the ASC score to move below 
the cut off of two. This finding raises questions on the use of the ASC as a 
dichotomous measure of CA in studies of MT and Botox, for which it may be better 
to examine movement between categories as an outcome rather than a cut off 
score.  
 
There was also an unexpected result in which the higher baseline ASC positively 
correlated with a move to the ‘much change’ PGIC category, which seemed to 
conflict with higher levels of ASC being a negative factor for the HIT6 responder 
outcomes. 
 
However, there is some evidence from previous studies that offered a possible 
explanation. Young et al. (2019) reported that the presence of CA in CM could affect 
Botox treatment outcome measures differently, e.g. headache frequency compared 
to quality of life measures, and concluded that the effect of CA on treatment 
outcomes remained unclear. Since HIT 6 is a measure of disability, and PGIC a 
measure of how the participant feels they have improved, the different construct 
validity of each may lead to different outcomes from changes in the same variables, 
as observed with other rating scales (Holroyd et al. 2009; Lati et al. 2010; Mannix et 
al. 2016).  Although the role of psychological stressors in mediating allodynia is a 
subject of debate (Lovati et al.2009; Crettaz et al. 2012; Dodick et al. 2019), there is 
agreement on a strong association between depression and CA, with depression 
found to mediate patient ratings of migraine severity to MIDAS outcomes (Tietjen et 
al. 2009; Ashina et al. 2012; Louter et al. 2013; Mendonca et al.2016;Sajobi et al 
2019). 
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It is therefore possible that a different mediating relationship exists between 
depression (or HADS_Total) and the HIT6 and PGIC constructs, resulting in the 
inconsistent outcomes observed (Young et al. 2019). To the knowledge of the 
author, this is the first study to report the potential relationship between ASC and 
PGIC outcomes in CM.  
 
The findings suggest support for a potential relationship between psychological 
stressors e.g. depression, and the development of allodynia. The results are also 
consistent with existing theories on the reduction in nociception from both MT and 
Botox, and suggest a new proposal that they work in combination to create an 
enhanced reduction in central sensitisation and consequently in CA. However, this 
was a small study for this type of analysis and conflicting evidence for the role of 
allodynia in CM, specifically its treatment with Botox, remains an area for further 
investigation. 
 
5.6.2. Coping behaviours 
Coping behaviour is as an important factor in chronic pain, as well as the 
management and chronification of headaches and migraines (Gamsa 1994 a,b; 
Siniatchkin et al. 1999; Rollnik et al. 2001; Samwel et al. 2007; Radat et al. 2009; 
Borsook & Kalso. 2013; Ruscheweyh et al. 2019). In this study the main coping 
behaviour reported was maladaptive avoidant, involving self-distraction, denial and 
behavioural disengagement. One of the key and unexpected findings, in both the 
HIT6 and PGIC responder outcomes, as well as PGIC categories, was the 
association of denial and self-distraction as beneficial to positive outcomes despite 
both being maladaptive avoidant, coping strategies. The Fear-Avoidance (F-A) 
model of pain (Appendix 28) developed out of musculoskeletal pain concluded that 
two modes of coping existed: avoidant maladaptive and adaptive (Lethem et al. 
1983). Those with an adaptive approach challenged the acute phase and actively 
performed actions designed to improve, whereas the avoidant people restricted 
activities and physical performance with over predictions of pain and strong 
correlates with self-reported disability (Black et al. 2015).  The F-A model also 
recognised that behaviours, such as withdrawing from daily activities, common in 
migraine, can contribute to the symptoms of depression and that it is possible these 
symptoms stimulate F-A pathways (Zale & Ditre. 2016).  In CM, there is also a 
history of reinforcing avoidant behaviour in the form of advice to avoid triggers 
(Hoffman & Recober. 2013).  Moreover, there is a view that this process builds a 
pattern of distraction and sensitisation that reduces tolerance and encourages a 
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greater use of medications (Martin et al. 2009; Gandolfi et al. 2019). The high levels 
of medication use and disability, with higher than normal levels of anxiety and 
depression in this study, regardless of group, is therefore consistent with F-A model 
studies that suggest avoidant behaviours might contribute to increased levels of 
anxiety / depression in CM and vice versa (Buse et al. 2010; Baskin & Smitherman. 
2016; Seng et al. 2017). 
 
In this study, higher baseline denial scores significantly increased the probability of 
participants being in the PGIC moderate change category, and substantially 
increased the odds of being a PGIC responder. Likewise, higher baseline levels of 
self distraction significantly increased the probability of being a HIT6 responder. This 
was an unexpected outcome, as denial and self-distraction are avoidant behaviours 
and generally considered negative influences on a variety of pain condition 
treatment outcomes (Norton & Asmundson. 2004; Castelnuovo et al. 2016; Edwards 
et al. 2016). In common with increased use of acute medication, they have also 
been found to be negative reinforcers of the F-A pattern (Siniatchkin et al. 1999; 
Vlaeyen & Linton. 2000; Ruscheweyh et al. 2019). Conversely, some studies have 
found those with higher levels of disability use avoidant coping behaviours to benefit 
outcomes in the short term, or in differing conditions, particularly if they feel the 
situation is not going to change (Philips 1987; Turk & Wilson. 2010; Biagianti et al. 
2014; Garcia et al. 2018).   
 
This mechanism and the F-A model may explain some of the unexpected findings in 
this study. Because the expectation of these highly disabled participants is almost 
certain access to Botox every 12 weeks, they can use avoidant coping behaviours, 
including significant levels of medication, to manage in the short-term. Therefore, 
this short-term coping strategy essentially avoids the need to develop a long-term 
strategy, and perhaps access to more beneficial long-term adaptive coping 
behaviours (Leeuw et al.2006; Cosio and Lin 2018). Therefore, in this study of 
refractory CM patients, the continued use of Botox may be a long-term enabler of 
chronicity rather than a short-term solution to help break the F-A pattern. 
Consequently, the possibility of a multi-modal solution for some participants, who 
might benefit from adjunctive psychological or active therapy is missed (Norton and 
Asmundson. 2004; Nicholson et al. 2007; Williams et al. 2007; Komandur et al. 
2018). This is an area for further research, as currently the evidence has focussed 
on psychological therapy as a standalone and not adjunctive or integrative approach 
with Botox in CM (Turk et al. 2008; Sharpe et al. 2019).  
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Interestingly the MSQ2.1 outcomes (section 5.4.2) supported the view that role 
restriction (avoidant behaviour) and emotional freedom were improved in Group M 
compared to Group C, suggesting a potential effect from MT on psychological 
behaviours that may have influenced the F-A process (Williams. 2007; Sung et al. 
2014).  This relationship was given some added support as the role of behavioural 
disengagement (giving up on trying to solve the issue) had a negative effect on 
PGIC outcomes, consistent with other studies of pain and migraine (Esteve et al. 
2007; Radat et al. 2008; Weiser 2012; Stanisławski 2019). However, it was also the 
only coping behaviour that reduced statistically over the 12 weeks and only in Group 
M. This may tentatively suggest a mediating role for behavioural disengagement in 
PGIC outcomes when using MT with Botox, in the same manner as ruminating 
(avoidant) behaviour has been shown to be a potential mediator between 
psychological distress and migraine severity (Kokonyei et al. 2016). It is possible 
that, by undertaking a more active role in treatment, Group M were challenging 
negative behaviours in the F-A model (Cosio & Lin. 2018).  This remains an area for 
further research and possibly development of a more active/engaged approach to 
management. 
 
5.6.3. Stress  
In this study stress was measured using the PSS10 and HADS instruments. The 
mean PSS scores in groups M and C were consistent with other CM studies: higher 
than a healthy population control (norm) and substantially higher than the norm for 
females (Moon et al. 2017; An et al. 2019). The proportions of depression and 
anxiety in both groups were also consistent with other CM studies, with participants 
having more than twice the anxiety and three times the level of depression expected 
in the general UK population (Zigmond & Snaith. 1983; Crawford 2001, Buse et al. 
2011; Yavuz 2013; Breeman et al. 2015).  The HADS_Total score was used as a 
measure of overall emotional (psychological) distress and was abnormal in three-
quarters of cases. These figures were not surprising in a group of long-term CM 
patients, and confirmed the well-established relationship between increased 
psychological comorbidities and poor outcomes in CM (Breslau et al. 2003; Antonaci 
et al. 2011; Ashina et al. 2012; Buse et al. 2013; Lampl et al. 2016; Seng et al. 
2017).  It nevertheless supported the view that the participants in this study were a 
highly refractory treatment group and any changes in treatment response were most 
likely the result of the treatment effect. 
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In this current study, HADS_Total (emotional/psychological distress) was a large 
contributor to the 40% variation in Group C HIT6 change but did not contribute to 
variation in Group M. This suggested that HADS_Total may have moderated the 
effects of Botox on outcomes in Group C (Figure 5.3).  The reason for apparent lack 
of effect on Group M is unclear, although one possibility is that the effect of the MT 
component in Group M on the HIT6 outcome was mediated directly or via an 
intervening variable, perhaps substance use or coping behaviours. Alternatively, the 
effect on outcomes of the MT component in Group M may have been moderated 
differently by HADS_Total. This points towards a possible role for MT in the 
management of CM via an influence on psychosocial factors as suggested by other 
studies (Williams et al. 2007; Saracutu et al. 2015; Wirth et al. 2016; Courtney et al. 
2017; Seng et al.2017). A similar response was reported by Holroyd et al. (2009), 
whereby the treatment effects of stress management (SM) and antidepressants 
were different, based on the absence or presence of mood and anxiety disorders, 
when comparing each of the individual components to the adjunctive antidepressant 
and SM group. Although a detailed modelling of this was beyond the scope of this 
study, it remains an area for future investigation with a much larger sample.   
 
5.6.4. Manual therapy 
Being in Group M was a large contributory factor to being a HIT6 and PGIC 
responder and conversely the chances of being a HIT6 or a PGIC responder were 
decreased significantly by being in Group C. The results also suggested that by 
being in Group M there was a significantly greater chance of being in the PGIC 
‘much change’ category than the ‘no change’. 
 
To date, the mechanism of action of Botox in CM is still unclear although it has been 
suggested that it acts by reducing peripheral nociception from extra and intercranial 
structures, including upper cervical structures and via the trigeminocervical complex 
(TCC) (Jakubowski et al. 2006; Burstein et al. 2014; Do et al. 2018; Melo-Carrillo et 
al. 2019).  Similarly, studies have indicated that MT leads to a reduction in the 
peripheral nociception from extra and linked intercranial structures in the cervical 
spine and via the TCC leading to diminished central sensitisation (Bartsch et al. 
2003; Scheuler et al. 2013; Courtney et al. 2017).  
The reduction in peripheral nociception via both MT and Botox has been explained 
by a reduction of sensitisation in the mechanoreceptors with inhibition of C fibres, 
decreasing activation of muscle spindles along with the reduction in, and mediation 
of, inflammatory neurotransmitter actions. Whilst the neurotransmitters involved in 
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Botox and MT are not the same, there is considerable overlap, including substance 
P, dopamine, serotonin and acetylcholine (Vigotsky & Bruhns. 2015; Do et al. 2018) 
which may provide another explanation for the study outcomes.  It has also been 
proposed that the actions of both Botox and MT are not just at the neuromuscular 
junction but also the spinal and supraspinal levels. This provokes an (indirect) effect 
on the CNS via plastic changes resulting, in part, from modulation of the peripheral 
sensitisation (Aoki et al. 2003; Schmidt et al. 2008; Bialosky et al. 2009; 
Ramachandran & Yaksh. 2014; Escher et al. 2017; Matak et al. 2019; Martinelli et 
al. 2020). Subsequently, these nociceptive changes can interact in the higher brain 
(e.g. thalamus, cortex) with inputs from the sensory pathways (psychological 
including emotions, beliefs and environmental challenges) being modulated by the 
descending analgesic system (Shacklock 1999; Dodick et al. 2019; Crettaz et al. 
2012; Jaime Kalach-Mussali & Algazi. 2018; Weise et al. 2019; Kumar 2018).  
 
It has also been shown that different types of MT act via different mechanisms within 
similar pathways e.g. SMT on cervical and thoracic spine produces hypoalgesia via 
mechanisms different from cold stretch for trigger point techniques (Bialosky et al. 
2009; Vigotsky & Bruhns. 2015). Therefore, a combined MT approach is likely to 
provide a greater response than a single one, as is a combination of Botox and MT. 
The differences in response to Botox in some individuals compared to others may 
be a result of individual differences in pathophysiology at the cellular level (Durham 
& Cady. 2011) and therefore the best responders to Botox might gain benefit 
through more than one pathway, whereas the more refractory group may be reliant 
on a more restricted number of mechanisms. 
 
In conclusion, the findings of this study are consistent with the proposed 
mechanisms of MT and Botox having worked in synergy to reduce peripheral 
nociception and consequently central sensitisation via similar pathways but not 
necessarily the same cellular processes. MT may have also impacted disability 
measures through an effect on both physical and psychological factors, consistent 
with components of both the allostatic and neurobiological models that formed a 







   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   








   
   
   
   
   
   
   
   
   
   
   
   
   
   




































































































































































































































































   
 




5.7. Clinical implications  
CM patients represent a high caseload in tertiary neurology clinics, one estimate 
being that approximately 50% of patients attending a tertiary headache clinic have 
CM (Kainth et al. 2018; Peres at al. 2019). They present a challenge, as they have 
tried many other interventions and commonly have comorbid psychological 
conditions such as depression and anxiety and are heavy users of acute 
medications (Breslau et al. 2003; Bigel et al. 2008; Lampl et al. 2016; Davies et al. 
2018). CM is a pain driven neurological condition in which the mechanisms are not 
fully understood and for which there were no specifically developed treatment 
options until Botox (May & Schulte. 2016; Dussor. 2019; Andreou & Edvinsson. 
2019). However, none of the available pharmacological interventions are successful 
in all cases and often yield limited results in many (Carod et al. 2014; Weatherall. 
2015; Agostini et al 2019). It is estimated that even after four or five rounds of Botox 
30% of patients are still classed as severely disabled (Cernuda-Morollón et al. 2014; 
Matharu et al. 2017; Parrales Bravo et al. 2018). Consequently, in light of multiple 
potential drivers and the less than satisfactory outcomes in the gold standard mono-
therapy, it is evident that a multi-modal approach to treatment may be more 
appropriate (Gaul et al. 2011; Wallasch et al. 2012; Grazzi 2013; Burstein et al. 
2015; Gaul et al. 2016; Grazzi & D’Amico, 2019). 
 
Hence, this study set out to establish if adjunctive MT affected the treatment 
outcomes in those with CM already using Botox. The results suggested that MT was 
a suitable adjunctive capable of achieving clinically and statistically significant 
beneficial outcomes in a group of female CM patients who had used Botox for a 
significant period. 
 
There are a several clinical implications from this study. Firstly, the findings concur 
with the view that not all CM patients benefit from Botox in the same way over time, 
and a significant proportion remain severely disabled. Early identification of the most 
refractory group of patients would enable quicker implementation of a multi-modal 
management approach to improve their outcomes. This study suggests that 
identifying and addressing medication overuse/high levels of substance use early in 
treatment would improve results as it was the only baseline factor that reduced the 
chance of being a responder in both groups. 
 




There should be encouragement for the use of validated electronic diaries/apps 
tracking a number of factors in real-time over time, rather than relying on the 
patients completing a single form and or historic diary at the time of their next 
appointment. This would reduce bias and enable better evaluation of patients’ 
outcomes and progression, providing opportunities for earlier intervention. 
 
Although the characteristics of the subgroup of patients who gained the greatest 
benefit from the combination of MT and Botox could not be accurately ascertained in 
this study, as it was not designed to do so, it provided a starting point for future 
development. The analyses suggested those with higher levels of cutaneous 
allodynia, maladaptive coping and psychological distress would gain greater benefit 
from a combined MT/Botox intervention than Botox alone. An initial evaluation of 
these factors prior to treatment could be a useful method to identify those who might 
be offered MT. 
 
The results from this study also suggest that future CM studies, involving refractory 
patients, may require a distinct set of guidelines on outcome measures that more 
accurately reflect the patient experience. The majority of studies use traditional 
comparison of active and /or placebo RCT trials with naïve patients, who are the 
most likely to respond according to the traditional instruments such as HIT6 and 
MSQ2.1. However, many, like those in this study, still have high level of disability, 
measured using HIT6 and other validated instruments, after treatment for long 
periods of time. It may therefore be of benefit to use the PGIC in clinics to gauge 
treatment outcome (Dworking et al. 2008, 2009). 
 
The findings of this study suggest that continuing long-term use of Botox in the most 
refractory patients may reinforce the fear-avoidance patterns and encourage poor 
coping skills rather than helping patients access more appropriate / beneficial 
interventions. Therefore, there may be a benefit from a detailed screening, including 
a psychological review, after four or five rounds of Botox to ascertain the progress of 
a patient and consider alternative/adjunctive interventions if they are exhibiting 
characteristics of a refractory patient (Aydinlar et al. 2017). 
 
Finally, the evidence presented is consistent with an integrated mechanism of action 
that combines the neurobiological and allostatic models of pain and migraine. 
Consequently, it supports the view that a tailored multi-modal approach to the 




management of CM, based on patient characteristics, may provide greater benefits 
to a wider range of patients rather than the continued use of a mono-
pharmacological therapy (Gaul et al. 2011; Wallasch et al. 2012; Grazzi 2013; 
Burstein et al 2015; Gaul et al. 2016; Grazzi & D’Amico, 2019; Borsook et al. 2019). 
 
5.8. Challenges 
Undertaking a clinically-based RCT in a busy NHS site, as part of a doctoral study, 
provided several challenges. As an NHS non-CTIMP randomised control trial, the 
normal Regional Ethics Committee (REC) involvement inevitably adds time, over 
and above University ethics, before the recruitment process can begin. The first 
challenge was therefore the requirement to resubmit the REC application due to a 
conflict with University policies. This required the original study design, involving two 
tertiary headache centres with 100 participants, to be restructured. The major centre 
was removed which meant having to renegotiate an increase in the number of 
participants at the smaller site. This added a delay of several months to the study 
and, to ensure the project was completed on time, required good project 
management, relationship building and communication skills. 
  
Working with the NHS also presented specific challenges in terms of the complexity 
and time needed to manage multiple interactions with participants, NHS research 
department, clinical and administrative staff as well as the administrative 
requirements of an RCT with the University and the Health Research Authority.  
One of the biggest challenges was ensuring a room was always available in a busy 
major hospital for participant interactions over the duration of the project. This was 
managed by ensuring a good relationship and regular contact with the decision-
makers. 
 
Recruitment clinics were also cancelled due to staff availability, disrupting 
recruitment and requiring ongoing changes to the 12-week recruitment schedule. 
Whilst this is all part of normal NHS life, and as such part of a pragmatic study, it did 
affect the recruitment time and data collection which required the author to be 
adaptable to changes, often at short notice, and to maintain a live project 
management system. A small extension to the original end date was agreed with the 
NHS and the REC to manage the impact of clinic closures on the recruitment 
schedule. 





A major challenge over the period of the study was the need for recruitment, data 
collection and treatment phases to run concurrently, requiring a complex approach 
to communication and implementation. Small groups of participants had to be 
managed in different phases of the study concurrently, including weekly contact with 
small numbers of participants for diary updates via text and emails as they 
progressed through the study, organising treatment schedules at three locations and 
arranging the follow up and end of study meetings. A detailed project plan and time 
management system was designed and actively managed to cope with the 
sometimes rapid and unexpected changes. 
 
5.9. Strengths and limitations of study 
 
5.9.1. Strengths 
This PhD study had a number of strengths. It included narrative and systematic 
reviews that identified a lack of research investigating CM and MT and highlighted 
issues surrounding the design and quality in headache studies. Consequently, the 
strength of the study was founded on the pragmatic RCT design, close adherence to 
CONSORT and IHS guidelines and, by dint of being an NHS non-CTIMP RCT 
study, the design had to satisfy the REC and HRA procedures as well as the 
University. 
 
The study was unique in that no other pragmatic RCT trial study involving MT and 
chronic migraine had taken place in a UK, let alone in an NHS tertiary headache 
clinic, with all participants diagnosed by experienced headache neurologist.  
Although previous studies have investigated MT as a standalone intervention for 
CM, as far as the researcher was aware, none have addressed it as an adjunctive 
therapy in comparison to the gold standard ‘care as usual’ (Botox) pharmacological 
intervention in a working clinic. The study was also unique as it demonstrated for the 
first time that undertaking a MT-RCT alongside standard interventions in an UK 
NHS setting is possible without disrupting the running of the organisation and that 
many people with CM are open to being involved. The study had data collection 
instruments (questionnaires and diary) professionally created and produced; 
designed to shape participant perception of the documents’ value and importance 
and encourage the completion and return of the information. This appeared to work 
well, with a 100% return and completion rate in questionnaires and 85% in diaries. 




The design of the booklets intentionally delivered the validated instruments as a 
series of questions in sections. This was intended to mitigate confirmation bias, by 
preventing experienced migraineurs from recognising commonly used instruments 
such as the HIT6 and adjusting their answers out of concern that they may lose 
access to their Botox intervention (Pannucci & Wilkins. 2010; Althubaiti 2016).  
 
To balance the 'contact' difference between the groups, reduce recall bias and 
maintain compliance, weekly text messages/emails were sent as reminders to 
complete the diary (Lin & Wu. 2016). This strategy worked well and gave the ‘care 
as usual’ group a stronger ‘buy–in’ to the study, evidenced by acknowledgement 
contact back from many of this group.   
 
At the time of the literature review, design and data collection, this study was the 
first Botox study to use the Patient Global Impression of Change (PGIC) in an RCT 
involving chronic migraine despite it being a recommended measure in the IHS 
guidelines (Tassorelli et al. 2018).  Although in a subsequent update to the literature 
search, a recent trial of a new calcitonin gene–related peptide (CGRP) for CM was 
found to have used it (Lipton et al. 2019) which bodes well for the future. 
 
5.9.1.1.  Internal and external validity 
As a pragmatic rather than explanatory design, one of the methodological objectives 
of this study was the preservation of high external validity to enable the application 
of the findings to clinical practice, rather than maximising internal validity by strict 
control of variables (Godwin et al. 2003, Louden et al. 2015). 
 
Nevertheless, a number of factors has been proposed that may affect external 
validity, including: the setting; selection of participants; characteristics of randomised 
participants; difference between the trial process and routine clinical practice, and 
relevance of outcome measures (Rothwell 2006). In this study, these factors were 
mitigated to increase external validity:  The setting was a routine tertiary clinic in the 
Outpatients department, with MT treatment in similar therapy room settings. 
Recruitment involved only female participants identified from ongoing clinical list, 
having had more than 2 cycles of Botox and therefore in a clinical stable situation. 
There was little difference between the groups after randomisation and the trial 
process was embedded in routine clinical practice with outcome measures as 
recommended by the IHS including patient centred outcomes. That said, whilst the 
study exhibited good external validity (Sedgwick 2014), this would have been 




augmented by being extended to the multiple tertiary centres as originally planned. 
The findings of this study have potential benefit for females with CM attending a 
tertiary clinic being treated with Botox on a 12-week cycle.   
 
However, it may also be possible that these findings are applicable to primary care 
since all other factors, apart from the tertiary care clinic setting for Botox injections, 
would be similar for any female being treated with Botox. One of the main caveats to 
this argument may be that as this study most likely involved refractory migraineurs 
they may not represent first time attendees in either tertiary or primary care clinics. 
However, it is well reported that people with CM are under/mis diagnosed in primary 
care and often experience a prolonged period of mismanagement. Thus, the 
participants in this study are likely to reflect those in primary care with a 
longstanding history classed as simply ‘migraine or chronic headache’ who are not 
fortunate enough to get to tertiary care. (Al-Hashel et al. 2013; Dodick et al. 2016). 
In part this may be because CM, like many other chronic pain conditions, currently 
lacks identifiers for best outcomes (treatable characteristics) with inclusion for 
appropriate treatment based on diagnostic labelling that is often very subjective. 
(Shrimanker et al. 2018).  
   
This study tried to maximise the internal validity through the application of the RCT 
process and the CONSORT guidelines (MacPherson 2004; Zwarenstein et al. 2008, 
2010). To ensure high internal validity, ideally there would be randomising of 
participants together with blinding of those handling data at any stage of the 
process. However, as part of a doctoral programme the lack of resource meant it 
was not possible to blind data collection, which should be seen as a limitation, 
although patients were successfully randomised and the data were re-coded by a 
supervisor prior to analysis. 
 
5.9.2. Limitations  
All research has its limitations. This study was no exception; the usual limitations on 
time and resources encountered by the majority of doctoral candidates were primary 
factors. 
 
Despite the impact of CM on the individuals and society, it is a relatively newly 
defined condition; this, together with the combination of CM with MT, resulted in a 
limited research base against which to evaluate the outcomes of this study. 
Conversely this provides an opportunity for significant development of 




understanding. Therefore, the lack of comparative studies found in the systematic 
literature review against which to evaluate the outcomes may be considered a 
limitation. The researcher's reliance on existing nursing staff in the NHS tertiary 
clinic supporting recruitment on a voluntary basis acted to some degree as a 
limitation in some of areas of the study process. Elements of miscommunication in 
the recruitment process may have contributed in part to the lower than anticipated 
conversion rate.  For example, potential participants were initially advised by NHS 
staff that they would have to attend the hospital for treatment if randomised to Group 
M. Consequently, they declined to progress in the recruitment process as travelling 
to and parking at the hospital is difficult. In fact, there were three treatment 
locations, awareness of which might have influenced the participation decision. 
Short notice changes to the planned 12 weeks follow up appointments also 
compromised researcher availability to attend on every occasion which sometimes 
meant rescheduling data collection, particularly in Group C. 
 
With hindsight, a limitation was the paper diary approach. Although it is 
recommended by the IHS (Tassorelli et al. 2018) and had a high compliance in this 
study, the design was not optimal and led to some limitations in analysis. For 
example, it would have been better to collect migraine attack data and non-migraine 
headache data separately rather than just headache data, and to use a four-point 
categorical scale for better comparison with existing studies. The use of mobile 
electronic diaries and migraine Apps was investigated during the design phase to 
help reduce recall bias inherent in paper (Althubiati 2016); a suitable option was not 
available and, although an online diary was made available, only three participants 
chose to use it. It is also the case that many current electronic diaries require high 
levels of IT and administrative support (Hanson 2016), which was not available in 
this study. Ease of use, security and quality of data are essential in diary data 
collection and future studies may benefit from the development of secure app data 
collection systems that are pre-validated by official research organisations such as 
universities. It was also evident from the initial randomisation meetings that MT was 
an attractive option for many participants, with disappointment resulting from an 
allocation to Group C. For this reason, collecting the participants’ expectations of 
likely outcome prior to treatment may have been an improvement; enabling an 
exploration of any possible association between initial beliefs and experienced 
outcomes, which has been shown to be a factor in other studies (Autret et al. 2012; 
Benedetti 2014; Frisaldi et al. 2017). 




The nature of the study prevented the implementation of a double-blind RCT as is 
always the case in studies involving MT. Whilst single blinding and the use of some 
form of placebo or sham group would have improved the strength of the findings, 
the resource limitations inherent in being part of a doctoral programme meant it was 
difficult to add an extra group. The issue of time resource in a doctoral study also 
prevented the inclusion of a follow-up period, as recommended by the IHS. An 
important limitation was the lack of knowledge of psychological comorbidities for 
which participants may or may not have been treated. The randomisation process 
equalised the balance of any co-morbidities between groups but the individual 
degree of co-morbidity may have influenced the final outcomes. 
 
The use of a single site in Salford could be viewed as a limitation. It is likely to have 
reduced the generalisability of the findings on a socioeconomic basis as Salford was 
the 22nd most deprived local authority area out of 326 in the UK (CQC, 2016).  
However, as the majority of the participants were from outside the Salford area 
(Figure 4.6) and comprised a wide range of socioeconomic status, generalisability is 
considered less of an issue. Although the sample size was consistent with other 
RCTs studies involving MT, migraine, CM, it was still a relatively small trial and 
should be seen as a limitation with regard to the power calculations.  This made the 
results of some of the more data intensive (e.g. regression) statistics more prone to 
uncertainty and they should be viewed as an exploratory step in developing models 
to identify those patients who may benefit from the combination of MT and Botox in 
the treatment of CM. 
 
5.10. Summary 
This chapter began with the background and rationale for this study. It then gave a 
reminder of the research questions, followed by a discussion the findings in relation 
to these questions and the relevant literature and theories underpinning the study. 
The characteristics of the two randomised groups were considered before 
discussing the similarities and differences between the primary and secondary 
outcome measures in research question one and the effect of baseline 
characteristics in research question two. A summary of clinical implications of the 
findings was then presented followed by the study strengths and limitations. The 
next chapter completes this body of work by providing a summary of conclusions 
that can be drawn from the findings, followed by the key contributions to knowledge 
and concludes with suggestions for areas of future research.




CHAPTER 6  CONCLUSIONS 
6.1. Introduction 
At the time of undertaking this PhD, the gold standard for CM treatment in tertiary 
clinics was the mono-therapy of Botox. Whilst this benefits many patients, often the 
effects are only partial, resulting in a substantial proportion of individuals still 
severely affected even after years of intervention. Consequently, there is potential 
for new approaches to be examined (Silberstein et al. 2014; Ahmed & Gooriah. 
2015; Sarchielli et al. 2017). 
 
A narrative review of literature was undertaken that concluded CM was a condition 
with multiple possible drivers and likely to benefit from a multi-modal approach to 
treatment including physical therapy, psychotherapy and pharmacological (Diener et 
al. 2015, Gaul et al. 2016).  It highlighted two theories that suggested MT was a 
potential adjunctive intervention. The first was a neurophysiological-pain model, the 
second the allostatic model, incorporating a wider range of biopsychosocial 
considerations (Borsook et al. 2012; May & Schulte. 2016; Bonivita et al. 2018). This 
was followed by a systematic literature review that confirmed gaps in research, with 
only two studies of MT as an adjunctive to ‘care as usual’ CM treatment (Botox) 
identified. These findings established the overall need for, and aim of the study, 
which was to evaluate the effect of MT as an adjunctive approach to treatment of 
CM. There were two main research questions. The first considered what effect 
adjunctive MT had on treatment outcomes in CM and comprised the primary 
outcome with additional secondary related outcomes.  The second considered the 
effect of participant baseline characteristics on outcomes.  
 
6.2. Research question one 
The results of the primary outcome and secondary outcome measures showed 
improvements in both disability and quality of life measures when adding MT to 
Botox over and above Botox alone. Previous studies into the role of MT in primary 
headaches were often criticised for their low quality and heterogeneity of approach 
(Fernadez-de-las-Penas 2006; Gonzales 2018).  To address this criticism the 
decision was made to design a pragmatic RCT in a tertiary CM clinic that followed 
International Headache Society and CONSORT guidelines (Boutron et al. 2017; 
Tassorelli et al.2018). However, significant variations in the results were found 




between this study and that of the main comparative study (Cerritelli et al. 2015) that 
were most likely the result of differences in design and recording of outcomes 
(particularly participant selection criteria). For example, compared to this study and 
larger CM studies, the participants in Cerritelli et al. (2015) had a lower severity in 
baseline headaches; participants were also excluded if they had common co-
morbidities. The proportion of male participants varied significantly between the 
intervention groups within the Cerritelli et al (2015) study and was much greater 
than in the majority of CM studies (Popescu et al. 2010; Buse et al. 2013; Scher et 
al. 2018; Sorge & Strath. 2018). As a result, it was concluded from this current study 
that heterogeneity in study design for CM was still an issue particularly affecting 
comparisons of efficacy. It was also concluded that naïve Botox users benefitted 
from early intervention gains in the first two cycles of treatment followed by reducing 
returns and a stabilisation after approximately four cycles (Guerzoni et al. 2017; 
Vernieri et al. 2019; Pijpers et al. 2019). Thus, outcomes in long-term users of 
Botox, who are still severely disabled, are unlikely to be comparable to naïve users.  
 
In summary, MT as an adjunctive to Botox provides a beneficial effect to females 
with CM in this study.  However, the boundaries of this conclusion may be limited by 
the CM patient group, which in this study are females who are still severely disabled 
after more than 4 cycles of Botox and by default most likely in need of an 
alternative, multi-modal approach to treatment. 
 
6.2.1. Responder rates 
This study reported HIT6 responder rates and was the first CM study to report the 
PGIC responder rates. The results were significantly in favour of adjunctive MT, 
concluding that MT is useful adjunctive to Botox. Nevertheless, the PGIC results 
were more significant than the difference in the primary outcome measure (HIT6) 
would have suggested. This could be seen to corroborate the conclusions of the 
IMMPACT group (Dworkin et al. 2008, 2009) in that the responder rates provide a 
broader overview of therapeutic benefit associated with treatment compared to 
group mean change scores. In contrast, there was no statistical difference in each 
group, or between groups, over 12 weeks in the responder rates for moderate to 
severe headache frequency; greater than 30% or 50% reduction (Tassorelli et al. 
2018). There was however a high number of participants with a 50% reduction in 
mild to moderate headache. This outcome was difficult to compare to similar studies 
as the definitions of a responder, in terms of the percentage reduction in frequency, 
and the quantification of severity of headaches, e.g. mild/moderate, varied.   




A further conclusion from this PhD study, consistent with long-term responder Botox 
studies, is that the definition of responders in CM studies is an area for further 
development to enable useful comparison of responder outcomes (Vernieri et al. 
2019). 
 
This was the first MT-CM study to use the ASC and presented new data on the 
reduction in levels (e.g. mild, moderate, etc) of CA. The results suggested that a 
higher proportion of those in Group M reduced their level of allodynia compared to 
Group C. From this, it was concluded that this may be a result of the adjunctive 
benefit of MT reducing central sensitisation and for which a mechanism of action 
was proposed. However, it was also concluded that using the ASC cut off score (≥2) 
as a binary measure of CA may mask important underlying clinical changes. At the 
time of writing and as far as the author is aware, the information presented on ASC 
outcomes in this study is novel and the first time it has been addressed in CM. 
 
In addressing research question one, both the primary and secondary outcome 
measures support the view that MT is an effective adjunct to Botox in CM for this 
group (severely affected female, long-term users of Botox). 
 
6.3. Research question two 
This section addresses research question two with regard to the baseline 
characteristics of participants that influence the outcomes, and that help to identify 
those patients who might benefit most from MT as an adjunctive treatment. This 
study was the first to explore the role of potential moderators in MT and CM and put 
forward initial suggestions on baseline participant characteristics, including 
biopsychosocial factors, that might be used to determine levels of response. It is 
important to acknowledge that, although the findings were consistent with other 
Botox studies (Probyn et al. 2017; Bottiroli et al. 2018), the analyses were made 
rooted in a small sample size. The results should therefore be seen as a basis for 
development and provide support for larger studies in the future.  The study 
highlighted four factors of interest in the models; central sensitisation (allodynia), 
stress related (depression/anxiety), coping behaviour and the relative role of the 
intervention (MT).  
 




6.3.1. Central sensitisation 
The higher allodynia scores appeared to be associated with negative changes for 
HIT6 outcomes and positive ones for PGIC outcomes. This supports the conclusion 
that allodynia may be mediated or moderated by factors, not considered in this 
study but have been in others (Sandkuller et al. 2009; Crettaz et al. 2012; Dodick et 
al. 2019). It also highlighted how the differences in construct validity of PROMS can 
produce seemingly contradictory results and reinforced the importance of selecting 




In this study the stressors identified were consistent with previous studies and 
included higher than normal levels of depression, anxiety and stress (PSS) and the 
presence of medication overuse in a high percentage of participants. It concluded 
that these factors are associated with a more refectory group of CM patients and 
poorer outcomes. Consequently, giving appropriate consideration to these 
comorbidities should be an essential part of a multi-modal intervention approach 
(Buse et al. 2011; Yavuz 2013; Breeman et al. 2015; Lampl et al. 2016; Probyn et 
al. 2017 Seng et al. 2017).   
 
6.3.3. Coping behaviours 
A significant and unexpected finding was the use of maladaptive coping behaviours 
in positive outcomes. This has been discussed in studies of the ‘fear-avoidance’ 
model in chronic pain and headaches. These suggest short term maladaptive 
coping can be useful, particularly in cases where patients believe there is no 
solution to their problem (Philips 1987; Gunnel & Akkaya. 2008; Turk & Wilson. 
2010; Biagianti et al. 2014; Garcia et al. 2018). An important conclusion therefore is 
that the long-term use of Botox in some patients may be enabling maladaptive 
avoidance coping, which provides a short-term fix, but could result in long term 
disability. This disability may then be reflected in, and affected by, a two-way 
relationship with stressors such as depression and musculoskeletal pain. This would 
support the chronification process for CM proposed in the allostatic model (Borsook 
et al. 2012).  
 




6.3.4. Medication use 
Although substance or medication use is a coping behaviour, it is important to 
highlight its negative influence at almost every stage of analysis in this study. 
Medication overuse was also the only factor that reduced the probability of being a 
HIT6 responder in both groups. This finding corroborates previous work into the 
negative influence of increased substance use i.e. medication overuse on treatment 
outcomes in CM (May & Schulte. 2016; Vandenbussche et al. 2018). 
 
6.3.5. Manual therapy, mediation and moderation 
The pragmatic conclusion in this study is that MT, as an adjunctive to Botox, 
improved the outcomes for Group M compared to Group C. However, conclusions 
on the potential roles of MT, outlined below, are areas for further development. The 
study indicated that the baseline HADS_Total may have moderated the effect of 
Botox in Group C whilst other, possibly different, unidentified mechanisms, reduced 
its effect on the combined MT and Botox in Group M. In addition, behavioural 
disengagement was the only coping factor that showed a significant reduction over 
the 12 weeks, in favour of Group M. From this, a tentative conclusion is that it may 
have a mediating role on Group M. These findings suggest a possible role for MT in 
the management of CM via an influence on psychosocial factors (Williams et al. 
2007; Wirth et al. 2016; Courtney et al. 2017; Seng et al.2017).  
 
Based on the changes seen in the ASC outcomes for CA in Group M, it might be 
concluded that if both Botox and MT reduce peripheral nociception (Scheuler et al. 
2013; Burstein et al. 2014; Courtney et al. 2017; Do et al. 2018; Melo-Carrillo et al. 
2019;) then there was an additive effect from MT which helped reduce nociceptive 
input compared to Botox alone.  Consequently, these nociceptive changes could 
have interacted in the higher brain (e.g. thalamus, cortex) with inputs from the 
sensory (psychological including emotions, beliefs and environmental challenges) 
which are then modulated by the descending analgesic system (Shacklock 1999; 
Crettaz et al. 2012; Kumar 2018; Dodick et al. 2019). Therefore, this study’s 
outcomes suggest an involvement with MT on both pain and psychological 
mechanisms of migraine as suggested in the allostatic and neurobiological models 
of migraine used to underpin the rationale for the study (Borsook et al. 2012; 
Schwedt 2014; May& Schulte. 2016; Bonivita et al. 2018; Borsook et al. 2019).  It 
was concluded that adjunctive MT provides a better response in HIT6 and PGIC 
responder outcomes than Botox alone in those patients who have maladaptive 
coping behaviours and higher levels of allodynia. 





This PhD study supports the view that severely affected female CM patients may be 
better helped by embracing a multi-modal model of treatment that addresses factors 
proposed in both the neurophysiological and allostatic models of CM (Figure 5.4) 
rather than a mono-therapeutic approach. A combination of Botox and MT is one 
such option. 
6.5. Contributions to knowledge 
The findings built on the work of Cerritelli et al. (2015) and Gandolfi et al (2017) 
adding new evidence for the role of MT as an adjunctive intervention for CM and 
built support for evidence-based multi-modal intervention options for those with CM.   
The study also identified a lack of consistency in the selection of participants, 
reporting of outcome measures and the measurement tools used in the two previous 
studies involving CM and MT. This represented an important finding as it highlighted 
the difficulties with comparing outcomes between studies and reinforced the drive 
for improvements in headache-MT study guidelines. 
 
At the time of writing this was the first CM study to use the PGIC outcomes to 
evaluate the difference in responder rates between two interventions and found a 
significantly higher responder rate for the adjunctive MT therapy over Botox alone. 
This outcome supported the view of the IMMPACT trial that a broader measure of 
treatment response (e.g. PGIC) may be required over and above just measures of 
power and differences in group mean change scores. The study also contributes 
new information by identifying baseline participant factors that might identify those 
females with long standing CM most likely to respond to MT as an adjunctive to 
Botox.  These are: central sensitisation, stress related (depression/anxiety) and 
coping behaviour. Although individually these have been linked to migraine and 
chronic migraine, no previous study has brought them together.  The movement 
between categories in allodynia, measured by the ASC, also suggested that 
examining these changes may be a better indication of treatment effect on central 
sensitisation rather than using the current dichotomous cut-off score. The analysis 
also provided both new and unexpected information on the use of maladaptive 
coping with denial and self-distraction both increasing the likelihood of being a 
responder in PGIC and HIT6, rather than the expected reduction. One interpretation 
of this finding is that, in this group of patients, the long-term use of Botox may be 
encouraging dependency and a failure to try potentially more useful coping 
strategies, which aligned with findings from studies of the fear-avoidance model in




 chronic conditions and has significant clinical implications. This was also the first 
study to explore the potential effect of moderating factors in MT and Botox in CM on 
outcomes.  As a result, the HADS_Total was found to affect the HIT6 outcomes in 
the Botox group but not the adjunctive MT group, which suggests that psychological 
stress (HADS_Total) might moderate the action of Botox and could be an important 
consideration in multi-modal treatment. All of the above analyses were made 
acknowledging the small sample size and propose that this study should be seen as 
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6.7. Suggestions for future research 
This study, as with others of MT in CM, had a relatively small sample size. There is 
a need for larger studies to build upon the findings of the few existing studies in the 
field. To achieve this, it would be useful to have multisite studies encompassing 
different geographic regions, as was originally planned for this PhD study. Such 
studies would also enable the impact of differences in day-to-day clinical practice on 
outcomes to be examined. Consistent with a larger and multisite study the use of a 
‘sham’ placebo group combined with ‘care as usual’ (and perhaps wait list groups) 




should also be encouraged. This would make outcomes more readily comparable to 
non-MT studies, and would also strengthen the external validity of the studies. 
However, because a true adjunctive sham MT intervention is difficult to create (as it 
is argued that any form of MT can create a potential effect) a different approach and 
reasoning for the sham might need considering.  The question often raised is the 
level of placebo effect from MT, over and above the ‘gold standard treatment’ in an 
adjunctive study. Since two factors, expectancy and conditioning (social interaction 
with clinician), are the most cited, then it may be possible to use an inert 
‘pill/medication’ as an adjunctive placebo.  The participants receiving ‘care as usual’ 
and the placebo could attend on the same basis as the MT sessions, during which 
similar measurements could be taken. This would have the effect of replicating the 
theorised placebo effect gained from the increased contact participants have with 
MT, without the application of any MT.  However, since the undefined psychosocial 
component of headache interventions is considered to add to the placebo effect, 
future research should focus on quantifying the differences that factors such as 
expectancy and time spent with the clinician make to outcomes.  
 
With the advent of more expensive pharmacological interventions such as the latest 
CGRP medications and the continuation of existing ones, the importance of 
identifying sub-groups of responders to treatment is paramount for both for the 
patients and also health care providers. Future adjunctive studies should be used to 
identify these subgroups from their baseline characteristics, which can only be 
achieved with appropriate study design. The evidence from existing studies shows 
there is a difference between outcomes in long term users of Botox and naive users, 
with most pharmacological studies involving a high proportion of naive users. This 
PhD study involved long term users of Botox, which most likely reduced the effect of 
Botox on the one hand but made the group as a whole more refractory to treatment. 
To make suitable clinical comparisons of treatment effect, future studies should 
consider comparative studies involving naive and long-term users to gauge the 
effect of MT alone, and as an adjunctive to Botox in CM.  
  
My PhD study also found that there is still limited understanding of the mechanisms 
of action of MT in CM. This needs to be addressed with clinical research, in order to 
help validate or modify existing models. This study suggested that MT helps reduce 
central sensitisation by adding to the reduction in nociception achieved with Botox. 
However other studies suggest MT may also have an effect on other 
neurotransmitters (including inflammatory neurotransmitters) associated with 




reductions in central sensitisation and CM outcomes. Future research into 
biochemical changes in CM, or chronic pain, that result from MT should be 
considered. Following on from this, since the development of central sensitisation 
and allodynia is an important step in CM and other chronic pain conditions. In this 
study, the ASC outcomes seemed to show that MT added to the effect of botox in 
reducing allodynia. Future research into the benefits of MT in CM or other chronic 
pain conditions using objective measures (rather than PROMs) of allodynia/central 
sensitisation would be valuable in the development of new approaches to 
management. 
 
One of the unexpected findings in this study was the influence that negative, 
avoidant behaviours appeared to play in positive outcomes which showed strong 
resonance with the FA models of pain behaviours. Thus, whilst many studies have 
identified an association between psychological factors and both treatment 
response and chronification in CM, no studies to date have explored the mediators 
or moderators in treatment response involving MT (or any other intervention). The 
sample size in this PhD study was designed to address the study’s primary objective 
and was unable to provide anything other than an indication of potential in the area 
of moderation and mediation. However, the results were consistent with studies for 
similar conditions such as fibromyalgia, chronic pain and tension headaches, in 
suggesting that certain psychological factors may mediate or moderate treatment 
outcomes. Support was also given to existing studies that MT may create effect 
through / on psychological factors. As many CM patients have similar psychological 
co-morbidities in common, fruitful areas for study could include: 
 (1) exploring the effect of MT as an adjunctive to psychological therapy for CM and 
EM, with a view to identifying those factors that lead to chronification and the role of 
the fear avoidance model. 
  
 (2) developing more substantive predictive models, using baseline psychological 
factors to identify those most likely to respond to Botox (or other intervention). 
 
All headache studies, including CM, rely on patient reported outcomes (PRO), in the 
absence of objective clinical measures. This has led to treatment outcomes 
focussed on change between group means measures and p values. However, for 
many of the PRO used there is no agreed MCID for CM (or other headaches) and 
the ensuing calculated clinical change may often not be seen as a beneficial or 
substantive change to the individual patients. This is especially true for CM patients 




when many are still classed as severely disabled by the HIT6 scoring after long term 
use of interventions such as Botox. A similar pattern is also seen in many clinical 
trials where, despite a statistically significant difference in group mean change 
scores using the HIT6 outcome, many participants are still classed as severely 
affected.   An example from this PhD study is the seemingly disproportionate PGIC 
responder outcomes when compared to the difference in the HIT6 between group 
mean change score outcomes.  This suggests the PGIC is measuring other 
attributes of treatment outcome that may have importance to the participants. For 
patients receiving long term intervention, but who remain severely disabled, future 
research should look to develop measurement instruments that can be used in 
clinical trials and clinical practice to better evaluate beneficial change at both 
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CHAPTER 8  APPENDICES 
 
Appendix 1. Systematic reviews explored 
 
Table of systematic reviews assessed for studies to include. 
 
Bronfort G. 
2001 Efficacy of spinal manipulation for chronic headache: A 
systematic review, Journal of Manipulative and 
Physiological Therapeutics 
Astin, J. A. 
2002 The effectiveness of spinal manipulation for the treatment 
of headache disorders: A systematic review of 




2010 Effectiveness of manual therapies: The UK evidence 
report 
Chiropractic and Osteopathy 
 
Chaibi, A. 
2011 Manual therapies for migraine: A systematic review 
Journal of Headache and Pain 
 
Posadzki P. 
2011 Systematic reviews of spinal manipulations for 




2014 Manual therapies for primary chronic headaches: a 
systematic review of randomized controlled trials Journal 
of Headache and Pain 
 
Clar C. 
2014 Clinical effectiveness of manual therapy for the 
management of musculoskeletal and non-
musculoskeletal conditions: Systematic review and 
update of UK evidence report 
Lopez L 
2014 Efficacy of manual therapy in the treatment of tension-
type headache. A systematic review from 2000 to 2013 
 
Wanderley D. 
2014 Manual therapies for pain relief in patients with headache: 
A systematic review Revista Neurociencias 




2018 Effectiveness of trigger point manual therapy on the 
frequency, intensity and duration of attacks in primary 
headaches: A systematic review and meta analysis of 
randomized controlled trials.  Frontiers in Neurology 
Falsiroli 
Maistrello L 
2019 Falsiroli Maistrello, L., Rafanelli, M. and Turolla, A., 2019. 
Manual Therapy and Quality of Life in People with 
Headache: Systematic Review and Meta-analysis of 
Randomized Controlled Trials. Current Pain and 
Headache Reports, 23 (10). 
Rist P M 
2019 Rist, P., Hernandez, A., Bernstein, C., Kowalski, M., 
Osypiuk, K., Vining, R., Long, C., Goertz, C., Song, R. 
and Wayne, P., 2019. The Impact of Spinal Manipulation 
on Migraine Pain and Disability: A Systematic Review 
and Meta-Analysis. Headache: The Journal of Head and 
Face Pain, 59 (4), 532-542. 
  






























Web of Science 574 90      
CinAhl 898 77      
Embase 1536 244      
Medline 
(pubmed) 
468 125      
PsychInfo 90 88      
Cochrane 23 23      
Science Direct 893 221      
Scopus 1276 75      
AMED 194 38      
Other sources  1      














1. Study population (30 points) 
A. Description of inclusion and exclusion criteria (1 point). Restriction to a 
homogeneous study population (1 point) 
- 
 
B. Comparability of relevant baseline characteristics: duration of complaint (1 point), 
value of outcome measures (1 point), age (1 point), recurrences (1 point), and 
radiating complaints/associated symptoms   (1 point) 
  
 
C. Description of the randomization procedure (2 points). Randomization procedure 
which excluded bias, ie, random numbers table (2 points)  
D. Description of dropout for each group and reason (3 points)  
E. Loss to follow up: < 20% (2points) OR < 10% (4 points)  
F. Sample size: greater than 50 subjects in the smallest group after randomization (6 
points), OR greater than 100 subjects in the smallest group after randomization (12 
points) 
 
2. Interventions (30 points) 
G. Correct description of the manipulative intervention (5 points). All interventions 
described (5 points)  
H. Pragmatic study: comparison with an existing treatment modality (5 points)  
I. Co-interventions avoided in the design of the study (5 points)   
J. Comparison with a placebo control group (5 points)  
K. Mention of the experience of the manipulative therapist (5 points)  
3. Measurement of effect (30 points) 
L. Placebo controlled studies: patients blinded (3 points), blinding evaluated and fully 
successful (2 points)  
OR  
Pragmatic studies: patients fully naive, evaluated and fully successful (3 points), time 
restriction of no manipulative treatment for at least 1 year (2 points)  
M. Outcome measures: pain assessment (2 points), global measure of improvement 
(2 points), functional status (2 points), spinal mobility  (2 points), medical consumption 
(2 points) 
 
N. Each blinded outcome measure mentioned under item L earns 2 points   
O. Analysis of post-treatment data (3 points), inclusion of a follow-up period longer 
than 6 months (2 points)  
4. Data presentation and analysis (10 points) 
P. Intention-to-treat analysis when loss to follow-up is less than 10% OR intention-to-
treat analysis as well as worst-case analysis for missing values when loss to follow-up 
is greater than 10% (5 points) 
 
Q. Corrected presentation of the data: mean or median with a standard deviation or 
percentiles for continuous variables 5 points  
 Total Score/100  
 Methodological Quality > 50 = Good  
Appendices                                  
244 
 
Appendix 4. Studies excluded from final screening 
 
Studies excluded from final eligibility screen (CM = chronic migraine) 
Author Title Brief description and 
reason for removal 
Adragn et al.  
2015 
 Migraine without aura and osteopathic medicine, a non-
pharmacological approach to pain and quality of life: open 
pilot study 
A small (n=8) migraine only 
study. Single treatment. Not 
CM. 
Akbayrak et  al. 
2001 
Manual therapy and pain changes in patients with migraine - 
an open pilot study 
A female only (n=30) study of 
migraine and connective tissue 
massage. Included physical 
therapy of a hot pack. Not CM 
Bevilaqua-
Grossi et al. 
2016 
 
Additional Effects of a Physical Therapy Protocol on 
Headache Frequency, Pressure Pain Threshold, and 
Improvement Perception in Patients With Migraine and 
Associated Neck Pain: A Randomized Controlled Trial 
A migraine study, plus neck pain 
. no CM included (n=50) this 
was an adjunctive study 
Boline, et  
al,1995 
 Spinal Manipulation vs Amitriptyline for the treatment of 
Chronic Tension Type Headaches -An RCT 
Large (n=150) study. All chronic 
tension-type. Not CM. 
Calandre et al.         
2003 
Effectiveness of prophylactic trigger points inactivation in 
chronic migraine and chronic daily headache with migraine 
features 
This is not manual therapy but 
injections using ropivacaine. 
Chaibi et al. 
2017 
Chiropractic spinal manipulative therapy for migraine: a three-
armed, 
single-blinded, placebo, randomized controlled trial 




Effects of Thai traditional massage on pressure pain threshold 
and headache intensity in patients with chronic tension-type 
and migraine headaches      
The group is described at 
chronic tension-type headache 
and migraine. No separate 
analysis of each is made and no 
mention of CM (n=72) 
Espí-López, et 
al.   2016 
 The effect of manipulation plus massage therapy versus 
massage therapy alone in people with tension-type headache. 
A randomized controlled clinical trial  
Tension type headache only. 
(n=105) compared SMT and 
massage versus massage 
Espí-López  et 
al. 2017 
Manual therapy as a proposed treatment for CM A position paper 
Ferracini et al.  
2017 
Myofascial Trigger Points and Migraine-related Disability in 
Women With Episodic and Chronic Migraine 
A study of characteristics not 
treatment. Did include CM 
(n=55) but no stratification of 
results 
Ferragut-
Garcıas et al. 
2016 
Effectiveness of a Treatment Involving Soft Tissue 
Techniques and/or Neural Mobilization Techniques in the 
Management of Tension-Type Headache: A Randomized 
Controlled Trial 
Tension type only. (n=97).  
Ghanbari et al.  
2015 
Migraine responds better to a combination of medical therapy 
and trigger point management than routine medical therapy 
alone 
An adjunctive study on migraine 
(n=22). Not CM. 
Happe et al.  2016  The efficacy of lymphatic drainage and traditional massage 
in the prophylaxis of migraine: a randomized, controlled 
parallel group study 
Migraine only, No CM. (n=64) 
Lawler & A randomized, controlled trial of massage therapy as a An RCT migraine study (n=48). No 
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Cameron,2006 treatment for migraine CM included. 
Nelson et al.1998 The efficacy of spinal manipulation, amitriptyline and the 
combination of both therapies for the prophylaxis of 
migraine headache 
Migraine study.CM people were 
included but had concomitant TTH 
and no stratified results were 
produced. 
Noudeh et al. 
2012 
Reduction of current migraine headache pain following 
neck massage and spinal manipulation 
Acute migraine males only (n=10) 
No CM. 
Parker, Tupling & 
Pryor, 1978 
A controlled trial of cervical manipulation of migraine Number of migraine days per month 
in subjects do not qualify as CM 
(n=99). 
Rolle et al. 2014 
 
 
Pilot Trial of Osteopathic Manipulative Therapy for  
Patients With Frequent Episodic Tension-Type Headache 
This is episodic tension-type 
headache (n=40) 
Schnider et al. 
2002 
 Physical therapy and adjunctive botulinum toxin type A in 
the treatment of cervical headache: A double-blind, 
randomised, placebo-controlled study 
This is cervicogenic headaches 
(n=33) and used his criteria. Not 
primary headache or CM. 
Tuchin, Pollard & 
Bonello et al. 
2000 
A randomized controlled trial of chiropractic spinal 
manipulative therapy for migraine 
The term CM didn't exist but figures 
supplied show that average 
frequency of attacks was only 7 pm 
which does not qualify as CM 
(n=127). 
Voight et al. 2011 Efficacy of Osteopathic Manipulative Treatment of Female 
Patients with Migraine: Results of a Randomized 
Controlled Trial 
This was migraine only (n=42). It 
was not compared against active 
intervention. 
Following studies were not included as details could not be obtained. 
Xu Ji-Hua et al. 
2017 
A randomized controlled trial of acupressure as an 
adjunctive therapy to sodium valproate on the 
prevention of chronic migraine with aura 
Study states CM in title but 
migraine in text and episodes per 
month average only 2 which is not 
CM (n=89). Author contacted 
Granato A, et 
al.2017 
Efficacy of onabotulinumtoxin A and physical therapy 
combined in treatment of chronic migraine  
Used CM although included 
exercises and no details on 






Manual therapy in the treatment of patients with cervical 
migraine 
Abstract indicates migraine. Full 
text requested although CM was 
not a common term in 1989 and 
text may indicate CM. 
Forbes et al. 2015   Use of physiotherapy by 83 people with chronic migraine 
undergoing treatment with botulinum toxin Type A (BTX-A) 
This was a physiotherapy not 
manual therapy study into CM. The 
author was contacted and sent 
details but it was not peer reviewed  
and not available in complete form 
so was excluded at this stage 
(n=83) 
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Appendix 5. Cerritelli et al. Study Quality by Score 
CERRITELLI ET AL ET AL. (2015) CLINICAL EFFECTIVENESS OF OSTEOPATHIC TREATMENT IN CHRONIC 
MIGRAINE: 3-ARMED RANDOMISED CONTROLLED TRIAL. 
1. Study population (30 points) 
A. Description of inclusion and exclusion criteria (1 point). Restriction to a homogeneous 
study population (1 point) 
- ICHD criteria for CM confirmed by neurologist  
- Inclusion and exclusion  
2 
B. Comparability of relevant baseline characteristics: duration of complaint (1 point), value 
of outcome measures (1 point), age (1 point), recurrences (1 point), and radiating 
complaints/associated symptoms          (1 point) 
- no difference between groups -  HIT 6 ( -2.3diff)  
3 
C. Description of the randomization procedure (2 points). Randomization procedure which 
excluded bias, ie, random numbers table (2 points) 4 
D. Description of dropout for each group and reason (3 points) 3 
E. Loss to follow up: < 20%( 2points)  OR < 10% (4 points) 4 
F. Sample size: greater than 50 subjects in the smallest group after randomization (6 
points), OR greater than 100 subjects in the smallest group after randomization (12 points) 0 
2. Interventions (30 points) 
G. Correct description of the manipulative intervention (5 points). All interventions 
described (5 points) 10 
H. Pragmatic study: comparison with an existing treatment modality (5 points) 5 
I. Co-interventions avoided in the design of the study (5 points) - not mentioned 0 
J. Comparison with a placebo control group (5 points) - used sham 5 
K. Mention of the experience of the manipulative therapist (5 points) 5 
3. Measurement of effect (30 points) 
L. Placebo controlled studies: patients blinded (3 points), blinding evaluated and fully 
successful (2 points) 5 
OR  
Pragmatic studies: patients fully naive, evaluated and fully successful (3 points), time 
restriction of no manipulative treatment for at least 1 year (2 points) 0 
M. Outcome measures: pain assessment (2 points), global measure of improvement (2 
points), functional status (2 points), spinal mobility -  (2 points), medical consumption 
(2 points) 
8 
N. Each blinded outcome measure mentioned under item L earns 2 points ( not clear what 
was) 2 
O. Analysis of post-treatment data (3 points), inclusion of a follow-up period longer than 6 
months (2 points) 3 
4. Data presentation and analysis (10 points) 
P. Intention-to-treat analysis when loss to follow-up is less than 10% OR intention-to-treat 
analysis as well as worst-case analysis for missing values when loss to follow-up is greater 
than 10% (5 points) 
5 
Q. Corrected presentation of the data: mean or median with a standard deviation or 
percentiles for continuous variables 5 points 5 
 Total Score/100 69 
 Methodological Quality  > 50 = Good Very Good 
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Gandolfi et al. (2017) - Does myofascial and trigger point treatment reduce pain and analgesic 
intake in patients undergoing OnabotulinumA injection due to chronic intractable migraine? - 
Pilot single blind RCT 
1. Study population (30 points) 
A. Description of inclusion and exclusion criteria (1 point). Restriction to a homogeneous 
study population (1 point)   
2 
B. Comparability of relevant baseline characteristics: duration of complaint (1 point), 
value of outcome measures (1 point), age (1 point), recurrences (1 point), and radiating 
complaints/associated symptoms (1 point)  
3 
C. Description of the randomization procedure (2 points). Randomization procedure which 
excluded bias, ie, random numbers table (2 points) 2 
D. Description of dropout for each group and reason (3 points) - none 3 
E. Loss to follow up: < 20%( 2points)  OR < 10% (4 points) 0 
F. Sample size: greater than 50 subjects in the smallest group after randomization (6 
points), OR greater than 100 subjects in the smallest group after randomization (12 
points) 
0 
2. Interventions (30 points) 
G. Correct description of the manipulative intervention (5 points). All interventions 
described (5 points) 10 
H. Pragmatic study: comparison with an existing treatment modality (5 points) 0 
I. Cointerventions avoided in the design of the study (5 points)   (tricky) 3 
J. Comparison with a placebo control group (5 points)  - TENs - not really placebo 3 
K. Mention of the experience of the manipulative therapist (5 points) -  0 
3. Measurement of effect (30 points) 
L. Placebo controlled studies: patients blinded (3 points), blinding evaluated and fully 
successful (2 points) 5 
OR 0 
Pragmatic studies: patients fully naive, evaluated and fully successful (3 points), time 
restriction of no manipulative treatment for at least 1 year (2 points) 0 
M. Outcome measures: pain assessment (2 points), global measure of improvement 
(2 points), functional status (2 points), spinal mobility -  (2 points), medical 
consumption (2 points) -  
10 
N. Each blinded outcome measure mentioned under item L earns 2 points 2 
O. Analysis of post-treatment data (3 points), inclusion of a follow-up period longer than 6 
months (2 points) 3 
4. Data presentation and analysis (10 points) 
P. Intention-to-treat analysis when loss to follow-up is less than 10% OR intention-to-treat 
analysis as well as worst-case analysis for missing values when loss to follow-up is 
greater than 10% (5 points) 
0 
Q. Corrected presentation of the data: mean or median with a standard deviation or 
percentiles for continuous variables 5 points 5 
 Total Score/100 51 
 Methodological Quality  > 50 = Good. NB this was a pilot study  Good 
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Appendix 7. TiDier Checklist - Cerritelli et al. (2015)  
Provide the name or a phrase that describes the intervention. Page 
1a. Osteopathic Manipulative Treatment versus  
1b. Sham Therapy (light manual contact) plus medication (triptans) and  
1c. Medication (triptans) 
150,151 
WHY 
2. Describe any rationale, theory, or goal of the elements essential to the intervention.  
150 
Migraine aetiology is thought to be the result of multifactorial epigenetic mechanisms. There is 
accumulating evidence to support that the central sensitization plays a critical role in migraine 
pathogenesis. This creates a functional alteration of key centers in the central nervous system (CNS), 
in particular the trigeminovascular nuclei. Neurogenic inflammation of meninges is considered to 
activate specific neural pathways transmitting pain signals to the trigeminovascular system and 
vegetative nervous system (VNS) nuclei. This condition may predispose to VNS dysfunctions which 
have been suggested to be one of the causes of headache. Therefore, dysfunctional nervous 
structures, inflammatory condition and functional alteration of the VNS may be responsible for the pain 
and contribute to migraine pathophysiology. Recent studies provided information about the possible 
association between manual therapies in particular osteopathic manipulative treatment (OMT) and its 
effects on migraine. Voigt et al. carried out an RCT showing the effects of OMT on migraineurs’ quality 
of life. The author claimed a significant improvement in the quality of life parameters as well as a 
reduction of pain. Another piece of research evaluated the effects of OMT in patients with headaches. 
Patients who received 8—12 osteopathic sessions showed a significant reduction of pain and 
frequency of attacks. In 2006 Anderson and Seniscal compared the effects of OMT to progressive 
muscular relaxation exercises on patients with tension-type headache. Subjects who under-went both 
treatments, showed significant improvement on joint and myofascial stiffness and reduction of pain 
com-pared to exercise only. 
WHAT 
3 N/A  
4a. Osteopathic manipulative treatment (OMT) based on an individual structural evaluation and an 
indirect technique treatment. 
151, 152 
(Table 1) 
Myofascial release & BLT:  A system of soft manual treatment directed to the muscles and fascia 
which engages the detection of restriction of motion and continual palpatory feedback to achieve 
release of myofascial tissues A complex of light manual movements that allows the practitioner to test 
the tension of ligaments, disengage the area with SD, find the point of balance and treat the area 
according to the existing range of motion 
BMT : Same as BLT but applied to the cranial field 
Cranial-sacrum : An approach that uses soft touch to explore the primary respiratory mechanism and 
treat any imbalance between sacrum (pelvis) and cranial bones motility 
4b. SHAM 
Sham treatment used light manual contact to ‘‘treat’’ the subject and was administered with subject 
lying supine on the treatment table.  
4c. Medication Care as Usual. Triptans 
4d. Secondary outcome measures were taken from the migraine diary. 
WHO PROVIDED 
5a. OMT and Sham provided by 6 osteopaths, ROI certified.  151 5b. Care as Usual medication provided by neurologist. 
WHERE 
7a. Recruitment and medication undertaken in Department of Neurology of Ancona’s United 
Hospitals. Actual OMT and SHAM treatment location is unclear.  150 
WHEN and HOW MUCH 
8a. OMT and sham therapy sessions were face to face and lasted 30 min. They were scheduled 
weekly for the first two sessions, biweekly for the subsequent two, then monthly for the remained four 
sessions 151 
8b. Medication  was On-going. 
TAILORING 
9a. OMT: A need-based patient treatment approach based on findings derived from the osteopathic 
evaluation and not based on a pre-determined protocol, was applied to the study group. Criteria 
considered for osteopathic evaluation and treatment were tissue alteration, asymmetry, range of 
motion and tenderness parameters. 151 
9b. Sham: The anatomical areas contacted were different across sessions and were based on the 
personal choice of the operator. There was no standardized protocol in terms of number, duration and 
typology of touching regarding the manual bodily contacts. 
MODIFICATIONS 
10a. Both OMT and Sham groups required to maintain stable medication regimens but could alter 
acute medication 151 10b. Care as usual group (medication) were able to adjust, change and optimize medication regimens 
as directed by the physician 
HOW WELL 
Clinical evaluations were performed at entry (T0) and after 24 weeks (T1) by the same neurologist 
who was blinded to the patient’s allocation and outcomes. 
150, 151 No planned assessment of adherence identified upfront. 
No final intervention assessment reported although figures suggest all randomised participants 
completed the study. 
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Appendix 7a. TiDier Checklist - Gandolfi et al. (2017)  
 
Provide the name or a phrase that describes the intervention. Page 
number 
1a. Manipulative techniques plus OnabotulinumA    
1b. Transcutaneous Electrical Stimulation (TENS) plus Onabotulinum 
 
WHY 
2a. Although Chronic migraine can be very disabling its pathophysiological mechanisms are not entirely 
understood, it involves dysfunctions in the pain-modulating network due to altered regulation of 
excitatory-inhibitory balance results in sensitization of the trigeminocervical caudalis nucleus that, in turn, 
lowers the threshold for developing new attacks. Factors besides neurovascular dysfunction that can 
contribute to migraine are myofascial trigger points which increase tension of the taut muscular bands 
and the facilitation of motor activity contribute to the development or maintenance of sensitization 
mechanisms by excitation of muscle nociceptors. During these sensitization phenomena, the dorsal horn 
neurons may become hyperexcitable with the presence of multiple (spatial summation) and active trigger 
points (temporal summation) provoking a continued nociceptive afferent barrage into the central nervous 
system.  
Patients with migraine exhibit active myofascial trigger points in the splenius capital, upper trapezius, 
and sternocleidomastoid muscles, which reproduce their migraine.  Standard preventive treatments 
include betablockers, topiramate or valproate though their tolerability and adverse effects often limit their 
use. Epidemiological studies have indicated that more than one in four migraineurs need prophylactic 
therapy, but only 33% of these patients receive it. In 2010, onabotulinumtoxinA injection was approved 
by the U.S. Food and Drug Administration for the preventive treatment of chronic migraine. 
Rehabilitation procedures (e.g., transcutaneous electrical nerve stimulation [TENS], physical therapy) 
play a key role in treatment programs addressed to mitigate neuromuscular dysfunction in headache 
patients. Manual therapies focus on soft tissue work, stretching, active and passive mobilization and 
manipulation techniques to treat musculoskeletal dysfunction. The effectiveness of manipulative 
treatment as an adjuvant therapy in the management of patients with neurological diseases has been 
recently reviewed. Results showed that studies on the efficacy and/or effectiveness of manipulative 
treatment are scarce.  
2,3 
2b. The aim of this study was to evaluate the feasibility of myofascial and trigger point treatment in 
chronic migraine patients receiving prophylactic treatment with onabotulinumtoxinA. To evaluate the 
treatment effects on headache frequency and intensity, analgesic consumption, cervical range of motion, 




4a. Manipulative treatment  
4,5 
Each session consisted of two steps: myofascial release and manipulative articulatory technique. The 
manipulative techniques were aimed at improving cervical and thoracic spine joint mobility and reducing 
soft tissue stiffness of the cervicothoracic spine. Cervical manipulative articulatory technique in side 
bending. Occipito-Atlant manipulative articulatory technique in side bending. Thoracic technique (Full 
details of all intervention are provided in paper) 
4b. TENS  
Delivered with a portable device (Master 932, Elettronica Pagani SRL , Milan, Italy) that generates 
symmetric, bi-phasic rectangular pulses 140 μs in duration. Current frequency was set at 150 Hz and 
intensity was increased up to the patient’s perception of paresthesia. The negative electrode was placed 
on the active trigger point of the upper trapezius muscle and the positive electrode on the insertion of the 
acromial tendon. Treatment frequency and duration were the same as described for the experimental 
group (EG) treatment (1 session/week for 4 weeks). 
4c. OnabotulinumA administered by injection for all treatments 
4d. Secondary outcome measures were taken from the migraine diary. 
WHO PROVIDED 
5a. Manual Therapy and TENS sessions were performed by one experienced physical therapist per 
group 4 
5b. OnabotulimumA injected by neurologist. 
WHERE 
7a. All treatment in Neurorehabilitation  Unit of AOUI of Verona (Italy). 3 
WHEN and HOW MUCH 
8a. Treatment consisted of 4 sessions (30 min/session, 1 session/week for 4 weeks). 4 
TAILORING 
9a. Manipulation plus Botox: The treatment processes were specific but the application was on an 
individual basis. 4 
9b. TENs plus botox : not tailored 
MODIFICATIONS 
10a. none  
HOW WELL 
11a. The planned assessment of adherence was identified up front. 4,5 
11b. Final intervention assessment was fully reported.  6,7 
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Appendix 8. PRECIS – 2. Study Analysis 
 
DOMAIN SCORE RATIONALE 
Eligibility Criteria 5 Females over 18 diagnosed with chronic 
migraine and without other neurological 
conditions. Not having had manual therapy in 
last 6 weeks. All having had at least 1 round 
of botox to minimize risk of medication over 
use. 
Recruitment Path 5 From consultant list. Everyone with chronic 
migraine attending for treatment 
Setting 5 In the neurology clinic with manual therapy at 




4 a trained manual therapist with relevant skills 
Flex of experimental 
intervention – Delivery 
5 The therapist has an open protocol for the 
intervention approach only subject to treating 
the upper body, head neck with manual 
therapy 
Flex of experimental 
intervention – 
Adherence 
3 Text messages are sent weekly to remind 
participants to complete diary and they are 
contacted when final information/examination 
is required. The Manual therapy group have 
set appointments which they attend. No 
specific methods to adhere are made 
Follow up 4 All participants complete a diary, a start and 
end questionnaire - very similar to their 
normal approach but including more data 
Outcome 5 The primary outcome is a change in their 
disability measure HIT6 with other patient 
reported outcomes used. 
Analysis 3 Participants who become excluded after the 
randomisation will not be included nor will the 
data from those who drop out. Partial data will 
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Appendix 10. Participant Information Sheet 
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the Faculty of Health and Social Sciences at 
Bournemouth University. If you are harmed during 
the study as a result of negligence, you may have 
grounds for compensation against Bournemouth 
University; however, you may have to pay your own 
legal costs. The National Health Service 
complaints service will be available to you. You will 
also be able to contact the Patient Advice and 
Liaison Service (PALS). 
 
Will my taking part in this study be kept 
confidential? 
Your information will be kept confidential as you 
would expect in all of your healthcare encounters. 
The questionnaires and diaries will not have your 
personal details attached, only an individual 
reference number. All information will be used for 
this research only and kept securely on password 
protected computers and only accessible by 
members of the research team. Any data that can 
identify a participant will be destroyed within 3 
months of final data collection. Anonymous data 
may be kept for up to 5 years on a secure university 
computer. 
Bournemouth University (BU) is the sponsor for this 
study based in the United Kingdom. We will be using 
information from you in order to undertake this study 
and will act as the data controller for this study. This 
means that we are responsible for looking after your 
information and using it properly.  
 
As a university we use personally-identifiable 
information to conduct research to improve health, 
care and services. As a publicly-funded 
organisation, we have to ensure that it is in the 
public interest when we use personally-identifiable 
information from people who have agreed to take 
part in research.  This means that when you agree 
to take part in a research study, we will use your 
data in the ways needed to conduct and analyse the 
research study 
Your rights to access, change or move your 
information are limited, as we need to manage your 
information in specific ways in order for the research 
to be reliable and accurate. If you withdraw from the 
study, we will keep the information about you that 
we have already obtained. To safeguard your rights, 
we will use the minimum personally-identifiable 
information possible. 
You can find out more about how we use your 
information by contacting 
researchgovernance@bournemouth.ac.uk, or for 
more general queries DPO@bournemouth.ac.uk.  
Salford Royal will use your name and contact details 
to contact you about the research study, and make 
sure that relevant information about the study is 
recorded for your care, and to oversee the quality of 
the study. Individuals from BU and regulatory 
organisations may look at your medical and 
research records to check the accuracy of the 
research study. Salford Royal will pass these details
to BU along with the information collected from you
The only people in BU who will have access to 
information that identifies you will be people who 
need to contact you in the event of major changes t
the study or audit the data collection process. The 
people who analyse the information will not be able 
to identify you and will not be able to find out your 
name or contact details. 
What will happen to the results of the research 
study? 
 
The results of the study will be presented in my PhD
thesis and submitted to Bournemouth University. 
They will also be presented at academic 
conferences and submitted for publication in 
international journals. Summaries of the findings wil
also be made available to migraine charities. If you 
would like a copy of the summary findings please 
contact me. 
 
Who is organising and funding the research? 
 
The study is being funded by a research grant from 
Bournemouth University, The McTimoney College o
Chiropractic and the Royal College of Chiropractors
 
Who has reviewed the study? 
 
The study has been reviewed by my supervisors 
Dr Carol Clark, Dr Jonny Branney and Dr Osman 
Ahmed. It has also been given a favourable 
opinion by the Research Ethics Committee. 
 
Further information and contact details: 
Mr Jim Odell 
Research Fellow Bournemouth University 
Tel 07413833690 
Email: JOdell@bournemouth.ac.uk 
Dr Carol Clark 
Supervisor, Associate Professor 
Head of Department Human Sciences and Public 
Health, R 612 
Tel 01202 963022 
Email: cclark@bournemouth.ac.uk 
Dr Jonny Branney 
Supervisor, Lecturer in Adult Nursing  
Faculty of Health and Social Sciences 
Bournemouth University, B211 
Tel 01202 967282 
Email: jbranney@bournemouth.ac.uk 
 
Dr Osman Ahmed 
Supervisor, Lecturer in Physiotherapy 
Faculty of Health and Social Sciences, R601 
Tel: 01202 968147 
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Appendix 12. Assessment and Treatment  
1. Assess upper bodya posture in sitting 
The aim is to identify which areas should be focussed on for 
treatment: Examples of observations include: anterior head 
carriage, tilt/rotation of head, protracted scapulae, 
glenohumeral joint internally rotated; increased/decreased 
thoracic curve, scoliosis; rotation of upper body). 
2. Assess active and passive neck range of motion (RoM) 
See picture below for active. Passive completed by 
therapist. Aim is to identify RoM restrictions comparing left 
to right and both to normal expected RoM and to identify 
any pain with movement. Muscles assessed include: upper 
cervicals, scaleni, sternocleiodomastoids, Cervical joints 
palpation: static and motion 
 
3.  Assess shoulder girdle range of motion by active and 
passive raising of each arm sideways (individually and 
together) from side of body up to ear (Pictures 10.2) 
Assessment points: Observe range of motion with raising of 
arms; singularly and then together. Note any compensations 
(e.g. shoulder hiking) to achieve movements and any  
pain with movement. Muscles assessed include latissimus 
dorsi, serratus, trapezius, levator scapula, pectoral 
 
 
Appendix 12. Picture 1. Cervical assessment.  Adapted from Musculoskeletalkey.com 
 
Appendix 12. Picture 2. Shoulder and Thoracic Assessment 
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Appendix 12 (contd). Assessment and Treatment 
 
4.   Assess the temporomandibular joint  
Check movements of jaw for deviations, pain or 
limitations.Palpate muscles including masseter, 
temporalis, pterygoids, mylohyoid    
 
5. Identify areas to treat in sitting position. 
             Examples include: cervical spine, trapezius muscles, 
rhomboids, levator scapula, thoracic spine down to 
T12 including obliques around thoracolumbar fascia 
6. Administer MT using mobilisation, manipulation and 
soft tissue release in sitting position 
7. Assess patient shoulder girdle, neck and head supine 
and prone (note: supine is assessed and treated then 
prone assessed and treated). Examples of approach 
include 
             Static and motion palpation of cervical joints, thoracic 
spine and ribcage. Palpation of anterior neck, 
pectoral muscles and thoracic musculature. 
8. Administer MT in supine and prone position 
             Comprises appropriate soft tissue release, 
mobilisation and manipulation as required. 
Chiropractic adjustments include HVLA (McTimoney) 
if appropriate. 
9. Following each session an outline of the MT used will 
be recorded. A total of 30 minutes will be allocated 
for each participant at these consultations  
 
a Upper body defined as from thoraco-lumbar junction 
upwards 
 
Appendix 12. Picture 3 TMJ Assessment 
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Appendix 12a. PREEMPT Protocol 
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              Appendix 12a. PREEMPT Protocol (Contd) 
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 The strong correlations (0.51 
to 0.87) between HIT6 scores 
and scale score support the 
validity of the test as a 






Internal consistency, alternate 
forms, and test–retest 
reliability estimates of HIT-6 
were 0.89, 0.90, and 0.80, 
validity in discriminating 
across diagnostic and 
headache severity groups, 
relative validity (RV) with 
coefficients of 0.82 and 1.00  
Construct validity with SF8 
factors between 0.31 and 0.45 





The Cronbach α coefficients 
for 14 languages was 
above the 0.70 criterion 
implying HIT-6 is reliable in all 
languages studied 
 







The HIT-6 showed high 
internal consistency reliability 
(Cronbach’s coefficient α = 
0.87). 
Construct validity correlating 
HIT-6 scores with the SF-36 
ranged from −0.22 for mental 
health to −0.57 for social 
functioning. Strongest 
correlations between HIT-6 
score and the role physical (r 
= −0.52) and social functioning 
(r = −0.57) 





High reliability with internal 
consistency (time1/time2) of 
0.83/0.87 in national survey 
headache impact and 
0.82/0.92 in HIT6-validation 
study. Intra-class correlation 
for test-retest reliability was 
very good at 0.77 
Construct validity HIT-6 scores 
correlated significantly 
(p<.0001)with total Migraine 
Disability Assessment Scale 
scores (r=.56),  
Zandifer et 
al. 2013 
Migraine and TTH 
n=274 (Persian) 
Internal consistency 
calculated Cronbach’s as 
0.74, 0.82, and 
0.86 for the 1st, 2nd, and 3rd 
visits, respectively Test-Retest 
reliability was evaluated at 
visit 2 vs. visit 1the Pearson’s 
correlation coefficient, 
r=0.50; P<0.001)  
Construct validity correlation 
between HIT6 and SF36 the 
total scores (range: 0.52–
0.77). 
 




Good reliability was observed 
across studies with 
Cronbach’s α: 0.75–0.92 
 
Correlations between HIT-6 
total scores and scale scores 
of the MSQ were above the 
recommended threshold of 
0.40 for convergent validity 
across studies and time 
points, ranging between −0.86 
and −0.59 








MCID 2.5-6, Between group 
1.5 
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Study title: A two-centre pragmatic randomised controlled trial on the 
effectiveness of manual therapy as an adjunct to tertiary 
management of chronic migraine 
IRAS project ID: 228901 
REC reference: 18/SC/0069 
Sponsor Bournemouth University 
I am pleased to confirm that HRA and Health and Care Research 
Wales (HCRW) Approval has been given for the above referenced 
study, on the basis described in the application form, protocol, supporting 
documentation and any clarifications received. You should not expect to 
receive anything further relating to this application. 
How should I continue to work with participating NHS organisations 
in England and Wales? You should now provide a copy of this letter to 
all participating NHS organisations in England and Wales, as well as any 
documentation that has been updated as a result of the assessment. 
Following the arranging of capacity and capability, participating NHS 
organisations should formally confirm their capacity and capability to 
undertake the study. How this will be confirmed is detailed in the 
“summary of assessment” section towards the end of this letter. 
You should provide, if you have not already done so, detailed instructions 
to each organisation as to how you will notify them that research 
activities may commence at site following their confirmation of capacity 
and capability (e.g. provision by you of a ‘green light’ email, formal 
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notification following a site initiation visit, activities may commence 
immediately following confirmation by participating organisation, etc.). 
It is important that you involve both the research management function 
(e.g. R&D office) supporting each organisation and the local research 
team (where there is one) in setting up your study. Contact details of the 
research management function for each organisation can be accessed 
here. How should I work with participating NHS/HSC organisations in 
Northern Ireland and Scotland? 
HRA and HCRW Approval does not apply to NHS/HSC organisations 
within the devolved administrations of Northern Ireland and Scotland. 
If you indicated in your IRAS form that you do have participating 
organisations in either of these devolved administrations, the final 
document set and the study wide governance report (including this letter) 
has been sent to the coordinating centre of each participating nation. You 
should work with the relevant national coordinating functions to ensure 
any nation specific checks are complete, and with each site so that they 
are able to give management permission for the study to begin. 
Please see IRAS Help for information on working with NHS/HSC 
organisations in Northern Ireland and Scotland. 
How should I work with participating non-NHS organisations? 
HRA and HCRW Approval does not apply to non-NHS organisations. 
You should work with your non- NHS organisations to obtain local 
agreement in accordance with their procedures. 
What are my notification responsibilities during the study? 
The document “After Ethical Review – guidance for sponsors and 
investigators”, issued with your REC favourable opinion, gives detailed 
guidance on reporting expectations for studies, including: 
Registration of research 
Notifying amendments 
Notifying the end of the study 
The HRA website also provides guidance on these topics, and is updated 
in the light of changes in reporting expectations or procedures. 
I am a participating NHS organisation in England or Wales. What should I 
do once I receive this letter? 
You should work with the applicant and sponsor to complete any 
outstanding arrangements so you are able to confirm capacity and 
capability in line with the information provided in this letter. 
The sponsor contact for this application is as follows: 
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Name: Assoc. Prof C Clark Tel: 01202 963022 
Email: cclark@bournemouth.ac.uk 
Who should I contact for further information? 
Please do not hesitate to contact me for assistance with this application. 
My contact details are below. Your IRAS project ID is 228901. Please 
quote this on all correspondence. 
Yours sincerely 
Juliana Araujo Assessor 
Email: hra.approval@nhs.net 
Copy to:  Sponsor Representative: Assoc. Prof C Clark, Bournemouth University Lead NHS R&D 
Office Representative: Katie Doyle, Salford Royal NHS Foundation Trust & The Pennine Acute 
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Brief Cope Pre and Post Means (SD) Mann-Whitney U Results 
difference in change scores 









Variable Pre (SD) Pre  (SD) Post(SD) Post (SD) Significance 
Self-distraction 5.28 (1.73) 4.93 (1.91) 4.59 (1.64) 
4.57 
(1.65) P=0.608 U=444, z= -0.513 
Denial 3.00 (1.55) 2.77(1.48) 2.63 (1.36) 
2.73 
(1.39) P=0.478 U= 434, z=-0.71 
Substance use 2.84 (1.48) 2.60(1.22) 2.41(1.19) 2.53(1.01) P=0.515 U=439 z= -0.65 
Behavioural 
disengagement 3.97(1.99) 3.07(1.55) 
3.16 
(1.48) 3.53(1.55) 
P=0.036 U=333 z=-2.1,  
η2=0.07 
Self-blame 4.50(1.90) 3.77(2.08) 4.16 (2.32) 3.83(2.02) P=0.685 U=451 z= -0.46 
Use of emotional 
support 5.06 (2.05) 4.30(1.62) 
4.03 
(1.87) 4.23(1.99) P=0.202 U= 390 z= -1.27 
Use of instrumental 
support 3.63 (1.21) 3.40(1.28) 3.34(1.29) 2.93(0.98) P=0.858 U= 492, z= -0.18 
Venting 4.34 (1.82) 3.17(0.99) 3.72(1.40) 3.33(1.21) P=0.167 U= 383 z=-1.38 
Religion 2.84 (1.17) 2.63 (1.59) 3.03 (1.69) 2.27(0.69) P=0.673 U=508 z= 0.422 
Humour 3.75 (1.80) 4.20(2.30) 3.75(1.80) 3.83(2.32) P=0.528 U=524 z= 0.63 
Acceptance 6.34 (1.33) 5.93 (1.51) 6.22(1.54) 5.67(1.86) P=0.870 U= 491 z= 0.163 
Positive reframing 3.84 (1.69) 4.30 (1.99) 3.97(1.49) 3.33(1.52) P=0.097 U=597 z= 1.66 
Planning 5.00 (1.92) 4.50 (1.87) 4.75(1.93) 3.83(1.60) P=0.598 U= 517 z= 0.53 
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Appendix 28. Fear-avoidance model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
